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1Summary
1.1 English
The inhibition of transcription factor activation can be translated into a novel therapeu-
tic strategy for a wide range of disease models. Decoy oligodeoxynucleotides (ODNs)
containing the consensus binding site of a target transcription factor (TF) subsequently
prevent binding of the TF to the promoter regions of its target genes associated with
certain disorders. Decoy ODNs were shown to be safe and effective, but until now the
main delivery route consisted of local application. However, depending on the target
organ, this approach is not always feasible. Therefore, the main aim of this study is the
establishment of an adeno-associated virus (AAV)-based method of decoy ODNs deliv-
ery, which allows continous generation of the therapeutic nucleic acid compound as a
short hairpin RNA (shRNA) in AAV-transduced cells.
In Marfan syndrome, increased Transforming growth factor-β (TGF-β) bioavailability
induces enhanced activity of activator protein-1 (AP-1), which in turn upregulates ex-
pression of matrix metalloproteinases (MMPs). These endopeptidases were proven to
be involved in the elastin degradation and aortic fragility which causes aortic aneurysm
formation and dissection. The effect of ”naked” hpAP-1 decoy ODNs application and
AAV9SLR transduction was analysed using primary mgR/mgR SMCs as an in vitro
model and AP-1 activation was induced by interleukin-1 β (IL-1β) treatment. Both
treatments led to decreased mRNA level of AP-1 target genes MMP9 and monocyte
chemotactic protein-1 (MCP-1), as well as decreased MMP activity and smooth mus-
cle cells (SMCs) migration capacity. Moreover, IL-1β-induced reactive oxygen species
(ROS) production was reduced.
In vivo experiments were performed using mgR/mgR mice. By F.I.S.H. experiments, the
expression of the hpAP-1 RNA decoy ODNs in endothelial cells and SMCs was demon-
strated, 4 weeks after ex vivo tissue transduction and reimplantation into mgR/mgR
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mice. Furthermore, AP-1 target genes MMP9 and MCP-1 were downregulated and
MMP protein level and activity was significantly reduced. Additionally, AAV9SLR
transduction caused a remarkable decrease in the number of infiltrating macrophages
and improved endothelial tight junction integrity. Importantly, AP-1 inhibition signifi-
cantly decreased the level of elastin degradation, as shown by a reduction in the number
of islands of damage.
The second aim of this study was the preclinical validation of AAV9 vector express-
ing hpNFAT decoy ODNs as a therapeutic approach in an experimental model of left
ventricular hypertrophy and heart failure in mice (transverse aortic constriction, TAC).
The effect of hpNFAT decoy ODNs and AAV9 transduction was first assessed in vitro
by employing the cardiomyocyte cell line HL-1, as well as primary neonatal cardiomy-
ocytes, which were treated with the pro-hypertrophic stimulus endothelin-1 (ET-1). The
results revealed a significant downregulation of the fetal gene programme, represented
by atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) as well as de-
creased myosin heavy chain-β (β-MHC) protein expression. Moreover, hpNFAT decoy
ODNs and AAV9 expressing hpNFAT RNA decoy ODNs reduced ET-1 induced protein
synthesis rate.
Two weeks prior to inducing myocardial hypertrophy through aortic stenosis by TAC
surgery, AAV9 was injected systemically. The vector led to the intracellular synthesis of
the active RNA decoy ODNs in cardiomyocytes and decreased expression of fetal gene
programme. In addition, markers of myocardial hypertrophy heart weight/tibia length
(HW/TL) and heart failure lung weight/tibia length (LW/TL) were significantly reduced
in treated mice. At the same time, heart function was markedly improved and fibrosis
markers were reduced by NFAT neutralization through AAV9 injection.
In conclusion, AAV-mediated decoy ODN delivery to the target organ may be a powerful
tool to regulate the expression of genes involved in the progression of certain diseases.
The present study showed the therapeutic efficacy of this concept by investigating two
cardiovascular disease models.
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1.2 German
Herz-Kreislauf-Erkrankungen stellen in der westlichen Welt die ha¨ufigste Todesur-
sache dar. Eine neuartige therapeutische Strategie zum Einsatz fu¨r ein breites Spektrum
dieser Erkrankungsarten ist es, die Transkriptionsfaktor-Aktivierung zu hemmen. In
dieser Studie werden zwei Erkrankungen betrachtet, zum einen die Aortenaneurysma-
Dissektion bei Patienten mit Marfan-Syndrom und zum anderen die Herzinsuffizienz.
Die molekularen Mechanismen und beteiligten Transkriptionsfaktoren dieser kardio-
vaskula¨ren Komplikationen wurden bereits in anderen Arbeiten intensiv untersucht.
Decoy Oligodeoxynucleotide (ODNs) enthalten die Konsensbindungsstelle eines Ziel-
Transkriptionsfaktors und verhindern so eine Bindung an die Promotorregion der Gene,
die mit bestimmten Erkrankungen assoziiert sind. Decoy ODNs erweisen sich als ef-
fektiv und sicher. Jedoch bestand der Applikationsweg bisher hauptsa¨chlich in der
lokalen Anwendung, was je nach Zielorgan allerdings nicht immer mo¨glich ist. Da-
her ist das Hauptziel dieser Studie die Etablierung einer AAV-basierten Methode, um
die kontinuierliche Bildung von Decoy ODNs als shRNA in den transduzierten Zellen
zu ermo¨glichen.
Die gesteigerte TGF-β Bioverfu¨gbarkeit ist fu¨r das Marfan-Syndrom kennzeichnend.
Sie induziert die Aktivierung des Transkriptionsfaktors AP-1, was eine gesteigerte Ex-
pression von MMPs zur Folge hat. Diese Endopeptidasen sind ursa¨chlich am Elastin-
abbau und der Fragilita¨t der Aorta beteiligt, welches zur Bildung bzw. Dissektion
eines Aortenaneurysmas fu¨hren kann. Der Effekt der nackten hpAP-1 Decoy ODNs
und der AAV9SLR Transduktion wurde zuna¨chst in prima¨ren kultivierten mgR/mgR
SMCs in vitro analysiert, bei denen IL-1β-vermittelt AP-1 aktiviert wurde. Beide
Ansa¨tze fu¨hrten zu einer Reduktion der mRNA-Expression der AP-1 Zielgene MMP9
und MCP-1. Ebenso konnten verminderte MMP Aktivita¨t und Migrationskapazita¨t der
SMCs beobachtet werden. Daru¨ber hinaus wurde die durch IL-1β-induzierte ROS-
Produktion gehemmt.
In vivo Experimente wurden mit Fibrillin-1-defizienten mgR/mgR Ma¨usen durchgefu¨hrt.
4 Wochen nach ex vivo Transduktion und Reimplantation in den mgR/mgR Ma¨usen
wurde mittels der F. I. S. H. Methode die Bildung der hpAP-1 RNA Decoy ODNs
in den Endothelzellen und SMCs der aortalen Transplantate erfolgreich nachgewiesen.
Daru¨ber hinaus konnte die Expression der AP-1 Zielgene MMP9 und MCP-1 und auch
die MMP-Aktivita¨t signifikant gehemmt werden. Zusa¨tzlich bewirkte die AAV9SLR
Transduktion eine Abnahme der infiltrierenden Makrophagen in der Aorta und ver-
besserte die Integrita¨t der endothelialen Zellkontakte. Insbesondere verhinderte die
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Hemmung der AP-1-Aktivita¨t das Fortschreiten der aortalen Elastolyse und somit die
Scha¨digung der Gefa¨ßwand.
Das zweite Studienziel war die pra¨klinische Validierung des AAV9-Vektors, der neutral-
isierende hpNFAT Decoy ODNs als therapeutischer Ansatz in einem experimentellen
Modell der linksventrikula¨ren Hypertrophie und Herzinsuffizienz bei Ma¨usen (TAC) ex-
primiert. Die Wirkung der hpNFAT decoy ODNs nach der AAV9 Transduktion wurde
zuna¨chst wiederum in vitro mit kultivierten Zellen der HL-1 Kardiomyozytenzellinie
sowie prima¨ren neonatalen Kardiomyozyten untersucht, die mit dem pro-hypertrophen
Stimulus ET-1 behandelt wurden. Die Ergebnisse zeigten eine signifikante Hemmung
der Aktivierung des pro-hypertrophen fetalen Genprogramms fu¨r ANP und BNP sowie
eine verminderte β-MHC Proteinexpression. Daru¨ber hinaus wurde die ET-1-induzierte
und fu¨r die Hyprophie-Entstehung charakteristische Steigerung der Proteinsynthese
durch die AAV9-meditierte Bildung von hpNFAT RNA Decoy ODNs gehemmt.
Zwei Wochen vor der durch die operative Aortenkonstriktion (TAC) induzierte Myokard-
hypertrophie wurde der AAV9-Vektor systemisch injiziert. Die intrazellula¨re Synthese
der hpNFAT Decoy ODN in den Kardiomyozyten hatte eine verminderte Expression
von fetalen Genen in den transduzierten Zellen zur Folge. Zusa¨tzlich waren die Marker
der Myokardhypertrophie (Herzgewicht/Tibiala¨nge) und der Herzinsuffizienz (Lun-
gengewicht/Tibiala¨nge) bei den behandelten Ma¨usen signifikant reduziert. Gleichzeitig
konnte durch NFAT-Neutralisation mittels AAV9-Injektion bei den behandelten Tieren
die Herzfunktion deutlich verbessert und die Fibrosemarker reduziert werden.
Zusammenfassend ist festzustellen, dass die AAV-vermittelte kontinuierlich la¨nger-
fristige Decoy ODN-Bildung in Zellen des Zielorgans eine therapeutische Mo¨glichkeit
ero¨ffnet, die Expression von Genprodukten zu hemmen, welche an der Pathogenese und
Progression bestimmter Krankheiten beteiligt sind. Die vorliegende Studie hat in zwei
Tiermodellen fu¨r kardiovaskula¨re Erkrankungen erfolgreich den Nachweis der thera-
peutischen Wirksamkeit dieses Konzepts erbracht.
2Introduction
2.1 Therapeutic value of decoy oligonucleotides
Transcription factors (TF) are proteins that play a crucial role in gene regulation by bind-
ing to the promoter region of target genes and initiating transcription. One approach of
controlling abnormal gene expression in a pathological context is to target the process
of transcription. Decoy oligodeoxynucleotides (decoy ODNs) are short double stranded
DNA molecules that harbour the sequence of the TF binding site in the promoter region
of the target gene [85]. After cellular uptake, decoy ODNs bind to the TF therefore in-
hibiting transcription. Hence, this approach can be translated into therapeutic strategies
to inhibit genes involved in disease initiation or development by neutralizing specific
TFs. The main advantage of the decoy ODNs technology is that gene transcription is
not totally abolished, which is beneficial for physiological processes.
Fig. 1: The mechanism of action of TF decoy ODNs. Decoy ODNs are taken up by cells either through a carrier-
mediated mechanism or receptor-mediated endocytosis. Afterwards, they bind to the target TF and gene transcription
is inhibited. (Reproduced from [191].)
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The therapeutic effect of decoy ODNs was proven in various preclinical disease mod-
els. Strategies of blocking nuclear factor kappa-light-chain-enhancer of activated B cells
(NF-κB) through decoy ODNs were shown to be effective in attenuating respiratory
disease [118], rheumatoid arthritis [202], myocardial infarction [139], abdominal aor-
tic aneurysm [135], atopic dermatitis [144] and some types of cancer [161] in animal
models. In addition, activator protein-1 (AP-1) and signal transducer and activator of
transcription 1 decoy ODNs were shown efficient in reducing transplant vasculopathy
[189] and a dual AP-1 and SMAD decoy ODNs injection reduced fibrosis in an acute
dermal wound repair mouse model [232].
Clinical trials making use of the decoy ODNs technology are summarized in Table 2.
These studies suggest the potential of decoy ODNs to be translated into therapeutic
approaches for diverse disease models. Moreover, the low toxicity of the compounds,
suggested in clinical trials, attests for the safety of these nucleic acid drugs. More tran-
scription factors targets and delivery options have to be investigated in order to turn
decoy ODNs into effective therapies.
Fig. 2: Main clinical trials employing decoy ODNs for various disease models. Reproduced from [85].
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2.2 Adeno-associated viruses as vectors for cardiovascular gene
therapy
First isolated as a contaminant during adenovirus production in HEK-293 (human em-
bryonic kidney-293) cells [5], adeno-associated viruses (AAVs) soon became feasible
and attractive tools for gene therapy. The main advantages are the non-pathogenic nature
and low immunogenicity of the AAVs. One of the most successful clinical trials involv-
ing AAV-mediated gene transfer was designed to treat hemophilia B, which showed
that a single AAV injection led to a stable expression of the transgene and induced no
immunogenic response or toxicity in hepatocytes [147]. Moreover, an AAV-based drug
was approved for use in Europe and in the United States in 2012 for the treatment of
lipoprotein lipase deficiency [218].
2.2.1 Life cycle of AAVs
AAVs belong to the family of Parvoviridae and require the presence of other viruses,
mostly adenoviruses to replicate [145]. Other virus types such as Herpes simplex virus
type 1, human Cytomegalovirus, Vaccinia virus and human Papilloma virus type 16
were shown to assist in promoting the life cycle of AAVs. The single-stranded genome
of about 4.8 kbp contains three genes: Rep (Replication), Cap (Capsid) and aap (As-
sembly). Palindromic inverted terminal repeats (ITRs) flank the Rep and Cap regions
and play an important role in AAV packaging and replication. In addition to Rep and
Cap, AAV production requires a helper plasmid which provides adenoviral genes [43].
One of the disadvantages of AAV design is the limited capacity of packaging. The first
step required for AAV infection is represented by binding of the capsid to cell mem-
brane receptors. Several receptors have been identified, depending on the AAV serotype
investigated. AAV2 and AAV3 anchor to heparan sulfate proteoglycan, while AAV9
employs O-linked galactose [6]. Several integrin types and laminin receptor were de-
scribed as coreceptors [133]. Recently, a previously uncharacterised transmembrane
protein was shown to be an essential AAV receptor [160]. Afterwards, cell entry is
carried out through clathrin-coated endosomes. The endosomal release of AAVs occurs
after acidification of the vesicles which precedes cytoplasmatic release. Subsequent to
nuclear translocation, the ds DNA is released from the capsid and emphRep genes are
expressed. Next, the genes required for capsid assembly are synthetized inside the nu-
cleus. Subsequently, the release of the newly produced AAV particles is mediated by the
helper virus (Fig. 3) [107].
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Fig. 3: The steps of AAV infection. AAV requires co-infection with a helper virus for production of the viral genes
and generation of the progeny AAVs. Reproduced from [10].
2.2.2 AAV gene delivery for the therapy of cardiovascular disease
Cardiovascular disease represents the main cause of mortality worldwide (World Health
Organization).The understanding of molecular mechanisms leading to various types
of cardiovascular complications enabled development of new therapeutic strategies.
Surgery or pharmacological treatment offer solely temporary beneficial effects and
symptom relief but in most of the cases do not provide a long-term solution [210].
Gene therapy using AAV as gene delivery systems was shown to be a feasible approach
by allowing the modulation of pathogenic gene levels.
Until now, 12 AAV serotypes have been characterized, each with distinctive tissue
tropism. AAV9 was shown to have elevated heart specificity, as well as high transgene
expression in cardiomyocytes, being a valuable tool for myocardial gene delivery [239].
AAV8 also led to cardiomyocyte transduction, while AAV1 and AAV6 efficiently trans-
duce neonatal mouse myocytes in vivo [214]. The performance of each AAV serotype
is highly dependent on the delivery route. Although systemic intravenous injection was
demonstrated to lead to cardiomyocyte transduction in mice, large animals require more
advanced delivery systems for successful infection. Retrograde injection through the
coronary veins was proven to be a feasible approach of gene delivery in pigs [162].
Directed injection into the myocardium was also shown to lead to transgene expres-
sion in large animals [153]. Moreover, ultrasound-directed microbubbles improved the
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directed myocardial delivery of the AAVs and increased significantly cardiomyocyte
transduction efficiency. In addition, substances that induce capillary permeability, such
as vascular endothelial growth factor (VEGF), serotonin or histamine were employed
to allow higher contact of AAVs and cardiomycytes by allowing the vector to pass the
endothelial barrier [168].
Recent advances in AAV research has made it possible to obtain highly specific vectors
which transduce the target organ. For example, small ligands or peptides have been in-
troduced in capsid structure in order to direct AAV to endothelial cells [188, 217, 208].
Another approach which was proven to be successful in improving the organ specificity
is the use of bispecific antibodies or biotin, that interacts with receptors on the cell mem-
brane [43].
In addition, the use of AAV vectors with cardiac-specific promoters have been devel-
oped, highly improving transduction specificity. These include α-myosin heavy chain,
cardiac troponin and myosin light chain 2 promoters [234].
Depending on the disease model, different AAV-based strategies have been employed:
Stimulation of therapeutic angiogenesis
Pro-angiogenic factors VEGF-165 and angiopoietin-1 overexpression through AAV9
injection was shown to lead to increased endothelial cell proliferation and therefore to
the formation of new blood vessels in a murine model of myocardium infarction [194].
Moreover, cardiomyocyte apoptosis was dramatically reduced. In order to minimize the
possible side effects that could occur after the overexpression of the pro-anigiogenic
factors, a hypoxia-responsive element was introduced, to induce transgene expression
only in hypoxic conditions [194]. Another approach consisted of AAV9-mediated deliv-
ery of angiogenin and human growth hormone, which significantly attenuated infarction
size [10].
Gene therapy of heart failure
The promising results obtained by SERCA2a (Sarcoplasmic/endoplasmic reticulum
Ca2+ ATPase 2a) overexpression in pre-clinical animal models [23] was followed by
CUPID phase 2b clinical trial [240]. However, the trial failed to reach its end point and
no significant differences were noted between treated and placebo groups (clinical trial
number NCT02346422). In another study, AAV9-mediated downregulation of phospho-
lamban, a SERCA2a inhibitor, inhibited heart failure in mice [195].
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AAV-targeting of the β-adrenergic receptor was also shown to be a novel approach
for the treatment of heart failure. The protein level of GRK2 (G protein-coupled re-
ceptor kinase 2) in cardiomyocytes was shown to be upregulated under stress condi-
tions and desensitizes β-adrenergic pathway, leading to decompensated cardiomyopa-
thy [166]. Downregulation of GRK2 through AAV9 transduction was shown to inhibit
myocardium hypertrophy transition into decompensated heart failure [185].
Correction of genetic cardiomyopathies
Several types of genetic cardiomyopathies have been described [24]. For these types
of disease, AAV9-mediated gene transfer is advantageous due to long-term correction
of the genetic defect. Through this method, the attenuation of Duchenne muscular dys-
trophy related cardiomyopathy was demonstrated in large animals [15]. Silencing of
mutant MHC transcripts which lead to heart failure by using RNA interference was
also proven successful in mediating gene expression in cardiomyocytes and exerting a
positive effect on cardiac function [97].
Gene therapy for aortic diseases
Targeting inflammation was shown to reduce the size of atherosclerotic plaques. For
example, AAV2/8-mediated gene transfer of forkhead box P3, a marker of regulatory
T cells, decreased aortic wall thickness and lowered systolic blood velocity as com-
pared to control animals [28]. Additionally, overexpression of interleukin-10 and STAT-
3 by AAV8 transduction of the aorta decreased atherogenesis in low density lipoprotein
receptor-knockout mice [27].
2.3 Marfan syndrome
2.3.1 General aspects
Marfan syndrome, first described in 1896 by Dr. Antoine Marfan, is a rare genetic dis-
order (2 individuals in 10,000, according to OMIM), caused by a loss-of-function mu-
tations in the fibrillin-1 gene (FBN1). This disease affects the skeletal, ocular and most
importantly, the cardiovascular systems. Cardiac complications observed in Marfan syn-
drome patients include aortic dilatation, thickening and prolapse of the aortic valves, as
well as dilated cardiomyopathy [101], [192], while the main mortality cause constitutes
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aortic aneurysm dissection [101].
More than 600 types of FBN1 mutations have been described, with 25 % of the cases
occuring de novo [169]. Fibrillin-1 is a 350 kDa glycoprotein and has been shown to
be one of the main components of the elastic fibers in blood vessels [212]. Moreover, it
was proven to be a structural substrate for elastin deposition and assembly during devel-
opment [42]. The internal elastic fibers anchor endothelial cells through integrins [222],
providing integrity to the endothelial monolayer (Fig. 4).
Fig. 4: The interaction between vascular cells and elastic fibers. The close proximity of endothelial cells, SMCs
and fibers shows the structural role of fibrillin-1 in the vessel. Reproduced from [223].
2.3.2 The importance of TGF-β and the AP-1 transcription factor family
Apart from its structural role, fibrillin-1 has a major effect on transforming growth fac-
tor β (TGF-β) bioavailability, as depicted in Fig. 5. TGF-β factors are synthesized as
precursor proteins, consisting of the latency associated peptide (LAP) in the N-terminal
domain, and the growth factor in the C-terminal domain. Two precursor proteins dimer-
ize through disulfide bonds and are afterwards cleaved in the Golgi apparatus leading
to the formation of the small latex complex (SLC). Under these conditions, the mature
TGF-β is non-covalently bound to the LAP. The SLC is bound to latent TGF-β binding
protein (LTGBP), constituting the complex called large latent complex (LLC). The LLC
can bind to extracellular matrix through the C-terminal domain of the LTGP. Through
this mechanism, the inactive TGF-β is localized close to the microfibrils and interacts
with fibrillin, which in turn can affect its activation status [99], [9], [236].
Functional fibrillin can bind TGF-β into an inactive form, whereas mutant fibrillin, char-
acteristic for Marfan syndrome, causes an increase in its bioavailability and hence ac-
tivity. Dysfunctional TGF-β signalling was shown to be the cause for the phenotype
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Fig. 5: The mechanism of TGF-β processing and the role of microfibrils in TGF-β inactivation. Reproduced
from [200].
observed in the mgR/mgR mouse model, including aortic aneurysm formation, skele-
tal defects, mitral valve prolapse and pulmonary complications [150, 37, 149]. These
studies suggest that Marfan syndrome is not only a structural defect of the connective
tissue caused by mutant fibrillin-1 protein and disorganized microfibrils, but is caused
by elevated TGF-β activity.
Consistently, an increased TGF-β protein level in plasma isolated from mgR/mgR mice
was measured in comparison to wild type littermate controls [130]. Moreover, TGF-β
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concentration correlated with the size of the aortic diameter. The same trend was ob-
served in human samples isolated from Marfan patients, who had significantly higher
amounts of circulating TGF-β related to healthy donors [130].
The importance of TGF-β in the pathogenesis of Marfan syndrome was confirmed by
administration of a TGF-β neutralizing antibody to young (4 weeks old) mgR/mgR mice
before aortic aneurysm formation was apparent. The treated mice presented with a sig-
nificant decrease in the aortic root diameter, as compared to the placebo-treated group.
Moreover, the aortic wall architecture was significantly improved, as suggested by the
decrease in the number of elastin breaks in aortic cryosections. [80].
The non-canonical TGF-β signalling pathway was shown to be critical for the aortic
aneurysm progression in the context of Marfan syndrome [88]. Fibrillin-1 deficient mice
were confirmed to have increased JNK (c-Jun N-terminal kinase) activity, which phos-
phorylates Jun proteins [88]. As a consequence, AP-1 (activator protein-1) target genes
are activated. Other studies confirm this hypothesis, showing that AP-1 transcription
factor family is activated by TGF-β [211].
AP-1 induces the expression of matrix metalloproteinases (MMPs), as well as pro-
inflammatory cytokines, which were demonstrated to be increased in the context of
Marfan syndrome [94]. Significantly higher protein levels of gelatinases MMP2 and
MMP9 were shown to be present in the plasma and aortic tissue isolated from mgR/mgR
mice, as compared to wild type controls [35]. Moreover, mgR/mgR mice treatment with
doxycycline, a non-specific MMP inhibitor, led to a significant increase in the mean
survival rate of the Marfan mice by decreasing the elastin fibers degradation through
diminishing MMP activity [228].
2.3.3 Current treatment options
Before the implementation of open-heart surgery, life expectancy of Marfan syndrome
patients was 45 years [141], with the leading cause of death being represented by aortic
aneurysm rupture. Recently, due to advances in the surgical management of patients,
the life span of Marfan patients was significantly increased to over 60 years [59]. The
1-year mortality rate of prophylactic surgery in case of extreme dilatation of the aorta
(larger than 50 mm) is under 2% [38].
Pharmaceutic therapy for Marfan patients involves β-adrenergic blockade through
propanolol administration. The treated group showed decreased rate of aortic root di-
latation in comparison to controls by negative chronotropic and inotropic effects of the
drug and therefore reducing the stress on aortic wall.
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Losartan, an angiotensin type II receptor antagonist, was previously proven to reduce
TGF-β plasma levels in a mouse model of hypertrophic cardiomyopathy [119] and allo-
graft nephropathy [26]. The efficiency of this drug was therefore studied in the context
of Marfan syndrome. Losartan solution was injected either pre- or post-natally, leading
to the normalization of aortic wall structure, which was undistinguishable to the wild
type control [80].
2.4 Heart hypertrophy and heart failure
2.4.1 General aspects
Heart failure is defined as a syndrome in which heart function cannot support the
metabolic requirements of the tissues. Common factors that trigger heart failure are
hypertension, myocardial infarction, coronary heart disease, inflammation and genetic
predisposition. Other conditions that increase the risk of heart failure are diabetes, thy-
roid disorders and the use of cardiotoxic substances [125]. Heart failure affects 3-4 % of
the people over 45 years of age in the Western world. With increasing rates of diabetes
and obesitiy, as well as with an aging population, the rates of this disease are expected to
grow [13]. Currently, no cure can reverse heart failure, and the prognosis of the patients
remains extremely poor, with a mortality of 1 in 3 patients one year after diagnosis [13].
In the presence of biomechanical stress, the myocardium undergoes the process of hy-
pertrophy which is an adaptive response to the increase in wall tension. This first step
consists of increase in myocyte dimensions, elevated protein translation rate and reac-
tivation of fetal gene program [64]. Cardiomyocytes are terminally differentiated cells
and stop dividing soon after birth. Therefore, stress stimuli cause growth in cardiomy-
ocyte size, without increase in cell number and re-activation of the fetal gene program,
atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and MHC-β which are
considered markers of hypertrophic response. Moreover, altered protein translation rate
is observed, caused by increase in the ribosome biogenesis, as well elevated translation
capacity [83]. On the functional level, reduced cardiomyocyte contractility and slow re-
laxation is observed. [84]. On the other hand, cardiomyocyte loss following myocardial
infarction leads to inflammatory cell infiltration and alteration in the extracellular ma-
trix, processes that contribute to infarct healing.
Other cell types participate in the development of heart disease. Fibroblast prolifera-
tion increase the extracellular matrix production, SMCs promote vascular stiffness and
endothelial cells become dysfunctional [22]. In turn, heart function rapidly deteriorates
2.4 Heart hypertrophy and heart failure 20
and the risk of sudden death increases [48].
In contrast, physiological hypertrophic response manifests through distinct mechanisms
and is a reversible process [7]. Stress induced by exercise or pregnancy preserves or
even enhances contractility. Additionally, a normal sarcomere organization is observed
[84]. Physiological hypertrophy does not involve fibrosis or cardiomyocyte apoptosis.
Pathological heart hypertrophy is a progressive disease. As it advances, myocardium
function decreases and the patient symptoms worsen. As cardiac hypertrophy becomes
maladaptive, cardiomyocyte death is observed, through apoptosis and necrosis. Au-
tophagy is also noted, accompanying cell death [216]. Pathological extracellular ma-
trix accumulation is another hallmark of heart failure. This process is driven by car-
diac fibroblasts, which proliferate in response to the stress stimuli and differentiate into
myofibroblasts. Collagen1, collagen3 and fibronectin are the main constituents of the
extracellular matrix observed in heart failure. Fibrosis can be detected in between cells
(interstitial fibrosis), in the perivascular areas or replacing lost cardiomyocytes. Exten-
sive fibrosis explains the arrhythmias that occur in heart failure patients [180].
Some studies showed that hypertrophy development in a pressure-overload mouse
model does not improve cardiac function, concluding that targeting hypertrophy can
be relevant in heart failure prevention [58]. Moreover, increased left ventricular mass
was proven to correlate with worse prognosis in patients at risk of developing heart
failure [116]. Therefore, the mechanisms leading to myocardial hypertrophy have been
intensively studied in order to advance new therapeutic strategies.
2.4.2 The role of NFAT in the development of heart hypertrophy
A number of transcription factors have been proven to play a central role in the devel-
opment of maladaptive cardiac hypertrophy. An enhanced activity of nuclear factor of
activated T cells (NFAT), myocyte enhancer factor-2 (MEF-2), GATA and HAND tran-
scription factor families was observed during pathological remodelling in heart failure
[3].
Chronic stress on the myocardium leads to increased cytosolic Ca2+ concentration,
which is a key molecule that induces pro-hypertrophic signalling pathways [235] and
regulates physiological processes such as EC-coupling, metabolism and cell death [52].
Reduced SERCA activity and increased Ca2+ leak through ryanodine receptor 2 (RyR2)
are the main causes of elevated Ca2+ concentration in the cytoplasm. Moreover, myocyte
hypertrophy causes an influx of Ca2+ through voltage-gated L-type Ca2+ channel or IP3
(inositol 1,4,5-trisphosphate) receptor. Continuous increase in cytosolic Ca2+ amount
leads to the activation of calcineurin/NFAT and Ca2+ calmodulin-dependent protein ki-
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nase II (CaMKII) pathways [52], as depicted in Fig. 6.
The role of calcineurin signalling was first characterized in the immune system. This
pathway is activated by elevations in Ca2+ concentrations [60]. Calcineurin dephos-
phorylates NFAT isoforms 1-4, enabling their translocation to the nucleus in the non-
phosphorylated form and therefore inducing the transcriptional activity of these proteins
[209].
The importance of calcineurin-NFAT pathway in the development of heart hypertrophy
was previously demonstrated in transgenic mice by using gain and loss of function stud-
ies. Cardiac-specific overexpression of the catalytic subunit of calcineurin under control
of the α-MHC promoter induced an elargement of myocardium size, reactivation of fe-
tal gene program and developement of heart failure[137]. In addition, transgenic mice
expressing only the active form of NFAT3, located constitutively in the nucleus, exhibit
a similar phenotype including cardiac fibrosis, cardiomyocyte hypertrophy and dilated
cardiomyopathy [137]. Administration of the immunosuppressant drug cyclosporin A
could reduce the severity of heart failure in these mice, further proving the importance of
this pathway. Moreover, NFATc2 deletion in mice caused resistance to TAC (transverse
aortic constriction)-induced heart hypertrophy and reduction in heart failure parameters
[16].
Calcineurin-NFAT pathway was shown to play a major role in pathological, but not
physiological cardiac hypertrophy. Pathological stimulation through myocardium in-
farction caused a significant increase in nuclear translocation of NFAT, while exercise-
induced hypertrophy did not [220]. In addition, VIVIT, a specific NFAT inhibitory pep-
tide, was proven to be effective in preventing heart hypertrophy in a pressure-overload
rat model. The systemic application of the compound led to downregulation of fetal
gene program and to a significant improvement in heart function parameters [112].
2.4.3 Current treatment options
Treatment strategies for heart failure include pharmacological drug treatments, implan-
tation of devices that improve heart contractility and surgery [110].
Angiotensin converting enzyme (ACE) inhibitors were first proven effective in treating
hypertensive disease, but their therapeutic effect was later shown in slowing the mal-
adaptive remodelling process in heart failure. This class of compounds could decrease
the hospitalization due to congestive heart failure and decreased the mortality rate [233].
Ramipril, an ACE inhibitor drug, was shown to decrease the cardiovascular events in the
case of diabetic patients with high risk of myocardial infarction and heart failure (HOPE
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Fig. 6: Calcium-dependent signalling during cardiomyocyte hypertrophic response. CaN: calcineurin, HDAC:
histone deacetylase, GPCR: G proteincoupled receptor, L-CaC: voltage-gated L-type Ca2+ channel, NCX: sodium-
calcium exchanger, PKC: protein kinase C, PKD: protein kinase D, PLC: phospholipase C, SOCaC: store-operated
Ca2+ channel, SR: sarcoplasmic reticulum. Reproduced from [52].
clinical trial) [41].
Inhibitory drugs that act on β-adrenergic signalling are currently used to treat hyper-
tension, arrhythmias and patients presenting signs of heart failure [227]. β-Blockers
reduce the severity of symptoms, improve heart function and were shown to increase
the survival rate of patients [227]. With progression of heart failure, diuretics are used
to diminish the symptoms associated with fluid retention [227].
Induction of signalling pathways associated with physiological hypertrophy through ex-
ercise was proven to be a safe and beneficial modality of improving maladaptive heart
hypertrophy and failure [148].
2.5 Aims of the projects
The main goal of the projects is the development of new therapeutic strategies for in-
hibiting aortic aneurysm formation in Marfan syndrome (first project) and heart hyper-
trophy and heart failure (second project), by means of decoy ODNs that neutralize the
main transcription factors involved in the progression of the two diseases.
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Previous studies showed the efficiency of decoy ODNs for therapeutic purposes in vari-
ous disease models. However, the application of nucleic drugs was made locally, which
requires continous administration of the compund to inhibit the disease progression. In
terms of further clinical treatments, this approach is not always feasible. Therefore, the
establisment of a long-term AAV-mediated delivery of the decoy ODNs into the target
tissue is more relevant in a medical context.
2.5.1 Aims of Marfan syndrome project
(1) Design of a hp (hairpin) AP-1 decoy ODN and its in vitro validation in isolated pri-
mary aortic mgR/mgR SMCs.
(2) Development of a long-term expression system of the hpAP-1 decoy ODNs in target
SMCs by means of AAV transduction.
(3) Ex vivo transduction of mgR/mgR thoracic aortic grafts with AAV9SLR
(4) Analysis of the effects of aortic grafts transduction with AAV9SLR expressing
hpAP-1 decoy ODNs on AP-1 target genes, inflammatory cells infiltration, tight junc-
tions integrity in endothelial cell layer and most importantly, on elastin architecture.
2.5.2 Aims of heart hypertrophy project
(1) Establishment of an in vitro hypertrophy model using HL-1 cells and primary neona-
tal cardiomyocytes.
(2) Design of a hpNFAT decoy ODN and evaluation of its in vitro effects on cardiomy-
ocyte hypertrophy.
(3) Development of a long-term expression system of the hpNFAT decoy ODNs in car-
diomyocytes by AAV6 transduction in vitro, and AAV9 tail vein injection in vivo.
(4) Assessment of the in vivo effects of systemic injection of AAV9 expressing hpNFAT
decoy ODNs on TAC-induced myocardial hypertrophy and heart failure.
3Materials
3.1 Chemicals
3.1.1 Stimulants, inhibitors and substrates
Stimulants, inhibitors and substrates used in the present study are listed in Tab. 1.
Tab. 1: List of cell culture stimulants and inhibitors
Reagent Provider Concentration
IL1-β R&D Systems, Wiesbaden, Germany 20 ng/mL
ET-1 Sigma-Aldrich, Munich, Germany 100 nM
MLS000048818 Mcule, Budapest, Hungary 10 µmol/L
520 MMP FRET Substrate XIV Anaspec, Go¨ttingen, Germany 0.1 µg/mL
Dihydroethidium Sigma-Aldrich, Munich, Germany 0.1 µmol/L
2,7-Dichlorofluorescin diacetate Sigma-Aldrich, Munich, Germany 5 µmol/L
Alamar Blue Sigma-Aldrich, Munich, Germany 10 %
3.1.2 Antibodies
A list of primary and secondary antibodies are given in Tab. 2 and Tab. 3 respectively.
The corresponding working dilutions and providers are also included. (ICC: immuno-
cytochemistry, IHC: immunohistochemistry, WB: Western Blot).
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Tab. 2: List of primary antibodies
Reactivity Provider/Catalogue Number Dilution Application
EGFP Abcam, Cambridge, UK 1:1000 ICC, IHC
ab111258
F4/80 Dianova, Hamburg, Germany 1:500 IHC
MOF4PU
CD31 Santa Cruz, Heidelberg, Germany 1:500 IHC
sc-18916
MMP2 Abcam, Cambridge, UK 1:1000 IHC
ab37150
MMP9 Abcam, Cambridge, UK 1:1000 WB, ICC,
ab38898 IHC
MMP12 Abcam, Cambridge, UK 1:1000 IHC
ab137444
MyHC-β Santa Cruz, Heidelberg, Germany 1:300 ICC, IHC
sc-20641
NFAT5 Abcam, Cambridge, UK 1:500 ICC
ab105886
SMA Abcam, Cambridge, UK 1:1000 IHC
ab5694
ZO-1 Thermo Fischer Scientific, Darmstadt, Germany 1:500 IHC
61-7300
Phospholamban Badrilla, Leeds, UK 1:1000 WB
A010-12
Puromycin Merck Millipore, Darmstadt, Germany 1:1000 ICC, IHC
MABE343
Tab. 3: List of secondary antibodies
Secondary antibody Provider Reactivity Dilution Application
Donkey IgG - Cy2 Dianova, Hamburg, Germany Mouse 1:300 ICC, IHC
Donkey IgG - Cy5 Dianovag, Hamburg, Germany Mouse 1:300 ICC, IHC
Goat IgG - Cy3 Dianova, Hamburg, Germany Rat 1:300 IHC
Goat IgG - Cy5 Dianova, Hamburg, Germany Rabbit 1:300 ICC, IHC
Goat IgG - HRP Sigma-Aldrich, Munich, Germany Rabbit 1:5000 WB
Goat IgG - HRP Sigma-Aldrich, Munich, Germany Mouse 1:5000 WB
3.1.3 Cloning enzymes
All enzymes used in cloning experiments were purchased from New England Biolabs
(Frankfurt am Main, Germany).
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Tab. 4: List of enzyme used in cloning experiments
Enzyme Catalogue number Recognised DNA sequence
KasI R0544S 5′-GGCGCC-3′
3′-CCGCGG-5′
XhoI R0146S5 5′-CTCGAC-3′
3′-GAGCTC-5′
Antarctic Phosphatase M0289S -
T4 DNA Ligase M0202S -
3.2 Oligonucleotides
3.2.1 Primers
Primers were purchased from Biomers (Ulm, Germany) or as a mix of forward and
reverse primer mix (QuantiTect Primer Assays, Qiagen, Hilden, Germany), as shown in
Tab. 5.
Tab. 5: List of primer sequences used in the present study.
Gene Primer sequence/Catalogue Number Annealing
ANP Qiagen (QT00250922) 55 °C
BNP Qiagen (QT00107541) 55 °C
CTGF Qiagen (QT00096131) 55 °C
EGFP
forward: 5′-AAGCAGCACGACTTCTTCAAGTC-3′
reverse: 5′-TCGCCCTCGAACTTCACCTC-3′
60 °C
H1 forward TCGCTATGTGTTCTGGGAAA (Sequencing
primer)
HSP70
forward: 5′-CCCGGTGTGGTCTAGAAAACA-3′
reverse: 5′-CCATGAAGAAGACTTTAAATAACCTTGAC-3′
57 °C
MCP-1
forward: 5′-TTCCTCCACCACCATGCAG-3′
reverse: 5′-CCAGCCGGCAACTGTGA-3′
60 °C
MMP9 Qiagen (QT00108815) 55 °C
RCAN1 Qiagen (QT01053430) 55 °C
RPL32
forward: 5′-GGGAGCAACAAGAAAACCAA-3′
reverse: 5′-ATTGTGGACCAGGAACTTGC-3
55 °C
SMIT Qiagen (QT00341355) 55 °C
TGF-β Qiagen (QT00145250) 55 °C
3.2.2 Decoy ODNs
Decoy ODNs were purchased from Biomers (Ulm, Germany). For decoy ODNs uptake
experiments, the DNA was labelled with Atto590 at 5′ end position.
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Tab. 6: Sequence of hp decoy ODNs used in the present study
Decoy ODN Sequence
hpAP-1 cons 5′-CTGCGGTGCTGACTCAGCACGAAACGTGCTGAGTCAGCACCGCAG-3′
hpAP-1 mut 5′-CTGCGGTGCTTACTTAGCACGAAACGTGCTAAGTAAGCACCGCAG-3′
hpNFAT cons 5′-GAGTGGAAACATACAGCCACTGAAACAGTGGCTGTATGTTTCCACTC-3′
hpNFAT mut 5′-GAGCTTAAACATACAGCCACTGAAACAGTGGCTGTATGTTTAAGCTC-3′
3.2.3 Molecular beacons
Molecular beacons (purchased from Biomers, Ulm, Germany) were used in F.I.S.H.
(fluorescent in situ hybridization) experiments and the sequences were designed as com-
plementary to the decoy ODNs. BHQ: black hole quencher.
Tab. 7: Sequence of molecular beacons used in F.I.S.H. experiments
Beacon Sequence
hpAP-1 cons 5′-CTGCGGTGCTGACTCAGCACGAAACGTGCTGAGTCAGCACCGCAG-3′
Modifications: 5′ - Cy5; 3′ - BHQ
hpNFAT cons 5′-GAGTGGAAACATACAGCCACTGAAACAGTGGCTGTATGTTTCCACTC-3′
Modifications: 5′ - Cy5; 3′ - BHQ
3.3 Plasmids and AAVs
A list of plasmids used for AAV production is shown in Tab. 8. Individual sequences of
Tab. 8: List of plasmids used in the present study
Plasmid Description Ref.
pDP9rs Derivate from pDP2rs, containing AAV9 capsid gene. [73]
Used as a helper plasmid for AAV9 production.
p5E18-VD9-SfiI1959-SLR Capsid plasmid used for AAV9SLR production [208]
pDS1-H1-AP1cons-EGFP hpAP-1 cons RNA decoy ODNs generating vector This study
pDS1-H1-AP1mut-EGFP hpAP-1 mut RNA decoy ODNs generating vector This study
pDS1-H1-NFATcons-EGFP hpNFAT cons RNA decoy ODNs generating vector This study
pDS1-H1-NFATmut-EGFP hpNFAT mut RNA decoy ODNs generating vector This study
decoy ODNs for cloning into pDS1-H1-AP1cons-EGFP plasmid were ordered as gene
synthesis (GeneArt Gene synthesis, Thermo Fischer Scientific, Darmstadt, Germany).
For insert isolation, the restriction sites for KasI (5′) and XhoI (3′) enzymes were added
to flank the designed sequence as shown in Tab. 9.
3.3 Plasmids and AAVs 28
Tab. 9: List of gene synthesis sequences. Sequences recognised by restriction enzymes are presented in italic and
decoy ODN sequences are shown in bold.
Plasmid Sequence
P-AP1 cons 5′-AGGCGCCCTGCAATATTTGCATGTCGCTATGTGTTCTG
GGAAATCACCATAAACGTGAAATGTCTTTGGATTTGGGA
ATCTTATAAGTTCTGTATGAGACCACAGTCGAC
CTGCGGTGCTGACTCAGCACGAAACGTGCTGAGTCAGCACCGCAG
CACCGCAGTTTCGACCTCGAGA-3′
P-AP1 mut 5′-AGGCGCCCTGCAATATTTGCATGTCGCTATGTGTTCTG
GGAAATCACCATAAACGTGAAATGTCTTTGGATTTGGGA
ATCTTATAAGTTCTGTATGAGACCACAGTCGAC
CTGCGGTGCTTACTTAGCACGAAACGTGCTAAGTAAGCACCGCAG
CACCGCAGTTTCGACCTCGAGA-3′
P-NFAT cons 5′-AGGCGCCCTGCAATATTTGCATGTCGCTATGTGTTCTG
GGAAATCACCATAAACGTGAAATGTCTTTGGATTTGGGA
ATCTTATAAGTTCTGTATGAGACCACAGTCGAC
GAGTGGAAACATACAGCCACTGAAACAGTGGCTGTATGTTTCCACTC
CACCGCAGTTTCGACCTCGAGA-3′
P-NFAT mut 5′-AGGCGCCCTGCAATATTTGCATGTCGCTATGTGTTCTG
GGAAATCACCATAAACGTGAAATGTCTTTGGATTTGGGA
ATCTTATAAGTTCTGTATGAGACCACAGTCGAC
GAGCTTAAACATACAGCCACTGAAACAGTGGCTGTATGTTTCCACTC
CACCGCAGTTTCGACCTCGAGA-3′
AAV serotypes were chosen according to the transduction specificity for particular cell
types. A summary of AAVs used in the study is shown in Tab. 10.
Tab. 10: List of AAV serotypes used in the present study
AAV serotype Target cells MOI Type of transduction
AAV9SLR SMCs, ECs 105 vp/cell In vitro
1012 vp/mouse Ex vivo
AAV2RGD, AAV2APV SMCs 105 vp/cell In vitro
AAV2NDV, AAV2DLG
AAV9NDV, AAV9RGD SMCs 105 vp/cell In vitro
AAV6 HL-1 cells 105 vp/cell In vitro
AAV9 Adult cardiomyocytes 1012 vp/mouse In vivo
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3.4 Growth media and buffers
All cell culture reagents were purchased from Thermo-Fischer Scientific (Darmstadt,
Germany) unless otherwise noted.
Tab. 11: List of growth media
Growth medium/Cell type Composition
Complete Claycomb medium Claycomb medium (Sigma-Aldrich)
(HL-1 cells) 5 % FBS (Sigma-Aldrich)
2 µ/L L-Glutamine
100 U/mL Penicillin
100 µg/mL Streptomycin
100 µmol/L Norepinephrine (Sigma-Aldrich)
Complete DMEM medium Low glucose DMEM
(Primary aortic SMCs) 15% FBS
2 mmol/L L-Glutamine
100 U/mL Penicillin
100 µg/mL Streptomycin
Complete M199 medium M199 medium
(Neonatal cardiomyocytes) 10% FBS
10 µmol/L Norepinephrine
100 U/mL Penicillin
100 µg/mL Streptomycin
LB medium (liquid) 10% bacto-tryptone
(Competent bacteria) 5% yeast extract
10% NaCl
(For selection: 100 µg/mL Ampicillin, Sigma-Aldrich)
LB medium (agar) 10% bacto-tryptone
(Competent bacteria) 5% yeast extract
10% NaCl
10 % agar
100 µg/mL Ampicillin, (Sigma-Aldrich)
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Tab. 12: List of buffers used in our study
Buffer/Purpose Composition
Heart buffer Ca2+/Mg2+ free HBSS, pH=7.4
(Neonatal cardiomyocytes isolation) 10 mmol/L HEPES
100 U/mL Penicillin
100 µg/mL Streptomycin
NCM digestion buffer Ca2+/Mg2+ free HBSS, pH=7.4
(Neonatal cardiomyocytes isolation) 10 mmol/L HEPES
0.5 µg/mL Trypsin (Sigma-Aldrich)
0.3 mg/mL Collagenase II (Worthington)
100 U/mL Penicillin
100 µg/mL Streptomycin
Digestion inhibition solution Ca2+/Mg2+ free HBSS, pH=7.4
(Neonatal cardiomyocytes isolation) 10 mmol/L HEPES
10 % FBS
100 U/mL Penicillin
100 µg/mL Streptomycin
Ca2+-free Tyrode solution 140 mmol/L NaCl
(Adult cardiomyocytes isolation) 5.4 mmol/L KCl
1.1 g MgCl2
5 mmol/L HEPES
1 mmol/L Na2HPO4
10 mmol/L Glucose
ACM digestion buffer Ca2+-free Tyrode solution
(Adult cardiomyocytes isolation) 50 µmol/L Ca2+
1 mg/mL Collagenase II
2 mg/mL Protease (Sigma-Aldrich)
TEN buffer 40 mmol/L Tris-HCl pH 7.5
(Decoy ODNs solubilization) 1mmol/L EDTA pH 8.0
150 mmol/L NaCl
Zinc fixative 0.1 M Tris-HCl pH=7.4
(Tissue fixation) 3.2 M Ca2+ acetate
35.9 ZnCl2
22.8 M Zn 2+ acetate
Blocking and permeabilization buffer PBS pH=7.4
(ICC, IHC) 3 % BSA
0.05% Triton-X100
Complete RIPA buffer RIPA buffer (Sigma-Aldrich)
(Total Protein extraction) 50 M Pefabloc SC (Sigma-Aldrich)
25 mol/L Protease inhibitors
0.1 M DTT
12 % Running acrylamide gel 1.2 mL H2O
(Western Blot) 2 mL Tris-HCl pH=8.8
1.7 mL Acrylamide
50 µL SDS 20 %
Continued on next page
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Tab. 12 – continued from previous page
Buffer/Purpose Composition
50 µL 10 % APS
3 µL TEMED
Stacking gel 1.1 mL H2O
(Western Blot) 188 µL Tris-HCl pH=6.8
200 µL Acrylamide
15 µL SDS 20 %
15 µL APS
Running buffer 25 mmol/L Tris HCl, pH 8.3
(Western Blot) 192 mmol/L Glycine
0.1 % SDS
15 µL 10 % APS
1.5 mL TEMED
Transfer buffer 25 mmol/L Tris HCl, pH=8.3
(Western Blot) 192 mmol/L Glycine
Tris-buffered Saline (TBS) 0.5 M Tris-HCl
(Western Blot) 1.5 M NaCl
Blocking buffer TBS
(Western Blot) 0.05 % Tween 20
5 % Non-fat dry milk (Roth)
Gelatin running gel Acrylamide 1 mL
(Getalin zymography) 1.25 mL Tris-HCl pH=8.8
50 µL SDS 1%
2 mL Gelatin 5 mg/mL
0.65 mL H2O
5 0µL APS 10 %
5 µL TEMED
Non-reducing sample buffer 5 mL Tris-HCl pH=6.8
(Gelatine zymography) 5 mL Glycerol
1g SDS
0.35 g Bromphenol blue
Wash buffer 0.1 M NaCl
(Gelatine zymography) 50 mmol/L Tris-HCl pH=7
0.025 % Triton X-100
Incubation buffer 10 mmol/L CaCl2
(Gelatine zymography) Tris-HCl pH=7
Staining buffer 50% Methanol
(Gelatine zymography) 7% Acetic acid
43 % H2O
0.001 % Comassie Brilliant Blue
Saline-sodium citrate buffer 20x 4 M NaCl
(F.I.S.H.) 100 mmol/L EDTA
200 mmol/L Tris-HCl pH 7.5
100 mmol/L NaH2PO4
Continued on next page
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Tab. 12 – continued from previous page
Buffer/Purpose Composition
Denhardt’s solution 100x 10 g ficoll
(F.I.S.H.) 10 g polyvinylpyrrolidine
10 g BSA
500 mL sterile RNase free H2O
Hybridization buffer 50% deionized formamide (Sigma-Aldrich)
(F.I.S.H.) 4x SSC
5x Denhardt’s solution
2.5 mg/mL Salmon DNA (Thermo Fischer Scientific)
0.5 mg/mL Yeast tRNA (Sigma-Aldrich)
TBE buffer 90 mmol/L Tris-HCl pH=7.5
(Agarose gel electrophoresis) 90 mmol/L Boric acid
4 mmol/L EDTA, pH=8
3.5 Kits
A list of kits used in the present study is shown in Tab. 13.
Tab. 13: List of kits used in our study
Product Supplier/Catalogue number
QIAprep spin miniprep kit Qiagen, Hilden, Germany (27104)
Maxiprep kit Qiagen, Hilden, Germany (740424.10)
ZymoPURE Plasmid Gigaprep Kit Zymo Research, Freiburg, Germany (D4204)
QIAquick Gel Extraction Kit Qiagen, Hilden, Germany (28704)
DNeasy Blood & Tissue Kits Qiagen, Hilden, Germany (69504)
RNAeasy mini kit Qiagen, Hilden, Germany (74104)
Sensiscript RT kit Qiagen, Hilden, Germany (205211)
QuantiTect SYBR Green kit Qiagen, Hilden, Germany (204243)
Brain Natriuretic Peptide EIA Kit Sigma-Aldrich, Munich, Germany (RAB0386-1KT)
Elastic Stain Kit Sigma-Aldrich, Munich, Germany (HT25A-1KT)
DCTM Protein Assay Bio Rad, Munich, Germany (5000111)
4Methods
4.1 Cell culture
4.1.1 Isolation and culture of primary SMCs
For the isolation of primary aortic SMCs, thoracic aorta of fibrillin-1 deficient mice
(mgR/mgR) was used (reference number T-17/14, animal experiments number 35-
9185.81/G-52/17). Mice were sacrificed by CO2 inhalation, the chest was cleaned with
70 % ethanol before opening and the heart was exposed. Next, 5 mL of cold sterile NaCl
solution (Braun, Melsungen, Germany) was perfused through the left ventricle using a
23 gauge needle syringe in order to remove the blood present in the aorta. The thoracic
aorta was isolated, cleared from fat and connective tissue and cut into small pieces un-
der sterile conditions in complete DMEM medium (Tab. 11, page 29). The tissue pieces
were incubated at 37 °C, 5% CO2 for 24 h in the presence of 100 µmol/L Collagenase
I (Worthington Biochemical Corporation, Lakewood, USA). Afterwards, medium was
replaced and explants were further cultured until cells reached 80% confluency. Lastly,
cells were passaged and either propagated, frozen in liquid nitrogen or used for ex-
periments up to passage 5, in order to avoid the phenotypical changes that occur with
long-term subculture of SMCs. Cells were cultured either on plastic, for RNA and West-
ern Blot experiments, or on gelatine-coated glass coverslips, when the assays demanded
the use of confocal microscopy.
4.1.2 Isolation and culture of primary neonatal cardiomyocytes
Neonatal cardiomyocytes were isolated as previously described [201]. For each cell iso-
lation, 8-9 neonatal mice (1-2 days old) were used (T-47/14, notification to sacrifice
animals for scientific purposes). In brief, mice were sacrificed by decapitation, hearts
were removed and placed in ice-cold sterile Ca2+/Mg2+-free heart buffer (composition
given in Tab. 12, page 30). Ventricles were separated, minced and incubated in NCM
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(neonatal cardiomyocyte) digestion solution at 37 °C under continuous shaking, in order
to induce cell dissociation. Every 5 min, dissociation solution was replaced and isolated
cells were collected and placed in digestion inhibition solution to inactivate the en-
zymes. These steps were repeated until no tissue pieces were visible. Finally, cells were
centrifuged at 1000 rpm for 5 min and the pellet was resuspended in complete M199
growth medium. The purification of the resulting cell suspension was achieved by differ-
ential attachment technique. Therefore, the cells were plated in a cell culture flask for 90
min at 37 °C in a cell culture incubator to allow fibroblast attachement, while cardiomy-
ocytes remained in culture medium. Neonatal cardiomyocytes were grown on collagen
(Biochrom, Berlin, Germany) pre-coated plates in complete M199 medium. For im-
munofluorescence analysis, cells were cultured on glass coverslips. Primary neonatal
cardiomyocytes were used within 3 days after isolation.
4.1.3 Isolation of adult cardiomyocytes
100 IU (international units) heparin (Ratiopharm, Ulm, Germany) were injected by in-
traperitoneal injection 10 min prior to mouse sacrifice to prevent blood cloths formation
(reference number T-16/15 notification to sacrifice animals for scientific purposes). The
chest was wiped with 70% ethanol, opened and the heart was isolated together with the
aorta and immediately placed in ice-cold Ca2+-free Tyrode solution. The thymus, fat
and lungs were trimmed and aorta was clamped to the cannula using surgical silk. The
heart was suspended on the Langendorf system (Schmizo, Oftringen, Switzerland) and
perfused with Ca2+-free Tyrode solution for less than 5 min. Afterwards, the perfusion
solution was changed to warm ACM (adult cardiomyocytes) digestion buffer (composi-
tion in Tab. 12, page 30). After 7-9 min, isolated adult cardiomyocytes were transferred
to Tyrode solution containing 100 µmol/L CaCl2, the ventricles were cut and Ca2+ con-
centration was slowly increased. Adult cardiomyocytes were then transferred in growth
medium and plated on laminin (10 µg/mL) coated glass coverslips with a seeding den-
sity of 104 rod-shaped cells/cm2. After one hour, medium was gently changed to remove
non-adherent cells. Isolated cells were used for hpNFAT decoy ODNs uptake experi-
ments the same day.
4.1.4 Culturing of HL-1 cells
HL-1 cells (Dr. William Claycomb, Louisiana State University School of Medicine,
New Orleans, USA, [36]) were cultured on gelatine-fibronectin coated dishes and main-
tained in complete Claycomb medium (Tab. 11, page 29). Cultures were grown in 37
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°C, 5% CO2 until high confluency was observed and then passaged 1:4. Stimulations,
transfections and transductions were carried out when HL-1 cells reached 90 % conflu-
ency.
4.1.5 In vitro hp decoy ODN treatment and AAV transduction
SMCs and cardiomyocytes were seeded in culture dishes the day before treatment and
allowed to adhere overnight. Hairpin decoy ODNs (sequences given in Tab. 6, page 27)
were added in cell culture medium to a final concentration of 10 µmol/L and incubated
for 2 h before stimulation with transcription factors activators. For Lipofectamine me-
diated hp decoy ODN uptake experiments, the DNA was incubated with 5µL Lipofec-
tamine 3000 (Thermo Fischer Scientific, Darmstadt, Germany) in OptiMEM medium
(Thermo Fischer Scientific, Darmstadt, Germany) in the absence of antibiotics for 15
min prior to addition to the cells.
AAV transduction was conducted at MOI=105 vp (virus particles)/cell in serum-free
medium. After the infection period (12-16 h), culture medium was replaced. Cells were
observed under fluorescence microscope (Zeiss, Oberkochen, Germany) for EGFP ex-
pression 3 days after vector application.
SMCs were treated with a series of virus serotypes with targeting capsides (AAV2NDV,
AAV2APV, AAV2DLG, AAV9RGDLLLG, AAV9SLR, AAV9WT, provided by Dr.
Karl Varadi, Prof. Oliver Mu¨ller, Clinic for Cardiology, Angiology and Pneumology,
University Clinic Heidelberg) expressing EGFP in order to detect the viral construct
which leads to the highest transduction efficiency. Fluorescence was visualized after 3
days using a fluorescence microscope.
HL-1 cells were transduced with AAV serotype 6.
4.1.6 Cell stimulation
In order to activate AP-1, SMCs were serum depleted overnight and IL1-β (R&D Sys-
tems, Wiesbaden, Germany) was supplemented to a final concentration of 20 ng/mL for
24 h for protein expression experiments or 8 h for examination of mRNA levels of target
genes.
Cardiomyocytes, both HL-1 cell line and primary neonatal cells were stimulated with
ET-1 100 nM (Sigma-Aldrich, Munich, Germany) after serum deprivation, for 24 h.
Transduced cells were stimulated 3 days after infection.
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4.1.7 Functional in vitro assays
SMCs migration assay
SMCs were cultured to a confluent layer in migration inserts (Ibidi, Munich, Germany)
and treated with hpAP-1 decoy ODN or transduced with AAV9SLR expressing hpAP-1
RNA decoy ODNs. Afterwards, IL1-β 20 ng/mL was added to the medium and inserts
were removed to allow the formation of free space in between cells, as shown in Fig. 7.
Pictures were taken at various time points between 0-24 h with a brightfield microscope
Fig. 7: Principle of Ibidi migration chambers (adapted from Ibidi website). 1: Silicone inserts are applied on cell
culture dishes. 2: Cells are seeded in the empty spaces of the chambers and allowed to adhere. 3: After cell treatments,
chambers are removed to allow empty space formation in between SMCs. 4: The area between cells is analysed at
different time points. Image adapted from ibidi website.
(4x magnification) and the area between cells was analysed using ImageJ (FiJi version
1.51p, National Institute of Health, USA). Relative migration capacity was calculated
as follows:
Percent Migration =
(Initial wound area− Final wound area)
Initial wound area
· 100 (4.1)
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Viability assay
Cell viability was measured by using AlamarBlue assay (Thermo Fischer Scientific,
Darmstadt, Germany). Resazurin, the active ingredient of the reagent, is taken up by
viable cells and reduced to resorufin, a highly fluorescent compound. The cells, cultured
in 96-well plates, were treated with AlamarBlue (1:10 dilution, in serum-free medium)
and incubated at 37 °C, 5% CO2, for 30 min. Afterwards, fluorescence intensity was
measured using a fluorescent reader (Fluoroskan Ascent, Thermo Fischer Scientific,
Munich, Germany).
4.2 AAV production
AAV production was performed in collaboration with Prof. Oliver Mu¨ller, Dr. Andreas
Jungmann, Clinic for Cardiology, Angiology and Pneumology, University Clinic Hei-
delberg according to standard protocols [208]. The full list of plasmids used for AAV
synthesis are recorded in Tab. 8, page 27.
4.3 Molecular biology
4.3.1 Hairpin decoy ODNs
The sequences of the designed decoy ODNs used in this study are summarized in Tab. 6,
page 27. The decoy ODNs were solubilized in sterile TEN buffer to a final concentration
of 500 µmol/L (stock solution) and incubated at 95°C for 7 min. Afterwards, they were
gradually cooled down at room temperature and transferred on ice in order to allow the
hybridization to a hairpin structure, which was confirmed by electrophoresis on 2.5%
agarose gels. Ethidium bromide (4 µL/gel) was added to visualize the DNA bands under
a UV light source illumination. In parallel with the samples, an ultra-low range ladder
(GeneRuler, Thermo Fischer Scientific, Darmstadt, Germany) was loaded to monitor the
DNA molecular weight. For decoy ODNs uptake experiments, a 5′-Atto-590 labelled hp
decoy ODN was used.
4.3.2 Cloning of hpRNA decoy ODNs expressing plasmids
The hpRNA decoy ODNs were generated as shRNAs under the H1 promoter (plasmid
backbone provided by Prof. Oliver Mu¨ller, Dr. Andreas Jungmann, Clinic for Cardiol-
ogy, Angiology and Pneumology, University Clinic Heidelberg). The plasmid contains
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EGFP as an expression marker, initiated by CMV promoter. The vector also includes
inverted terminal repeats (ITR) sequences, which are crucial for AAV production. The
individual sequences for each shRNA subcloning were ordered as gene synthesis (9,
page 28). The synthetized gene sequence contains a part of the H1 promoter (5′ end)
and the shRNA (3′ end), flanked by KasI and XhoI restriction sites.
Maintainence of bacterial cells
For AAV plasmid cloning, recombination-deficient SURE2 (Stop Unwanted Rearrange-
ment Events 2) bacterial cells (Agilent Genomics, Waldbronn, Germany) were used, in
order to prevent the deletion of ITR sequences. Liquid cultures, grown in sterile LB
medium (composition given in 11, page 29) were expanded at 37 °C under continuous
agitation (150-200 rpm) in a bacterial incubator. Bacteria stocks for transformation were
stored as 50 µL aliquotes at -80 °C.
Digestion of plasmid DNA
Plasmid digestion with KasI and XhoI restriction enzymes was performed in the corre-
sponding buffers for 2 h for each µg plasmid DNA, at 37 °C. Reaction efficiency was
analysed by agarose gel electrophoresis (100V for approximately 70 min). A molecular
weight ladder was used to determine band size (GeneRuler 1kb DNA Ladder, Thermo
Fischer Scientific, Munich, Germany). The DNA was imaged by using GelDoc XR
unit and analysed with Quantity One software package version 4.06 (Bio Rad, Mu-
nich, Germany). The DNA bands corresponding to the backbone and the insert were
cut and DNA was purified from the gel using QIAquick Gel Extraction Kit (Qiagen,
Hilden, Germany) according to manufacturer’s instructions. Eluted DNA concentration
was measured using NanoDrop Spectrophotometer (PeQlab Biotechnologie, Erlangen,
Germany).
Modification of DNA ends
In order to reduce the process of backbone religation, 5′ phosphate ends were removed
by using Antarctic phosphatase (New England Biolabs, Frankfurt am Main, Germany).
The gel-purified vector backbone was incubated with the enzyme in the specific buffer
for 30 min at 37 °C. Phosphatase heat-inactivation was afterwards performed at 65 °C
for 30 min on a thermoblock (Eppendorf, Hamburg, Germany).
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Ligation of plasmid DNA
Ligation of DNA fragments was performed in a ratio 1:4 backbone:insert ration by using
T4 DNA ligase in the specific ATP-containing buffer provided by the producer. For
each ligation reaction, 50 µg backbone was used. The dephosphorylated backbone was
incubated with the insert in the presence of ligase for 16 h at 16 °C using a thermoblock.
The reaction mixture was further used for bacteria transformation.
Bacteria transformation
50 µL of bacteria were allowed to thaw on ice and then incubated with the ligation mix-
ture for 30 min at 4 °C. Heat-shock was performed at 42 °C for 45 s, on a thermoblock.
Afterwards, bacteria were transferred on ice for 10 min and then cultured for 30 min
at 37 °C in 300 µL LB medium without antibiotics. Next, the suspension was spread
on sterile LB-plates with 15% agar and 100 µg/mL ampicillin (Sigma-Aldrich, Munich,
Germany). Plates were incubated overnight at 37 °C to allow colony formation. Individ-
ual bacterial colonies were randomly picked and further cultured in 5 mL LB medium
with ampicillin for 16 h. Plasmid DNA was isolated QIAprep Spin Miniprep Kit (Qia-
gen, Hilden, Germany) according to manufacturer’s instructions.
The presence of the insert was confirmed by KasI and XhoI digestion as well as DNA
sequencing (Eurofins Genomic, Luxembourg). Positive colonies were expanded in 1 L
of ampicillin containing LB medium overnight and DNA was isolated using ZymoP-
URE Plasmid Gigaprep Kit (Zymo Research, Freiburg, Germany) according to manu-
facturer’s instructions. Each preparation yielded at least 1.5 g plasmid DNA, which was
further used for AAV preparation.
4.3.3 Quantitative real time PCR
Total RNA was extracted from adherent cells or tissue using RNeasy Mini Kit (Qiagen,
Hilden, Germany) following the manufacturer’s instructions and the concentration was
measured using NanoDrop Spectrophotometer (PeQlab Biotechnologie, Erlangen, Ger-
many). First strand synthesis of cDNA was completed using Omniscript Reverse Tran-
scriptase kit (Qiagen, Hilden, Germany) and OligodT primers (Promega, Mannheim,
Germany), starting from equal amount of RNA for each sample. SYBR Green (Qia-
gen, Hilden, Germany) qRT-PCR was performed using Qiagen Rotor-Gene machine, in
reactions of 20 µL (10 µL SYBR Green, 2 µL primer mix, 3 µL RNase free water, 5
µL cDNA). cDNA was amplified using specific primers for the investigated genes, as
shown in Table 5, page 26.
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The qPCR program consisted of an initial denaturation step of at 95 °C for 5 min, fol-
lowed by 40 cycles of denaturation (95 °C for 60 s), annealing (primer dependent tem-
perature, 25 s) and elongation (72 °C, 60 s), followed by melting curve. The presence
of a single amplicon was determined by the existence of a single peak in the melting
curve graph. Data was analysed by relative quantification method, double delta Ct (cy-
cle threshold) method, using RPL32 as a housekeeping gene [158]. The Ct was defined
as the cycle number at which the fluorescence signal crosses the fluorescence threshold,
considered as background. Corresponding controls (non stimulated cells or samples iso-
lated from control mice) were used for relative gene expression calculation. In order to
quantify the change in gene expression levels, the following equation was used [158]:
Ratio =
2Cttarget,untreated−Ctreference,untreated
2Cttarget,treated−Ctreference,treated
(4.2)
4.3.4 In situ hybridization
For the detection of RNA decoy ODNs both in vitro and in vivo, samples (tissue sec-
tions or cells) were subjected to RNA in situ hybridization. In brief, cells cultured on
gelatin coated glass coverslips or 5µm tissue cryosections were fixed with DEPC (di-
ethyl dicarbonate)-treated 4 % PFA (Sigma-Aldrich, Munich, Germany) for 10 min fol-
lowed by incubation with 20 µg/mL Proteinase K (Sigma-Aldrich, Munich, Germany)
at 37 °C for 15 min in order to induce tissue permeabilization and antigen retrieval. As
a probe we used a molecular beacon (Biomers, Ulm) with complementary sequence to
the hp decoy ODNs (Tab. 7, page 27), with 5’-Cy5 labeling and 3’-BHQ-2 (Black Hole
Quencher) as a quencher. In a hybridized state the molecular beacon itself does not emit
fluorescence signal due to the dye and the quencher being located proximally. After hy-
bridization to the target sequence, red fluorescence can be detected, as shown in Fig. 8.
Prior to hybridization, the molecular beacon was heated at 95 °C and gradually cooled
down to room temperature to allow the hairpin structure formation; afterwards it was
kept on ice until use.
Samples were incubated overnight at 55 °C with the probe dissolved in hybridization
buffer in a humidified atmosphere. As blocking reagents we used salmon DNA and
yeast tRNA (complete hybridization buffer composition is listed in Tab. 12, page 30)
which were added in the mixture. After extensive washes (3x20 min) in hybridization
buffer and DEPC-treated PBS (1x15 min) in order to remove non-hybridized molecu-
lar beacon, EGFP immunofluorescence staining was performed. Finally, DAPI staining
was performed (Ex/Em=358/461) for nuclei visualization using Fluoroshield with DAPI
mounting medium (Sigma-Aldrich, Munich, Germany).
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Fig. 8: The use of molecular beacons for RNA sequences detection. A. The hybridized molecular beacon, as a
hairpin form, does not emit fluorescence. B. As soon as the probe binds to the target RNA, fluorescence can be
detected. Scheme was adapted from [219].
4.4 Protein methods
4.4.1 Protein extraction and Western blot analysis
Total protein was extracted from SMCs using complete RIPA buffer and quantified us-
ing Bradford method (Bio Rad, Munich, Germany). The lysate was snap-frozen and
stored at -80 °C until further use.
In order to isolate total protein extract from heart tissue, a piece of the left ventricle was
cut, briefly washed with NaCl to remove blood residuals, and treated with 300 µL of
ice-cold complete RIPA buffer. Afterwards, a Dounce homogenizer was used to disrupt
the tissue. Protein lysates were snap frozen and maintained at -80 °C before completing
downstream measurements.
30 µg of protein were denatured by incubation at 95 °C for 10 min with 4x sample buffer
(Roth, Karlsrue, Germany) and loaded into SDS-12% acrylamide gels (composition is
given in Tab. 12). A pre-stained protein standard (Bio Rad, Munich, Germany) was used
for molecular weight estimation. Separated proteins were transferred on a methanol pre-
activated PVDF (polyvinylidene difluoride) membrane (Merck Millipore, Darmstadt,
Germany) with pore size 0.45 µm. Ponceau staining was used to prove equal loading
of protein samples. For this purpose, membranes were incubated with the dye (Roth,
Karlsrue, Germany) for 5 min, until red lines were visible, representing the transferred
proteins. Afterwards, extensive washing in H2O was carried out until red, clearly de-
fined bands were observed on white, destained background. The membranes were then
digitized using a Lexmark scanner. Prior to further processing, the membranes were
completely destained by TBS washing.
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Blocking was made using 5% non fat dry milk diluted in TBS-T for one hour, followed
by overnight incubation at 4 °C, under continuous shaking with primary antibodies
(listed in Tab. 2, 25). β-actin was used as a loading control. After washing, membranes
were incubated with corresponding horseradish-peroxidase labelled secondary antibod-
ies (summarized in Tab. 3, page 25) for one hour at room temperature. Membranes were
developed with the chemoluminescent substrates Luminata Classico for β-actin and Lu-
minata Forte for MMP9 and phospholamban detection (Merck, Darmstadt) for 3 min.
Afterwards, membranes were imaged using ImageQuant LAS 4000 mini system (GE
Healthcare Life Sciences, Munich, Germany). The band intensities were analysed and
related to β-actin using ImageJ software.
4.4.2 ELISA
ELISA (Enzyme-linked immunosorbent assay) was used for the assessment of in vitro
BNP protein level secreted in cardiomyocyte supernatant and total cell lysate. In addi-
tion, BNP concentration in left ventricular protein extracts and in plasma were mea-
sured. For this purpose, a Brain Natriuretic Peptide EIA Kit (Sigma-Aldrich, Mu-
nich, Germany) was used, following the instructions provided by the producer. The ab-
sorbance were read using a colorimetric plate (BioTek, Bad Friedrichshall, Germany).
The absorbance of samples and standards were measured in duplicates. A standard curve
for the target protein (provided by the producer) was plotted in each experiment. The
amount of BNP protein was normalised to the total protein content of the samples, de-
termined by Bradford method.
4.4.3 Immunocytochemistry
For immunocytochemistry experiments, SMCs or HL-1 cardiomyocytes were plated
on glass coverslips pre-coated with gelatine. After treatments, cells were washed with
PBS and fixed with 4% PFA for 5 min. Subsequently, the glass slides were washed
and blocked in 3% BSA (Sigma-Aldrich) and 0.05% Triton-X100 as a permeabiliza-
tion reagent, dissolved in PBS. Primary antibodies (summarized in Table 2, page 25)
were diluted in blocking buffer and incubated overnight at 4°C. Next, a set of 3 washing
steps with PBS were performed, followed by fluorescently labelled secondary antibody
incubation (listed in Tab. 3, page 25) for one hour at room temperature and DAPI nu-
clear staining. Images were taken using confocal microscopy (Leica TCS SP8, Leica
Microsystems, Mannheim) and mean fluorescence intensity was calculated using Im-
ageJ.
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4.4.4 Immunohistochemistry
Aortic and heart tissues were collected and washed in NaCl in order to remove blood
residuals. Next, tissue was embedded into optimal cutting temperature medium Tis-
sueTek (Leica Biosystems, Wetzlar, Germany) and snap-frozen by immersion into liquid
nitrogen. A cryotome (Leica, Mannheim, Germany) was used to section the frozen tis-
sue (cryosectioning temperature: -21°C). 5µm thick cryosections were fixed with Zinc
fixative (composition provided in Tab. 12, page 30) and blocked with PBS containing
3% BSA and 0.05% Triton-X100 for one hour. Primary antibodies against the proteins
of interest were diluted in blocking buffer and incubated overnight at 4°C in a humidi-
fied athmosphere. A list of primary antibodies and the working dilution are provided in
Table 2, page 25. As secondary antibodies, compatible Cy3 or Cy5 labelled IgG were
used, diluted in blocking buffer. Nuclei were visualised by DAPI counterstaining and
images were recorded by confocal microscopy. Relative mean fluorescence intensity
was measured using ImageJ as previously described [96] and related to corresponding
controls.
4.4.5 Zymography
Gel zymography
Gel zymography was used for the detection of MMP activity secreted by SMCs. Cell
culture supernatant was incubated for 24h on a rotor at 4 °C with gelatin- coated beads
(Sepharose 4B Beads, Sigma Aldrich, Munich, Germany) in order to concentrate the
MMPs present in the medium. Afterwards, MMPs were eluted using non-reducing sam-
ple buffer followed by electrophoretic separation on 5 mg/mL gelatine-containing acry-
lamide gels. A standard ladder was used to identify the molecular weights of the bands.
Following electrophoresis, gels were incubated for 2 h in wash buffer containing Triton
X-100 in order to remove the SDS and renature the enzymes. Afterwards, gels were
placed in a 37 °C incubator overnight, in incubation buffer (composition is presented in
12), which contains CaCl2, essential for enzymatic activity of MMPs. Gels were then
transferred to Coomassie Brilliant Blue staining solution for one hour at room tempera-
ture under shaking and afterwards incubated in destaining buffer until clear bands were
visible on the blue background. The bands correspond to the level of gelatinase activity,
and were further quantified. For this purpose, gels were scanned and the relative band
intensity was measured using ImageJ.
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In situ zymography
In situ zymography was performed using a broad spectrum MMP substrate (520 MMP
FRET Substrate XIV, Anaspec, Go¨ttingen, Germany), which detects the activity of
MMP-1, 2, 3, 7, 8, 9, 12, and 13 present in the sample. For in vitro measurement of
MMP activity, SMCs were treated with the substrate to a final concentration of 0.1
µg/mL in serum-free medium for 1 hour at 37 °C. After cell fixation with PFA 4% and
DAPI staining, the cells were visualised using a confocal microscope and red fluores-
cence (Ex/Em=494/521 nm) was analysed as a measure of MMP activity.
Similarly, MMP activity was analysed in 5 µm aortic cryosections. The tissue was fixed
with Zinc fixative and incubated with the substrate at 37 °C for 4 h in a humidified
atmosphere to avoid the evaporation of the substrate solution. The sections were then
extensively washed to remove the non-bound substrate. Red fluorescence intensity was
measured and reported to the wild type control aorta values.
4.4.6 SUnSET assay
SUnSET (Surface sensing of translation) assay was used for measurement of total pro-
tein translation rate as previously described [181]. For in vitro protein translation mea-
surements in HL-1 cells, a viability curve was performed to determine the suitable con-
centration of the compound to be used in further experiments. For this purpose, HL-1
cells, cultured in 96-well plates were treated with increasing concentration of puromycin
(0.1, 0.5, 1, 5, 10, 50, 100 µmol/L) for 30 min, followed by Alamar Blue viability test
(described in detail in section 4.1.7, page 36).
Afterwards, either cardiomyocytes or 5 µm heart cryosections were incubated with
puromycin 10 µmol/L for 30 min, followed by PFA fixation. Then, anti-puromycin an-
tibody was diluted in blocking buffer, added to samples and incubated overnight at 4
°C. After 3 steps of PBS washing, a Cy5-labelled secondary antibody was used. Red
fluorescence signal was recorded using a confocal microscope and relative means were
analysed using ImageJ.
4.5 ROS measurement
4.5.1 In vitro
The level of oxidative stress in vitro was measured using 2′,7′-Dichlorofluorescin diac-
etate (DCFDA, Sigma Aldrich, Munich, Germany) or, when SMCs were transduced
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with EGFP expressing AAV, with Dihydroethidium (DHE, Sigma Aldrich, Munich,
Germany). For this purpose, cells were cultured on gelatine-coated glass coverslips and
subjected to hp decoy ODNs treatement or AAV transduction. Afterwards, cells were
incubated with DCFDA (5 µmol/L) or DHE (0.1 µmol/L) for 30 min at 37 °C in serum-
free medium. The dye was then removed by PBS washing and cells were stimulated with
IL1-β for 6 h. Non-stimulated cells were used as control. Next, coverslips were washed
again with PBS and fixation was performed using methanol. After DAPI nuclear stain-
ing, cells were visualised using a confocal microscope (DCFDA:Ex/Em=485/535nm;
DHE:Ex/Em=518/605) and the fluorescence intensity was measured using ImageJ.
4.5.2 In tissue cryosections
Aortic cryosections were fixed with 4% PFA for 5 min and rinsed in PBS. DHE was
applied to the tissue to a final concentration of 10 µmol/L and incubated at 37°C for 30
min in a humidified atmosphere. The sections were then briefly washed with PBS and
visualised by confocal microscopy. Mean fluorescence intensity was measured using
ImageJ.
4.6 Other tissue based methods
4.6.1 Cell size measurement
WGA (Wheat Germ Agglutinin) staining is an already established method for analysis
of cell size in cardiac tissue [82]. Left ventricles embedded in TissueTek medium were
sectioned (5 µm) and the cell orientation was observed. The analysis was made on both
short and long axis. Cryosections were fixed with PFA 4% for 5 min and stained with
WGA-Alexa Fluor 594 (Thermo Fischer Scientific, Darmstadt, Germany, 1:400 diluted
in PBS). The incubation with the dye was performed at room temperature, for 10 min.
Afterwards, tissues were briefly washed with PBS and mounted. Images were taken
using confocal microscopy and cell diameter was analysed using ImageJ.
4.6.2 T-tubule analysis
After WGA staining, T-tubule organization was assessed using ImageJ, as previously
described [215]. In brief, cells were analysed individually, by application of Fast fourier
transformation (FFT), as described in Fig. 9. This method allowed the identification of
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repeating patterns and the frequency with which they appear (T-power). The peak corre-
sponding to the 2 µm distance was further analysed. In addition, the percentage of cell
area occupied by T-tubules (T-index) was calculated by using threshold method deter-
mined in ImageJ. This parameter was defined as the area above-threshold divided by cell
cross-sectional area. Cardiomyocytes presenting a T-index above 2 % were considered
to be tubulated, in a similar manner as other studies [65]. The level of tubularization was
defined as the percentage of tubulated cells in each treatment group.
Fig. 9: Image analysis of T tubule organization. (A) Original image after background removal. (B) The power
spectrum obtained after performing FFT and the corresponding plot profile. The second peak was further used for
analysis, designating the 2 µm distance between single T-tubules.
4.6.3 Heart histology
Masson’s Trichrome Staining
Heart histology was performed in collaboration with Prof. Dr. med. Hermann-Josef
Gro¨ne, German Cancer Research Center, Heidelberg. Hearts were fixed in 4% PFA
overnight at 4 °C and embedded in paraffin prior to histological assessment. For vi-
sualization of collagen fibers, sections were subjected to Masson’s Trichrome Staining
according to standard protocols [14]. Images were taken in random areas of the left
ventricle using a brightfield microscope with 20x magnification (Leica DM500, Leica
Microsystems, Mannheim, Germany). Collagen was stained blue, muscle and cytoplasm
appeared red and nuclei were visualized as being dark brown to black. Both perivascular
and interstitial fibrosis were analysed using a quantification software written in QT/C++
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based on image processing and segmentation libraries. In a first step, interfering back-
ground of all images was masked out by subsequently applying threshold and erosion
filters. Further, the fibrotic area was determined using hsv-thresholding with a 10 % tol-
erance on the hue component, followed by numerical quantification of the percentage
area covered. A sample result image is provided in Fig. 10.
Fig. 10: Quantification of perfentage of fibrotic area. The image on the left represents the original picture of the
stained tissue. On the right, the blue region, representing collagen staining, was selected for analysis and the area was
calculated.
Hematoxylin-eosin staining
Cardiomyocyte architecture was assessed by H&E (Hematoxylin-eosin) staining of
paraffin sections, performed in collaboration with Prof. Dr. med. Hermann-Josef Gro¨ne,
German Cancer Research Center, Heidelberg, according to standard protocols [117].
Stained tissue sections were visualised using a brightfield microscope (Leica DM500,
Leica Microsystems, Mannheim, Germany). Following the procedure, nuclei appeared
blue, while cardiac tissue was stained pink. Cardiomyocytes were identified according
to their specific shape and their area on the long axis was measured using ImageJ and
normalized to the cell size of sham operated mice.
Verhoeff-van Gieson Staining
Elastic van Gieson staining was performed using Elastic Stain Kit (Sigma Aldrich, Mu-
nich, Germany) according to manufacturer’s instructions. In brief, 5 µm cryosections
were fixed with 4% PFA (paraformaldehyde) and allowed to dry at room temperature.
Afterwards, sections were stained with working elastin solution (20 mL hematoxylin
solution, 3 mL FeCl3, 8 mL Weigerts iodine solution, 5 mL deionized H2O) for 10 min
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and briefly washed with deionized H2O. Aortic tissue was then differentiated in 3%
FeCl3 for 1 min, rinsed in 95% ethanol and stained with Van Gieson solution for one
min. The sections were washed with 95% ethanol and mounted. Images were taken us-
ing brightfield microscopy with 10x magnification. Elastin fragmentation was assessed
by counting the number of islands of damage by two researchers blinded to the treat-
ment. An island of damage was defined as breaks in two neighbouring elastic fibers
surrounded by conjunctive tissue [132].
4.7 Mouse models and techniques
4.7.1 Animal models
Mouse models were used to prove the in vivo reproducibility of the results obtained
using cell culture models. All animal experiments were carried out under the approval
of the regional committees (Regierungsprsidium Karlsruhe, permit numbers G187-11
and G-52/17 for Marfan syndrome project and G180/12 for heart hypertrophy project,
applicants Prof. Dr. Klaus Kallenbach, Prof. Dr. Oliver Mu¨ller). Animals were kept in
the Interfaculty Biomedical Facility (IBF), Heidelberg, under standard conditions with
12h light, 12h night cycle; water and food was offered ad libitum.
4.7.2 Aortic grafts transplantation
For the Marfan syndrome project, 6-9 weeks old female mice were used. The animals
are underexpressing fibrillin-1 due to a hypomorphic mutation (mgR/mgR), as previ-
ously described [183]. Male mice were excluded because they present a significantly
lower survival. As comparison we used age-matched wild type littermates.
AAV9SLR-EGFP, AAV9WT and AAV9SLR expressing the hp RNA decoy ODNs were
applied at the level of the aorta ex vivo by means of a heterotrophic infrarenal transplan-
tation model as previously described [184]. The surgeries were performed by Dr. Rawa
Arif and Maximilian Franz, Clinic for Cardiac Surgery, Heidelberg University Hospi-
tal. Donor mgR/mgR mice were euthanized with CO2, the thorax was open and 5 mL
of cold sterile saline solution was injected systemically through the left ventricle. The
thoracic aorta was gently removed and grafts were incubated with gentle shaking on a
tumbling table for 30 min with 50 µL AAV solution (1012 virus particles/mL, diluted in
NaCl) at room temperature. In order to demonstrate that AAV transduction itself has no
effect on elastin structure, mgR/mgR grafts were treated with PBS as a control. Recipi-
ent mgR/mgR mice were anesthetized with isoflurane and the abdomen was open. The
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infrarenal part of the aorta was visualized under the microscope (25-40x magnification)
and vessel clips were placed in between the left renal artery and the aortic bifurcation
prior to cutting it. The ex vivo transduced aortic graft was implanted, the clips were
detached and the abdomen was closed. The following 3 days after surgery, analgesic
treatment (Novalgin, Camprofen) was provided. Grafts were removed for analysis 30
days after surgery.
4.7.3 Transverse aortic constriction and echocardiography
Transverse aortic constriction was performed in 10 weeks old C57BL/6N mice for in-
ducing heart hypertrophy which develops into heart failure, as previously described
[115]. The surgery was performed in collaboration with Prof. Oliver Mu¨ller, Theresa
Ruf, Lin Ding, Internal Medicine III, Clinic for Cardiology, Angiology and Pneumol-
ogy, University Clinic Heidelberg.
The substrain choice was made due to the findings published by Garcia-Menderez et
al [69], which show that C57BL/6N mice are a better animal model for TAC-induced
cardiac hypertrophy than other commonly used substrains, such as C57BL/6J. A 27-
gauge needle was used for inducing the stenosis. Successful ligation was confirmed by
measuring the right carotid/left carotid flow velocity ratio. Changes in heart function
were determined every 2 weeks by echocardiography in non-anesthetised mice using
VisualSonics Vevo 2100 imaging system and the 40 Hz MS-550D micro scan trans-
ducer. The measurements were performed by an experimenter blinded to the treatment.
Long axis and M-mode short axis cine loops were recorded. EF (ejection fraction),
FS (fractional shortening) and left ventricular mass was determined using VisualSonics
software. The mice were sacrificed by CO2 asphyxiation 6 weeks after surgery. Heart
weight/tibia length ratio was measured as a marker of cardiac hypertrophy, as well as
lung weight/tibia length ratio for monitoring heart failure induced lung edema [30].
Furthermore, mice weight was as well tracked every week.
4.8 Statistical data analysis
The statistical data evaluation was made using GraphPad InStat 3.06 software. Dif-
ferences between 3 or more different groups were assessed using One-way ANOVA,
followed by a Tukeys multiple comparison test for particular pairs of groups. Mann-
Whitney U test was used to compare two groups. A p value <0.05 was considered
significant. In vitro experiments were repeated at least 4 times. The mean fluorescence
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intensity of at least 20 images/group was analysed in the immunocytochemistry and im-
munohistochemistry experiments, using ImageJ (FiJi version 1.51p). Gel zymography
and Western blot data were evaluated as well using ImageJ. Data are presented as mean
± SD of n individual experiments. Graphs were generated using GraphPad Prism 7 (San
Diego, California, USA).
5Results
5.1 Cloning of the AAV vectors
5.1.1 Digestion of the vectors
Hairpin RNA decoy ODNs were individually cloned into a pDS vector backbone un-
der the control of H1 promoter. Transduced cells were identified by CMV promoter-
dependent EGFP expression. Separate vectors containing the sequence of hpRNA de-
coy ODNs (hpAP-1 cons, hpAP-1 mut, hpNFAT cons, hpNFAT mut) flanked by KasI
(5) and XhoI (3) were employed to isolate the insert DNA.
Both pDS vector and the gene synthetized plasmid for each decoy ODN (GeneArt,
Thermo Fischer Scientific) were digested with the KasI and SalI enzymes and the result-
ing DNA was further analysed using agarose gel electrophoresis to prove the successful
digestion. As shown in Fig. 11, the detected bands corresponding to the digested vector
(5,980 bp) as well as to the insert (164 bp) were cut out and purified using QIAquick
Gel Extraction Kit. The pDS vector, kindly provided by Prof. Dr. Oliver Mu¨ller, Clinic
for Cardiology, Angiology and Pneumology, University Clinic Heidelberg, contained
the sequence of an unrelated shRNA, which was detected after KasI and XhoI digestion
as a 164 bp band following agarose gel electrophoresis, as demonstrated in Fig. 11. The
band corresponding to the pDS vector backbone was identified as the high molecular-
weight fragment and was further gel-purified.
5.1.2 Analysis of cloned plasmids
After ligation and transformation steps, single colonies were cultured and plasmid DNA
was isolated. In order to show proper ligation and to distinguish self-ligated pDS back-
bone, SalI digestion was performed, taking into account that the restriction site of this
enzyme was present only in the designed insert and not in the initial pDS vector, as
shown in Fig. 12.
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Fig. 11: Cloning strategy for the individual AAV vectors used in the present study. A. Plasmid maps used for
backbone and insert isolation respectively. B. Agarose gel detection of plasmid (pDS and RNA decoy ODNs vector)
digestion efficiency with KasI and XhoI.
Fig. 12: Confirmation of presence of insert in isolated plasmids. Agarose gel analysis of SalI digested plasmids
isolated from picked colonies. The 6,000 bp bands show successful digestion. The non digested plasmid appears as
a high molecular weight DNA fragment due to the relaxed structure which migrates with a lower speed than other
fragments.
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5.2 Marfan syndrome project
5.2.1 ”Naked” hpAP-1 decoy ODNs uptake by SMCs
First, hpAP-1 decoy ODNs uptake by aortic SMCs was assessed. For this purpose, pri-
mary SMCs isolated from the thoracic aorta of mgR/mgR mice were treated either with
Atto-590 fluorescently labelled decoy ODNs alone or with the same amount of DNA
pre-incubated with Lipofectamine 3000 as transfection reagent. The distribution of red
signal within the cells was analysed by confocal microscopy. The results confirm that 2
h incubation with the labelled hpAP-1 decoy ODNs is sufficient for the decoy uptake by
SMCs. On the other hand, when Lipofectamine was pre-mixed with the DNA, a signif-
icant lower amount of DNA was detected whithin SMCs, as proven by red fluorescent
quantification in Fig. 13.
Moreover, an increased localization of the decoy ODN in the nucleus was observed
when the DNA was added alone in the medium, whereas in Lipofectamine-mediated
delivery group decoy ODNs were mostly detected inside vesicles. Therefore, in order to
assess hpAP-1 decoy ODNs efficiency in SMCs in following experiments, no liposomal
transfection reagents were used.
5.2.2 ”Naked” hpAP-1 consensus decoy ODN effects on mgR/mgR SMCs
Expression of AP-1 target genes
Having shown that SMCs can be successfully transfected with hpAP-1 decoy ODNs,
the analysis of its effect on AP-1 target genes MMP9 and MCP-1 was determined. The
two genes have major roles on aortic aneurysm development in Marfan syndrome [92].
MMP9 was already shown to be upregulated in mgR/mgR mice [228] and its deletion
decreased the rate of thoracic aortic aneurysms dissection [93]. On the other hand, MCP-
1 is a major chemotaxis agent for inflammatory cells and its concentration correlates
with disease severity in Marfan patients [164].
In order to induce AP-1 transcription factor family activation, IL-1β was applied to
serum depleted SMCs. As expected, 8 h treatment with the stimulus caused a significant
increase in the expression of both analysed genes, whereas pre-treatment with hpAP-1
cons decoy ODNs for 2 h led to a significant reduction in the mRNA levels of both
MMP9 and MCP-1. The control hpAP-1 mut decoy ODNs had no effect in this context,
as shown in Fig. 14, further proving the specificity of the designed decoy ODNs.
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Fig. 13: Hairpin AP-1 decoy ODNs are taken up without auxilliary means by mgR/mgR SMCs. Representative
fluorescence images showing the uptake of Atto590 fluorescently labelled hp AP-1 decoy ODN (red) with or with-
out liposomal transfection reagent. Cell membranes were marked with WGA-Alexa488 (green). The graph shows
statistical quantification of red signal detected in confocal images, proving that Lipofectamine mediated transfection
is less effective than simple decoy ODN addition to cell culture medium. The scale bar represents 10 µm; Lipo:
lipofectamine treatment. (n=3, ** p=<0.001).
MMP expression and activity in SMCs
To confirm the results of gene expression analysis on protein level, Western blot ex-
periments were performed using a specific antibody directed to MMP9. As a result, a
high molecular weight protein band was detected in mgR/mgR SMCs lysates, which
had a higher intensity than the expected 105 kDa band. To prove that the 220 kDa
band represents a MMP9 dimer and not a non-specific binding of the antibodies, SMCs
were treated with a compound which was validated as a specific MMP9 dimerization
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Fig. 14: Hairpin AP-1 consensus decoy ODNs but not the mutated control ODNs significantly decrease the
mRNA levels of AP-1 target genes. MMP9 and MCP-1 gene expression was normalised to RPL32 (ribosomal
protein L32) as housekeeping gene. (n=5, * p<0.05).
inhibitor, by blocking its PEX domain [53]. When SMCs were incubated with this com-
pound for 24 h but not with DMSO as control, MMP9 dimerization was completely
abolished and the high molecular band was not present, as depicted in Fig. 15B. This
led to the conclusion that in mgR/mgR aortic SMCs MMP9 could be detected mainly
as homodimer in SMCs protein lysates, even under denaturing and reducing conditions.
Thus further data analysis was made using the 250 kDa protein.
MMP9 expression levels were analysed in SMCs following treatment with hpAP-1 con-
sensous decoy ODNs. As shown in Fig. 15A, MMP9 homodimer expression was signifi-
cantly decreased by 74% following hpAP-1 cons decoy ODNs application. As expected,
the control mutated decoy ODNs had no effect on MMP9 protein level.
Additionally, MMP activity in the cell culture setup was analysed. For this purpose,
serum-free cell culture supernatant was subjected to MMP concentration using gelatine
beads, followed by gel zymography. In our hands, the 105 kDa band corresponding to
the monomeric MMP9 had the highest gelatinolytic activity in mgR/mgR SMCs condi-
tioned medium and was therefore analysed. In consistence with the Western blot results,
SMCs treatment with hpAP-1 consensous but not with the mutated decoy ODNs led to
a marked decrease of MMP9 proteolytic activity, as shown in Fig. 16A.
In order to evaluate if the activity of non-secreted MMPs follows the same trend, a
broad spectrum FRET substrate was employed, which was applied to SMCs in serum
free medium. The substrate is cleaved by MMP-1, 2, 3, 7, 8, 9, 12, and 13, leading to the
generation of a red fluorescent compound which was further visualized and quantified in
confocal images. As demonstrated in Fig. 16B, 24 h incubation with IL-1β significantly
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Fig. 15: Hairpin AP-1 consensus decoy ODNs significantlydecrease IL-1β-induced MMP9 protein level in
aortic SMCs. (A) MMP9 Western blot analysis of SMCs lysates. β-Actin was used as a loading control and relative
protein levels were normalized to IL-1β (20 ng/mL) stimulated SMCs. (n=4, *** p<0.001). (B) Evaluation of the 250
kDa band detected in the Western blot experiments. By using a small molecule which blocks MMP9 dimerization,
the high molecular weight homodimer was not detected.
increased MMP activity in SMCs, which was largely diminished by hpAP-1 consensus
decoy ODNs application prior to stimulation.
The aforementioned findings demonstrate that AP-1 neutralization through hpAP-1 con-
sensus decoy ODNs can downregulate the mRNA levels of genes controlled by this tran-
scription factor family and activated by IL-1β stimulation. Moreover, decreased MMP9
protein level and activity in SMCs was observed.
Reactive oxygen species generation
An important role in the development and rupture of aortic aneurysms in Marfan syn-
drome patients was attributed to disturbances in reactive oxygen species (ROS) home-
ostasis whithin the aortic tissue. ROS are generated by increased TGF-β signalling and
were shown to correlate with the rate of aortic aneurysms rupture [29]. Furthermore,
AP-1 inhibition was proven to decrease ROS production through reduced NADPH ox-
idase activity in human aortic SMCs [128]. Therefore, the effect of hpAP-1 consensus
decoy ODNs on ROS production in the context of Marfan syndrome was determined.
For this purpose, ROS production was measured by incubating the cells with CM-
H2DCFDA after decoy ODNs treatment. The CM-DCF green fluorescence intensity
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Fig. 16: Hairpin AP-1 consensus decoy ODNs decrease IL-1β-induced MMP activity in aortic SMCs. (A)
MMP9 gelatinolytic activity as shown by gel zymography. The graph depicts desitometric analysis of the bands,
normalized to IL-1β (20 ng/mL) stimulated group. (n=4, * p<0.05) (B). Intracellular MMP activity was analysed
using a FRET substrate specific for 12 different MMPs. Red signal represents the fluorescence generated by cleaved
substrate and correlates with the total activity of intracellular MMP. The graph shows the statistical quantification of
mean red fluorescence intensity of the indicated treatment groups. Cell nuclei were stained with DAPI. The scale bar
represents 75 µm, 20 images analysed/group. (n=4, *** p<0.001, ** p<0.01).
significantly increased in IL-1β stimulated SMCs, as compared to control cells, proving
a higher amount of ROS in the presence of the stimulus. However, following 2 h incuba-
tion with hpAP-1 consensus decoy ODNs prior to IL-1β addition to the medium, SMCs
showed a significant decrease in the level of ROS, as demonstrated by the quantification
of fluorescent images in Fig. 17.
Migration rate
In was previously shown that thoracic aneurysms are correlated with phenotypic switch
of vascular SMCs, process characterized by increased proliferation, enhanced MMP ac-
tivity and decreased SMA (smooth muscle α-actin) expression. [129]. Moreover, SMCs
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Fig. 17: Hairpin AP-1 consensus decoy ODNs decrease IL-1β-induced ROS production in aortic SMCs. Rep-
resentative images showing CM-DCF fluorescence, recorded using confocal microscopy on the green channel. Mean
fluorescence intensity was analysed and normalized to non-stimulated control. The scale bar represents 75 µm, 20
images analysed/group. (n=4, *** p<0.001, ** p<0.01).
injury correlates with increased migratory phenotype of the cells. Taking these observa-
tions into account, SMC migration rate was analysed in the presence of hpAP-1 decoy
ODNs by using ibidi inserts. IL-1β significantly increased the migratory capacity of
SMCs. On the other hand, the migration rate of SMCs pre-treated with hpAP-1 consen-
sus decoy ODNs, but not with the mutated control decoy ODNs almost declined to the
basal level (Fig. 18).
5.2.3 Transduction efficiency of SMCs with AAV9 modified with targeting capsid
peptides
Previous research demonstrated that AAV transduction efficiency and specificity can
be markedly improved by the use of targeting capsid peptides [140, 208]. Neverthe-
less, the transduction efficiency of the AAV serotype 9 with targeting peptide SLRSPP
(AAV9SLR) was only shown in human endothelial cells and SMCs in vitro. There-
fore, we wanted to confirm that AAV9SLR is a suitable vector for transduction of
mouse mgR/mgR SMCs. For this purpose, cells were transduced with EGFP expressing
AAV9SLR and SMCs were visualised using fluorescence microscopy after 3 days. In
addition, AAV9 with 2 other selected peptides were tested, as well as AAV2 with modi-
fied capsids. As controls, wild type non modified AAV9 (AAV9WT) and non-transduced
SMCs were used. The results in human primary cells could be reproduced in mouse
aortic SMCs, namely the targeting capsid peptide SLRSPP significantly improved the
transduction efficiency of the wild type vector, as shown in Fig. 19. Using this AAV
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Fig. 18: Hairpin AP-1 consensus decoy ODNs significantly decrease the migration rate of vascular SMCs.
Depicted are representative images of SMCs immediately after removal of the inserts (0 h), and after 24 h stimulation
with 20 ng/mL IL-1β. The graph shows relative migration rate of SMCs in the 4 treatment groups. (n=4, *** p<
0.001).
construct, a greater than 70% transduction efficiency was achieved on average, while
the other serotypes only led to extremely low amount of EGFP positive cells (less than
5%). AAV9WT failed to transduce mgR/mgR SMCs in vitro.
Expression of hpRNA decoy ODNs after AAV9SLR transduction
Having identified the most efficient AAV serotype for in vitro transduction of primary
SMCs, the production of shRNA-expressing vectors was performed. The hpAP-1 con-
sensus and hpAP-1 mutated control decoy ODNs were cloned into the designed plas-
mids and afterwards AAVs were generated. F.I.S.H. experiments were carried out 3 days
after infection to confirm that RNA decoy ODNs are expressed in transduced cells. We
used a directly labelled probe with complementary sequence to the hpAP-1 cons decoy
ODNs and we showed its specificity in situ. The molecular beacon emits no fluores-
cence as a hairpin structure due to the close proximity of the fluorofore (Cy5) and the
quencher (BHQ-2). However, as soon as it hybridizes to its target, namely the hpAP-1
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Fig. 19: Transduction efficiency of different AAV serotypes with modified capsid. Representative images of
mgR/mgR aortic SMCs 3 days after transduction with tested vectors. EGFP fluorescence (green) was analysed as
a marker of transduction efficiency of the indicated vectors and the percentage of transduced cells was calculated.
Nuclei were marked using DAPI in order to count the number of cells/field of view. Scale bar represents 82µm. (n=4,
*** p< 0.0001, compared to AAV9WT.)
consensus RNA decoy ODN, red fluorescence can be detected. After the harsh washing
steps during this procedure with hybridization buffer containing formamide, a dramatic
loss of the EGFP fluorescence in SMCs was observed. Therefore, EGFP immunocy-
tochemistry was conducted subsequently, in order to identify successfully transduced
cells.
Cy5 signal was detected only in EGFP positive cells, showing the accuracy of the
method. In contrast, substantially lower or no red fluorescence was found in AAV9SLR
EGFP or non-transduced SMCs, as shown in Fig. 20. Hairpin AP-1 RNA decoy ODNs
were identified in the nuclei of transduced cells, but they were also expressed in the
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perinuclear region.
Fig. 20: AAV9SLR-mediated expression of hpAP-1 consensus RNA decoy ODNs in vascular SMCs. Red signal
shows F.I.S.H. probe hybridization to its target, proving the generation of shRNA in transduced, EGFP-positive cells
(green). Non-transduced SMCs as well as AAV9SLR-EGFP treated cells served as controls . DAPI staining (blue)
was employed to visualize the nuclei. The scale bar represents 75 µm. (n=3, exemplary pictures).
5.2.4 Effect of AAV9SLR-mediated hpAP-1 RNA decoy ODNs generation in
primary mgR/mgR SMCs
Expression of AP-1 target genes
To further investigate whether AAV9SLR-mediated hpAP-1 consensus RNA decoy
ODNs delivery in vascular SMCs is able to neutralize the transcription factor with a
similar efficiency as the DNA decoy ODNs, the mRNA levels of MMP9 and MCP-1
was analysed. Similarly to previous experiments, AP-1 was activated by addition of IL-
1β to SMCs 3 days after AAV transduction in serum-free medium. As shown in Fig. 21,
transduction with AAV9SLR expressing hpAP-1 consensus RNA decoy ODNs resulted
in a significant decrease in both genes mRNA expression levels, while the mutated con-
trol AAV had no effect on the analyzed AP-1 target genes.
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Fig. 21: AAV9SLR-mediated expression of hpAP-1 consensus RNA decoy ODNs significantly decreases AP-1
target genes in vascular SMCs. mRNA levels of MMP9 and MCP-1 were compared to RPL32 as a housekeeping
gene. Values were normalized to the non-stimulated controls. (n=4, * p<0.05).
MMP expression and activity in SMCs
To further support the mRNA data and to prove efficient AP-1 neutralization by the
designed vector, MMP9 protein level was analysed by immunocytochemistry. Red flu-
orescent signal, corresponding to the MMP9 antibody, was analysed in EGFP positive
cells. MMP9 content was significantly higher in IL-1β stimulated SMCs in compar-
ison to non-stimulated cells (Fig. 22). Transduction with hpAP-1 RNA cons decoy
ODNs producing AAV9SLR significantly downregulated MMP9 protein level, while
the AAV9SLR expressing hpAP-1 mutated RNA decoy ODNs had no effect (Fig. 22).
Next, the effect of transduction on secreted and intracellular MMP activity in mgR/mgR
SMCs was determined. Gelatine zymography experiments pointed out that AAV9SLR-
mediated hpAP-1 consensus, but not mutated RNA decoy ODNs generation led to a
dramatic decrease in MMP9 gelatinolytic activity in SMCs supernatant, as shown in
Fig. 23A. As is previous experiments, the most prominent band observed in the analysis
corresponded to 105 kDa, equivalent to the MMP9 monomer which was further quanti-
fied.
Similar results were obtained when a fluorescent broad spectrum MMP substrate was
employed to measure the intracellular MMP activity. The main advantage of this tech-
nique is that it allows the identification and measurement of the activities of several
MMPs expressed by SMCs, i.e. MMP-1, 2, 3, 7, 8, 9, 12, and 13 activities. Moreover,
the Ex/Em curves of this substrate is highly compatible to EGFP fluorescence and can
be detected in parallel by confocal microscopy. The results of this experiment demon-
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Fig. 22: AAV9SLR-mediated expression of hpAP-1 consensus RNA decoy ODNs significantly decreases MMP9
protein level in vascular SMCs. Detection of MMP9 (red) was made by immunocytochemistry. Successful transduc-
tion was confirmed by EGFP fluorescence (green). The graph summarizes the statistical quantification of the mean
red fluorescence intensity of individual experiments. Nuclei were visualized by DAPI staining (blue). The scale bar
represents 25 µm. (n=4, 20 images analysed/group, ** p<0.01).
strate that AAV9SLR-mediated AP-1 neutralization significantly decreased MMP activ-
ity, which was brought back to basal conditions, while the mutated control AAV9SLR
had no effect on MMP enzymatic activity. Representative images and quantifications
are depicted in Fig. 23B.
Reactive oxygen species generation
To determine whether hpAP-1 consensus RNA decoy ODNs delivery in SMCs by
AAV9SLR transduction affects the level of ROS in a similar manner as hpAP-1 con-
sensus decoy ODNs application, DHE was used as an indicator of oxidative stress.
CM-DCF could not be used as in previous experiments due to the expression of EGFP
fluorophore of the AAV9SLR transduced cells, which would interfere with detection of
the oxidized dye. Upon entry into the cells, DHE reacts with superoxide ions, yielding
oxyethidium. This compound in turn interacts with nucleic acids and emits nuclear red
fluorescence which can be detected in parallel with the green signal given by EGFP pos-
itive cells. The quantification of DHE oxidation levels shows that AAV9SLR expressing
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Fig. 23: AAV9SLR-mediated expression of hpAP-1 consensus RNA decoy ODNs significantly decreases MMP
activity in vascular SMCs (A) Gelatinolytic activity of MMP9, detected as 105 kDa white bands on Coomassie
Brilliant Blue stained zymography gel. The graph shows statistical quantification of relative densitometric analysis
of the bands obtained in individual experiments. Values were normalized to the non-stimulated control group (n=4,
* p<0.05). (B) Representative images of SMCs treated with MMP substrate after AAV9SLR transduction and IL-1β
stimulation. Red fluorescence is proportional to the amount of cleaved MMP substrate. Transduced EGFP positive
cells (green, underlined with white) were selected for analysis. Scale bar represents 25µm. (n=4, 20 images anal-
ysed/group, ** p<0.01).
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hp AP-1 consensus but not the mutated RNA decoy ODNs can significantly decrease the
amount of IL-1β-induced ROS generation by SMCs, as shown in Fig. 24.
Fig. 24: AAV9SLR-mediated expression of hpAP-1 consensus RNA decoy ODNs decreases the amount of ROS
in vascular SMCs. Representative images showing the measurement of superoxide in mgR/mgR SMCs following
AAV9SLR transduction. The graph pictures the statistical quantification of relative mean red fluorescence intensity
levels as compared to the non-stimulated control. EGFP fluorescence (green) shows successfully transduced cells.
Scale bar represents 25 µm. (n=4, 20 images analysed/group, * p<0.05).
5.2.5 Ex vivo transduction of murine mgR/mgR aortic grafts with AAV9SLR
First, the in vivo capacity of AAV9SLR to transduce aortic SMCs was verified by inject-
ing the EGFP expressing vector systemically through the tail vein of mgR/mgR mice.
After 30 days, thoracic aortae of injected mice were removed and tested for EGFP ex-
pression in frozen sections by immunohistochemistry. Moreover, the aortae were di-
gested and single cell suspensions were prepared and subjected to FACS analysis to
determine EGFP fluorescent cells. Nevertheless, no EGFP positive cells, neither SMCs
nor endothelial cells, could be detected (data not shown).
Therefore, ex vivo treatment of aortic grafts with AAV9SLR-EGFP and wild type
AAV9WT-EGFP as a control was performed, followed by infrarenal reimplantation into
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recipient mice. This method allows a local application of the vectors to yield a higher
AAV transduction rate and the chance of vector neutralization by antibodies in serum
is reduced. Under these conditions, successful transduction by AAV9SLR but not by
AAV9WT was proven. EGFP expression was found not only in endothelial cells, but
also in SMCs, the target cells of this study. An antibody specific for EGFP was used
in order to distinguish between elastin fibers autofluorescence on the green channel and
EGFP fluorescence. Another reason for EGFP detection by immunohistochemistry was
that rapid loss of green fluorescence was observed during fixation and staining proce-
dures. An antibody for CD31 was used to mark endothelial cells. Representative im-
munohistochemistry images are shown in Fig. 25A.
Fig. 25: Capsid peptide SLR significantly enhances ex vivo transduction efficiency of AAV9 in mgR/mgR aortic
tissue. (A) Illustrative immunohistochemistry images showing EGFP expression (green) in CD31-positive endothe-
lial cells (red), as well as in smooth muscle cells in the media (magenta). (B) EGFP expression on the genomic DNA
level is increased in AAV9SLR transduced grafts as compared to AAV9WT treated tissue, 30 days after transduction
and reimplantation. Scale bar represents 25 µm. (n=4, *** <0.001).
To bring more evidence to support these observations, genomic DNA was isolated
from aortic grafts and EGFP expression was analysed by qPCR using specific primers.
Through this method, a prominent rise in EGFP expression was demonstrated in
AAV9SLR transduced grafts as compared to AAV9WT control treated tissue.
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These data demonstrate that AAV9SLR can transduce SMCs of ex vivo treated aortic
grafts, but fails to infect target cells when administered systemically into the circula-
tion.
5.2.6 Effect of ex vivo transduction with AAV9SLR expressing hpAP-1 consensus
RNA decoy ODNs
Expression of hpAP-1 RNA decoy ODNs in transduced aortic grafts
After having found a reliable and reproducible method to transduce SMCs in explanted
aortic tissue, thoracic aortic grafts were treated ex vivo with AAV9SLR expressing
hpAP-1 cons RNA decoy ODN, as well as hpAP-1 mut RNA decoy ODNs as a control.
The presence of RNA decoy ODNs following vector treatment was first demonstrated
by F.I.S.H. For this purpose, the molecular beacon validated in the in vitro F.I.S.H. anal-
ysis was used. The results point out that aortic grafts treated ex vivo with the designed
AAV9SLR express high levels of hpAP-1 RNA decoy ODNs, as shown by red fluores-
cence intensity which is consistent with the amount of probe hybridized to the shRNA.
As a negative control a non-transduced graft isolated from a mgR/mgR mouse was used,
which showed almost no fluorescence on the Cy5 channel, accounting for the specificity
of the method (Fig. 26).
Fig. 26: Hairpin AP-1 RNA decoy ODNs are expressed in ex vivo transduced mgR/mgR aortic grafts,
four weeks after vector treatment. RNA F.I.S.H. was performed to show shRNA expression in cryosections of
AAV9SLR treated grafts, 4 weeks after transduction. DAPI staining (blue) was used to visualize nuclei. Red fluores-
cence represents hybridized probe to the target. hpAP-1 RNA decoy ODNs were detected both in the nucleus and in
the cytoplasm of transduced cells. The scale bar represents 25 µm. (n=4, exemplary images).
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Expression of AP-1 target genes in transduced aortic grafts
In order to demonstrate that AAV9SLR-mediated hpAP-1 consensus RNA decoy ODNs
delivery in aortic tissue can lead to neutralization of the transcription factor, the mRNA
levels of AP-1 target genes were assessed. As previously reported in patient samples
[94], MMP9 and MCP-1 mRNA levels were significantly increased in the aorta of
mgR/mgR mice which did not receive AAV treatment, as compared to WT controls
(Fig. 27). Similar to the results of in vitro experiments, transduction with AAV9SLR
expressing the mutated form of decoy ODNs had no effect on the analysed genes (Fig.
27). Remarkably, AAV9SLR-mediated generation of hpAP-1 cons RNA decoy ODNs
in aortic grafts led to a significant decrease in both analysed AP-1 target genes.
Fig. 27: AAV9SLR-mediated delivery of hpAP-1 consensus RNA decoy ODNs significantly decreases AP-1
target genes in ex vivo transduced mgR/mgR aortic grafts. MMP9 and MCP-1 mRNA levels of AAV9SLR trans-
duced aortic grafts were normalised to RPL32 as housekeeping gene and normalized to aortic samples isolated from
age matched wild type mice. (n=6, *** p < 0.001).
MMP2 and MMP9 protein levels in transduced aortic grafts
Having shown a clear and significant effect of AAV9SLR-mediared hpAP-1 consen-
sus RNA decoy ODNs generation on AP-1 target gene expression, the protein levels of
gelatinases were further investigated in transduced tissue. Thus, immunohistochemistry
was performed for assessment of MMP2 and MMP9 in treated grafts. The experiments
revealed that both MMP2 and MMP9 protein levels were significantly increased in non-
treated mgR/mgR thoracic aorta as well as in mutated AAV9SLR transduced grafts in
comparison to control (Fig. 28). In consistence with the mRNA results, a dramatic de-
crease in the expression of both gelatinases was noted in thoracic aortae treated with
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active AAV9SLR expressing hpAP-1 consensus RNA decoy ODNs. Representative im-
ages and analysis are shown in Fig. 28.
Fig. 28: AAV9SLR-mediated expression of hpAP-1 consensus RNA decoy ODNs significantly decreases MMP2
and MMP9 protein levels in ex vivo transduced mgR/mgR aortic grafts. Illustrative images of immunohistochem-
istry experiments showing MMP2 and MMP9 immunohistochemsitry (red). DAPI staining (blue) was used to mark
nuclei. Relative mean fluorescence intensity was analysed and normalized to values of the WT control mice. The
scale bar represents 25 µm. (n=6, 20 images analysed/ treatment group, ** p< 0.01).
MMP12 protein level in transduced aortic grafts
MMP12 or macrophage elastase was another target protein investigated in the context of
Marfan syndrome. The importance of MMP12 in the dissection of aortic aneurysm was
previously shown [187]. MMP12 does not only cleave elastin, but also other components
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of the extracellular matrix such as collagen and laminins and hence can be an important
factor in the development of elastin fragmentation noted in Marfan syndrome.
To determine which cell types express MMP12 in aortic tissue isolated from mgR/mgR
mice, co-staining with SMA was performed. Immunohistochemistry analysis showed
that MMP12 was expressed not only by SMCs cells in the media, but also by cells in
the adventitia. (Fig. 29).
Fig. 29: MMP12 protein expression in mgR/mgR aorta. Representative fluorescent images of MMP12 immuno-
histochemistry analysis (red) and SMA (magenta) in Marfan aortic frozen. Overlay with DAPI (blue) and elastin
autofluorescence (green) is shown. Scale bar represents 50 µm. (n=3, exemplary images).
Having shown a high MMP12 protein expression in the thoracic aorta of mgR/mgR
mice, the level of this elastase was evaluated following viral treatment. As shown in
Fig. 30, MMP12 protein level in mgR/mgR mice is remarkably increased in comparison
to WT controls. Moreover, immunohistochemistry experiments proved that AAV9SLR
expressing hpAP-1 consensus but not mutated RNA decoy ODNs caused a significant
2-fold decrease in MMP12 protein levels of mgR/mgR aortic grafts.
MMP activity in transduced aortic grafts
To test whether transduction with AAV9SLR expressing hpAP-1 consensus RNA decoy
ODNs has an effect not only on MMP protein level in aortic grafts but also on total MMP
activity, the tissue was treated with the previously used FRET substrate. Cryosections
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Fig. 30: AAV9SLR-mediated delivery of hpAP-1 consensus RNA decoy ODNs significantly decreases MMP12
protein level in ex vivo transduced grafts. Representative MMP12 (magenta) immunohistochemistry images and
statistical quantification of the mean fluorescence intensity, normalized to the WT control mice. Elastin autofluores-
cence was recorded on the green channel. Scale bar represents 50 µm. (n=6, 20 images analysed/group, ** p< 0.01).
were incubated at 37 °C in Ca2+-containing buffer, to allow substrate degradation and
red fluorescence intensity was measured. A red signal was observed in target SMCs,
but non-specific binding of the substrate to elastin fibers was noted, which could not
be successfully eliminated by washing steps. Therefore, the fluorescent intensity which
does not overlay with the green autofluorescence of elastin fibers was analysed.
Consistent with the MMP immunohistochemistry analysis, this experiment showed that
mgR/mgR aortic frozen sections, as well as AAV9SLR control treated grafts present el-
evated MMP activity in comparison to the wild type cryosections. However, AAV9SLR-
mediated neutralization of AP-1 led to a pregnant decreased MMP activity in SMCs, as
shown in Fig. 31.
Reactive oxygen species generation in transduced aortic grafts
Having previously demonstrated that transduction with AAV9SLR expressing hpAP-1
consensus RNA decoy ODNs has a beneficial effect on IL-1β-induced oxidative stress in
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Fig. 31: AAV9SLR-mediated expression of hpAP-1 consensus RNA decoy ODNs significantly decrease MMP
activity in ex vivo transduced mgR/mgR aortic grafts. Representative images depicting the fluorescence of cleaved
MMP substrate in aortic cryosections (red). Elastin fibers were detected by imaging the autofluorescence on the green
channel. Nuclei were detected by DAPI staining (blue). The graph shows statistical quantification of relative mean red
fluorescence intensity of the different treatment groups. MMP activity was normalized to the values of WT control
cryosections. Scale bar represents 25 µm. (n=6, 20 images analysed/group, * p< 0.05).
vitro in SMCs, we next investigated if a similar result can be obtained in ex vivo treated
grafts. In situ ROS detection in cryosections using DHE showed a significant decrease
in the amount of superoxide ions following AP-1 neutralization. The cryosections of
wild type aortic tissue showed no DHE fluorescence, as depicted in Fig. 32.
ZO-1 protein level in transduced aortic grafts
Low protein levels of tight junctions such as ZO-1 (zonula occludens-1) in endothe-
lial cells was shown to be related to aneurysm formation. Moreover, a decrease in the
number of tight junctions is correlated with infiltration of inflammatory cells, especially
monocytes [199]. In accordance with these results, a much higher transduction effi-
ciency of SMCs in aortic grafts of mgR/mgR mice was observed, in comparison to WT
mice, proven by EGFP immunohistochemistry (Fig. 33). Endothelial cells, visualized
by CD31 staining, were transduced efficiently in both mgR/mgR and WT mice. These
results show an increased permeability of the endothelial cell layer in mgR/mgR mice,
allowing the viral vector to reach the media.
We then wanted to investigate whether the endothelial barrier permeability is caused
by disruption of ZO-1 protein in mgR/mgR aorta. As hypothesised, ZO-1 immunohis-
tochemistry proved a significant 60% decrease in ZO-1 protein level in endothelial cells
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Fig. 32: AAV9SLR-mediated expression of hpAP-1 consensus RNA decoy ODNs significantly diminishes the
amount of ROS generated in ex vivo transduced mgR/mgR aortic grafts. DHE nuclear fluorescence (red) was
quantified in the indicated treatment groups and normalized to non-treated mgR/mgR DHE mean fluorescence inten-
sity. Scale bar represents 25 µm. (n=6 for mgR/mgR mice, 20 images analysed/group, * p < 0.05).
Fig. 33: Ex vivo transduction of aortic grafts with AAV9SLR-EGFP in wild type and mgR/mgR mice. En-
dothelial cells were labelled using CD31 antibody (red). EGFP immunohistochemistry (magenta) was used to show
successful transduction. DAPI marks nuclei (blue) and elastin autofluorescence (green) was visualized in the green
channel. The scale bar represents 25 µm. (n=3, exemplary images.)
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of mgR/mgR mice, as compared to wild type controls. A co-staining with CD31 anti-
body was used to label endothelial cells specifically, as pictured in Fig. 34. Since ZO-1
Fig. 34: AAV9SLR-mediated expression of hpAP-1 RNA decoy ODNs significantly increase ZO-1 protein level
in ex vivo transduced mgR/mgR aortic grafts. Representative images showing ZO-1 immunohistochemistry in WT
as well as mgR/mgR mice. CD31 (green) and ZO-1 (red) overlay was performed to assess ZO-1 protein expression in
endothelial cells. The graph represents the statistical quantification of fluorescence images. The scale bar represents
75 µm. (n=3 for WT mice, n=6 for mgR/mgR mice, 20 images were analysed/group, * p < 0.05).
protein level is downregulated by oxidative stress [165] and is a substrate for MMPs
[199], the next question was whether ZO-1 protein level can be restored in endothelial
cells following AAV9SLR-mediated AP-1 neutralization. The results show that indeed,
generation of hpAP-1 RNA decoy ODNs by AAV9SLR transduction in aortic grafts led
to a marked increase in ZO-1 protein level as compared to controls (Fig. 34).
Monocyte infiltration into the thoracic aorta
The pro-inflammatory component of Marfan syndrome has already been well estab-
lished [164]. The thoracic aorta of Marfan patients, as well as mgR/mgR mice present
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a strong infiltration of monocytes and T cells, which secrete MMPs and in turn con-
tribute to formation of elastin breaks. After having found that treatment with the de-
signed AAV9SLR expressing hpAP-1 consensus RNA decoy ODNs can significantly
downregulate MCP-1 which acts as a chemoattractant for inflammatory cells, it was hy-
pothesized that in transduced grafts the level of macrophages is also reduced.
For this purpose, F4/80 immunohistochemsitry was performed and macrophage density
in aortic grafts was analysed. As previously reported, [164] most of the macrophages
were detected in the adventitia of mgR/mgR mice, whereas the sections of WT mice
presented no inflammatory cells (Fig. 35). The density of F4/80 positive cells was not
affected by treatment with control AAV9SLR, while transduction with AAV9SLR ex-
pressing hpAP-1 cons RNA decoy ODNs resulted in a significant 38% decrease in the
infiltration of macrophages.
Fig. 35: AAV9SLR-mediated expression of hpAP-1 RNA decoy ODNs significantly decrease the macrophage
infiltration in the adventitia of ex vivo transduced thoracic aortae. Representative images showing F4/80 im-
munohistochemistry (red), used to mark macrophages. Elastin autofluorescence was recorded in the green channel
and DAPI (blue) was used to mark cell nuclei. The graph shows relative macrophage density in the adventitia, nor-
malized to WT control counts. The scale bar represents 50 µm. (n=6, 20 images analysed/group, ** < 0.01).
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Effect of AAV9SLR-mediated decoy ODNs expression on aortic elastolysis
To explore the effect of AAV9SLR-mediated hpAP-1 RNA consensus decoy ODNs gen-
eration on elastin architecture of aortic mgR/mgR grafts, elastic van Gieson staining was
carried out and the degree of fragmentation was measured. As a read-out, the number
of islands of damage was counted, as previosly described [132]. An island of damage
was considered as a defined area where an elastin break can be detected, surrounded by
conjective tissue.
In non-treated as well as in AAV9SLR control transduced mgR/mgR cryosections, a
high number of islands of damage was observed. On the other hand, grafts treated with
AAV9SLR expressing hpAP-1 consensus RNA decoy ODNs showed a significant de-
crease in the occurrence of islands of damage. These findings show that AAV9SLR-
mediated AP-1 neutralization can inhibit elastin loss in mgR/mgR mice and therefore
stabilize the aortic aneurysms dissection, which is a characteristic feature of Marfan
syndrome.
Fig. 36: AAV9SLR-mediated expression of hpAP-1 consensus RNA decoy ODNs significantly improve elastic
fiber structure in ex vivo transduced mgR/mgR thoracic aortae. Representative images of elastin van Gieson
histologic stainings and statistical quantification of the frequency of islands of damage per field of view, shown by
black arrows. Scale bar represents 50 µm. (n=6 for mgR/mgR mice, 30 images analysed/group, *** p< 0.001).
Activation of KLF4 in aortae of mgR/mgR mice
Other transcription factors besides AP-1 could play major roles in aortic aneurysm for-
mation and dissection in Marfan syndrome. One candidate which was described in liter-
ature is KLF4 [196]. In order to determine the activation pattern of KLF4 (Kruppel-like
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factor 4) in aortic frozen sections isolated from mgR/mgR mice, imuunohistochemistry
using a specific antibody was performed. Following DAPI staining, the percentage of
positive cells was calculated. The quantification shows a clear increase in KLF positive
nuclei in mgR/mgR mice as compared to wild type aortae, as demonstrated in Fig. 37.
Fig. 37: KLF4 nuclear translocation is increased in mgR/mgR aorta. Representative images showing KLF4
immunohistochemistry (red) and DAPI (blue). The statistical quantification of the percentage of KLF4 positive nuclei
in the two groups is shown. Scale bar represents 25 µm. (n=3, 12 images analysed/group, *** p< 0.001).
5.3 Heart hypertrophy project
5.3.1 ”Naked” hpNFAT decoy ODNs uptake by cardiomyocytes
First, cardiomyocyte ability to take up hpNFAT decoy ODNs was analysed. For this pur-
pose, HL-1 cells, neonatal as well as adult cardiomyocytes were treated with Atto-590
labelled hp decoy ODNs at a final concentration of 10 µmol/L in complete Claycomb
medium. After 2 h, cells were fixed with PFA and the membranes were marked using
WGA. Confocal images show that hpNFAT decoy ODNs can be efficiently taken up
without any auxiliary means by cardiomyocytes. Red fluorescence was detected in the
nuclei, as well as in the cytoplasm, as depicted in Fig. 38.
Next, the effect of Lipofectamine-mediated decoy ODN delivery in HL-1 cells was ad-
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Fig. 38: Hairpin NFAT decoy ODNs are taken up by cardiomyocytes without auxilliary means. (A) Represen-
tative images of cardiomyocytes treated with Atto590-hpNFAT decoy ODNs (red) for 2 h and stained with WGA
(green). DAPI (blue) was used to mark cell nuclei. (B) Three dimensional reconstruction of Z-stack confocal images
showing nuclear and cytoplasmic localization of the decoy ODNs. The scale bar represents 25 µm. (n=4, exemplary
images).
dressed. Atto-590 labelled hpNFAT decoy ODNs were incubated with the transfection
reagent prior to addition to cell culture medium and the localization of red fluorescent
signal was assessed. As shown in Fig. 39, the efficiency of uptake through direct appli-
cation of the ”naked” decoy ODNs was significantly higher than the efficacy obtained
using the liposomal reagent. Consequently, for the next experiments no transfection
reagents were used for hpNFAT decoy ODNs delivery in cardiomyocytes.
5.3.2 ”Naked” hpNFAT decoy ODNs effect on cardiomyocyte hypertrophy
Fetal gene program
Having proven that decoy ODNs can be taken up by HL-1 cells and primary cardiomy-
ocytes, the next aim was to analyse the effect of NFAT1-4 neutralization on ET-1 in-
duced hypertrophy. Cells were treated with the active hpNFAT consensus decoy ODNs,
as well as control hpNFAT mutated decoy ODNs for 2 h after serum deprivation and
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Fig. 39: Lipofectamine-based transfection does not improve hpNFAT decoy ODNs uptake by HL-1 cells. Rep-
resentative images of Atto-590 labelled hpNFAT decoy ODNs (red) transfection with and without Lipofectamine.
Membranes were stained with WGA, visualized on the green channel. The graph summarises statistical quantifica-
tion of mean red fluorescence intensity of images in the two treatment groups. The scale bar represents 25 µm. (n=4,
20 images analysed/group, ** p< 0.01).
stimulated with 100 nmol/L ET-1 for 24 h. As a read-out, expression of fetal genes ANP
and BNP was analysed. In addition, BNP protein levels in the supernatant and in HL-1
cell lysates were measured.
As expected, exposure to ET-1 for 24 h led to an increase in fetal gene expression (Fig.
40A). NFAT1-4 neutralization by hpNFAT consensus decoy ODNs application prior to
stimulation decreased the expression of the two analysed pro-hypertrophic genes. On
the other hand, application of the inactive hp NFAT mutated decoy ODNs had no effect
on the investigated genes, as shown in Fig. 40A.
Similar to the mRNA results, a significant increase in BNP protein level was detected
by ELISA follwing 24 h ET-1 stimulation, as compared to control, while hpNFAT cons
decoy ODNs supplementation prior to ET-1 stimulation normalized BNP concentration
to the basal level, both in cell lysates and in supernatant. No significant effect on BNP
protein was observed in hpNFAT mutated decoy ODNs treated HL-1 cells, as depicted
in Fig. 40B.
Given the clear effect of the hpNFAT consensus decoy ODNs on ET-1 induced pro-
hypertrophic markers in HL-1 cell line, its efficiency in primary cardiomyocytes was
further investigated. For this purpose, isolated murine primary neonatal cardiomyocytes
were used. Comparable to the previous results, ET-1 induced a significant re-activation
5.3 Heart hypertrophy project 80
Fig. 40: Hairpin NFAT consensus decoy ODNs decrease ET-1 induced fetal gene program in HL-1 cells. (A)
mRNA levels of ANP and BNP were analysed in HL-1 cardiomyocytes as markers of ET-1 (100 nmol/L) induced
hypertrophic response. Gene expression was normalizeed to RPL32 as a housekeeping gene. (B) BNP protein levels
were measured in HL-1 cells supernatants and lysates using ELISA and reported to the concentration measured in
non-stimulated control cells. (n=4, * p< 0.05).
of the fetal gene program, which was abolished with hpNFAT cons decoy ODNs sup-
plementation in the medium 2 h before ET-1 stimulation, as depicted in Fig. 41.
Protein translation level
Hypertrophic growth of cardiomyocytes is accompanied by an increased rate of total
protein translation rate [83]. Therefore, the effect of hpNFAT decoy ODNs on this pa-
rameter was investigated by employing the non-radioactive SUnSET assay. First, HL-1
cells were treated with increasing concentrations of puromycin, ranging from 0.1 to 100
µmol/L in order to determine the optimal concentration of the compound to be further
used. Using high amounts of puromycin (> 50 µmol/L), a significant decrease in viable
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Fig. 41: Hairpin NFAT consensus decoy ODNs decrease fetal gene program in neonatal cardiomyocytes. Sta-
tistical quantification of ANP and BNP mRNA levels in neonatal cardiomyocytes in the indicated treatment groups.
RPL32 was used for gene expression normalization and non-stimulated HL-1 cells served as a control. (n=4, * p<
0.05.)
cells was observed, as proven by Alamar Blue assay (data not shown). On the other
hand, when less than 1 µmol/L puromycin was added to the medium, low fluorescent
signal was detected following anti-puromycin immunocytochemistry. Consequently, 10
µmol/L puromycin was chosen for subsequent experiments.
HL-1 cells were treated with hpNFAT decoy ODNs for 2 h in serum-free medium and
stimulated with ET-1 for 24 h. Afterwards, cardiomyocytes were subjected to puromycin
treatment and the amount of nascent proteins was detected by immunofluorescence
methods using a specific anti-puromycin antibody.
Exposure of HL-1 cardiomyocytes to the pro-hypertrophic stimulus ET-1 in serum-free
medium led to a significant increase in protein translation level, as shown in Fig. 42.
Pre-incubation with hpNFAT conensus decoy ODNs triggered a significant decrease of
ET-1 induced protein translation rate, while the hpNFAT mutated decoy ODNs had no
effect. Taken together, these results demonstrate that hpNFAT consensus decoy ODNs
reduce ET-1 induced HL-1 cells hypertrophy by decreasing the fetal gene program, and
additionally affecting cellular metabolism characteristic for hypertrophic growth.
5.3.3 AAV6 effect on cardiomyocyte hypertrophy
Fetal gene program
After having demonstrated that hpNFAT consensus decoy ODNs can attenuate the hy-
pertrophic changes induced by ET-1, the next aim was to investigate whether the same
effect can be achieved by expression of hpNFAT RNA decoy ODNs through AAV6
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Fig. 42: Hairpin NFAT consensus decoy ODNs decrease the level of total protein translation in HL-1 cells.
Representative images showing anti puromycin immunocytochemistry in different treatment groups. A Cy5 labelled
secondary antibody (red) was used and nuclei were marked by DAPI staining (blue). The graph summarizes the
statistical quantification of mean red fluorescence intensity in the indicated treatment groups. (n=4, 20 images anal-
ysed/tretament group, ** p< 0.01)
transduction. Therefore, AAV6 generating hpNFAT consensus as well as mutated RNA
decoy ODNs were produced. Using AAV6 at MOI=105 vp/cell, the transduction effi-
ciency measured as EGFP positive cells by fluorescence microscopy was determined to
be 80% in HL-1 cells. In addition, cell viability after transduction was not influenced
by AAV6 treatment, as indicated by Alamar Blue assay (data not shown). Three days
after vector treatment, HL-1 cells were stimulated with ET-1 100 nmol/L for 24 h after
serum-deprivation.
The results of gene expression analysis show that AAV6 expressing hpNFAT consensus
RNA decoy ODNs markedly reduced the expression of fetal gene program represented
by ANP and BNP almost to basal level, as shown in Fig. 43. In a similar manner, BNP
protein level in HL-1 cells supernatant was significantly downregulated after transduc-
tion with hpNFAT consensus RNA decoy ODNs producing AAV6. The control AAV6
expressing a mutated form of the RNA decoy ODNs had no effect, neither on the anal-
ysed genes nor on BNP protein level (Fig. 43).
Protein translation level
The effect of AAV6-mediated hpNFAT RNA decoy ODNs delivery on ET-1 induced
protein translation level was further analysed by SUnSET assay as measured before in
Chapter 5.3.2. For this purpose, AAV6 transduced cells were treated with puromycin
after 24 h ET-1 stimulation. The analyses of confocal fluorescence images following
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Fig. 43: AAV6-mediated delivery of hpNFAT consensus RNA decoy ODNs decreases ET-1 induced fetal gene
program in HL-1 cells. A. Fetal genes ANP and BNP was analysed on mRNA level in AAV6 transduced HL-1
cardiomyocytes. The analysis was made using RPL32 as a housekeeping gene for mRNA expression analysis. (n=5,
* p< 0.05, ** p< 0.01). B. BNP protein level in cardiomyocyte supernatants was measured using ELISA and values
were normalized to the BNP concentration of non-stimulated control cells. (n=4, * p<0.05, ** p<0.01).
immunostaining with anti-puromycin antibody confirmed, similarly to previous exper-
iments, that ET-1 application caused a pronounced increase in total protein translation
rate as compared to non-stimulated control. On the other hand, NFAT1-4 neutraliza-
tion caused a significant reduction in the rate of protein translation. Treatment with the
control mutated AAV6 did not affect this parameter, as shown in Fig. 44.
5.3.4 NFAT5 activation in the presence of hp decoy ODNs
The designed hpNFAT decoy ODNs has high specificity to NFAT1, NFAT2, NFAT3 and
NFAT4, but does not neutralize NFAT5 due to its different binding matrix. NFAT5 is a
critical transcription factor for heart development and response to hyperosmotic stress.
Consequently, knockout of this transcription factor causes embryonic lethality and ab-
normal cardiomyocyte function [127]. Moreover, hearts isolated from NFAT5 knock-out
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Fig. 44: AAV6-mediated expression of hpNFAT consensus RNA decoy ODNs decrease ET-1 induced protein
translation rate. Representative confocal images showing anti-puromycin staining (red) in HL-1 cells. A Cy5 la-
belled secondary antibody (red) was used in the present experiment. Nuclei were labelled with DAPI (blue). The
graph represents the statistical summary of mean red fluorescence intensity of indicated treatment groups. Non-
stimulated cells served as controls. Scale bar represents 10 µm. (n=4, 20 images were quantified/group, ** p<0.001).
embryos present with decreased cardiomyocyte density and extreme thinning of the ven-
tricular wall [127].
Taking into account the major role of this transcription factor in cardiomyocyte physi-
ology, the expression and activation of NFAT5 in the presence of NFAT1-4 neutralizing
”naked” hp decoy ODNs as well as RNA decoy ODNs delivered through AAV6 trans-
duction was further addressed. For this purpose, HL-1 cells were treated with the hpN-
FAT decoy ODNs or transduced with AAV6 expressing hpNFAT RNA decoy ODNs and
afterwards subjected to hyperosmotic stress induced by LiCl 100 mmol/L treatment.
As expected, the analysis of immunofluorescence images showed a dramatic close to 5-
fold increase in nuclear NFAT5 translocation in response to LiCl treatment (Fig. 45A).
Moreover, the results demonstrate that neither hpNFAT decoy ODNs treatment, nor
transduction with the designed AAV6 had an effect on NFAT5 activation, as depicted in
the quantification of NFAT5 positive nuclei in Fig. 45A.
To further support these data, the mRNA levels of NFAT5 target genes SMIT and HSP70
were analysed. qPCR analysis revealed a significant increase the mRNA levels of both
investigated genes following LiCl exposure, which was not affected by NFAT decoy
ODNs pre-treatment or AAV6 transduction, as shown in Fig. 45B.
These data demonstrate that NFAT5 nuclear translocation and function is not impaired
by the hpNFAT decoy ODNs or hpNFAT RNA decoy ODNs.
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Fig. 45: Hairpin NFAT consensus decoy ODNs do not affect NFAT5 translocation and function under hypos-
motic stress induced by LiCl treatment. (A) Analysis of NFAT5 distribution in HL-1 cells subjected to hypertonic
stress (100 mmol/L LiCl). The graph shows statistical quantification of NFAT5 (red) positive nuclei, marked using
DAPI (blue) staining. Scale bar represents 25 µm. (n=4, 20 images analysed/group, *** p<0.001).(B) Gene expres-
sion analysis of NFAT5 target genes SMIT (sodium/myo-inositol cotransporter) and HSP70 (heat shock protein 70).
RPL32 was used as a housekeeping gene and the measurements were normalized to the control non-treated cells.
(n=4, ** p<0.01).
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5.3.5 In vivo hpNFAT RNA decoy ODNs effect
The in vitro experiments indicate reduced ET-1 induced hypertrophic response of car-
diomyocytes treated with both hpNFAT consensus decoy ODNs and AAV6 expressing
hpNFAT consensus RNA decoy ODNs. In order to prove the in vivo efficiency of the
designed AAV, heart hypertrophy was induced by transverse aortic constriction (TAC)
The surgery was performed by Theresa Ruf and Lin Ding, Internal Medicine III, Clinic
for Cardiology, Angiology and Pneumology, University Clinic Heidelberg. AAV9 was
previously shown to be the most effective virus serotype to transduce cardiomyocytes
in vivo following systemic tail-vein injection [95]. Hence, the delivery of hpNFAT RNA
decoy ODNs was made by using this virus serotype (1012 genomic particles/mouse) 2
weeks before surgery, in order to allow the generation of RNA decoy ODNs into the tis-
sue. The survival rate after TAC was 95% (19 surviving mice out of 20). One mouse in
the control AAV9 injected group lost a significant amount of weight, developed drastic
dilated heart failure with extremely low ejection fraction (20%) and died 5 weeks after
surgery.
EGFP and RNA decoy ODNs expression after transduction
Successful cardiomyocyte transduction by AAV9 was demonstrated employing EGFP
immunohistochemistry 2 weeks after injection. As shown in Fig. 46A, EGFP protein
was detected in the myocardium of both AAV9-injected groups, while control PBS
treated mice did not present any EGFP signal in cardiomyocytes. These data suggest that
cardiomyocyte transduction can be achieved by systemic tail-vein injection of AAV9.
The next aim was the detection of hpNFAT RNA decoy ODNs in the cardiomycytes
of AAV9 injected animals. Hence, 5 µm heart frozen sections were subjected to RNA
F.I.S.H. The detection of shRNAs was carried out using a molecular beacon with com-
plementary sequence of the decoy ODNs and which emits red fluorescence when bound
to the target. As a control, heart cryosections of PBS-injected mice were used. As pre-
sented in Fig. 46B, hpNFAT RNA decoy ODNs were expressed in the tissue isolated
from AAV9 injected mice, while samples of PBS treated mice presented no fluores-
cence signal.
Effect of AAV9 injection on heart function
Having determined that AAV9 systemic application leads to cardiomyocyte transduction
and subsequently to hpNFAT RNA decoy ODNs production, its effect on heart function
was further investigated.
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Fig. 46: Transduction efficiency of cardiomyocytes of AAV9 injected mice, 2 weeks after virus injection. (A)
Representative images showing EGFP immunohistochemistry (green) performed in heart cryosections. (B) Detec-
tion of hpNFAT consensus RNA decoy ODNs in heart cryosections by F.I.S.H. Red fluorescence corresponds to
hybridization of the probe to the target and proves the generation of decoy ODNs. Scale bar represents 10 µm. (n=3
for PBS injected mice, n=8 for AAV9 injected groups, exemplary pictures).
Echocardiography was performed 2 weeks after AAV9 injection, to analyse the effect of
the designed AAV9 before TAC-induced heart hypertrophy. As shown in Fig. 47, AAV9
expressing neither hpNFAT consensus, not mutated RNA decoy ODNs had any effect
on the ejection fraction at baseline. Consistently, no differences were observed in the
calculated LV mass values.
Having established that AAV9 expressing hpNFAT decoy ODNs does not affect heart
function on the basal level, TAC was performed in AAV9 injected mice and the effect
of NFAT1-4 neutralization in this heart hypertrophy model was analysed. Mice were
sacrificed 6 weeks after surgery.
Since a high variation of body weight was observed between groups (Fig. 49), the ratio
heart weight/tibia length (HW/TL) was used as an established readout for myocardial
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Fig. 47: Echocardiographic assessment of heart function in AAV9 injected mice prior to hypertrophy induction
by TAC. Representative M-mode echocardiograms and analysis of ejection fraction as a functional cardiac parameter
and LV mass on basal level. EF: ejection fraction; LV: left ventricle. (n=3 for PBS injected group, n=8 for AAV9
injected groups).
hypertrophic growth [206]. The measurements showed that AAV9 mediated hpNFAT
consensus RNA decoy ODNs expression significantly reduced left ventricular hypertro-
phy (HW/TL) as compared to PBS treated group, while the mutated control AAV9 had
no effect. Moreover, heart failure induced lung edema was analysed. In accordance to
HW/TL measurements, the results prove a dramatic improvement of this parameter by
a significant decrease in the group treated with AAV9 expressing hpNFAT consensus
RNA decoy ODNs,as compared to controls (Fig. 48A).
Follow-up echocardiography showed as well an amelioration of heart function param-
eters after NFAT1-4 neutralization by RNA decoy ODNs. As expected, stenosis of the
transverse aorta by surgery led to a significant increase in LV mass. Correspondingly,
heart function severely deteriorated, as demonstrated by a dramatic decrease in EF, as
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Fig. 48: AAV9-mediated generation of hpNFAT consensus RNA decoy ODNs decreases TAC-induced heart
hypertrophy (A) The graphs summarize the statistical quantification of markers of heart hypertrophy (HW/TL)
and heart failure (LW/TL). The pictures on the left show gross morphology of the different AAV9 injected groups
after TAC. (n=3 for PBS injected group, n=8 for AAV9 injected groups, ** p<0.01). (B) Representative M-mode
echocardiograms of control mice and of animals subjected to TAC. On the right, the graphs present statistical analysis
of calculated LV (left ventricle) mass and EF (ejection fraction). (n=3 for PBS injected group, n=8 for AAV9 injected
groups ** p<0.01; HW: heart weight, TL: tibia length, LW: lung weight, LV: left ventricle, EF: ejection fraction).
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Fig. 49: Mice body weight measurements before and after TAC surgery. (n=3 for PBS injected group, n=8 for
AAV9 injected groups)
compared to pre-TAC values. However, the injection of AAV9 expressing hpNFAT con-
sensus RNA decoy ODNs, but not the mutated control had a beneficial effect on both
LV mass and EF (Fig. 48). Thus, echocardiographic measurements confirm that hpN-
FAT cons RNA decoy ODNs can successfully improve cardiac performance 6 weeks
post TAC.
5.3.6 Effect of AAV9 injection on phospholamban phosphorylation status
Phospholamban (PLN) is an important regulator of cardiac contractility and inhibits
SERCA Ca2+ release. Under pathological stress conditions, PLN is phosphorylated by
protein kinase A (PKA) at serine 16 (Ser16) [62]. Hence, the phosphorylation status of
PLN was further addressed in protein extracts isolated from AAV9 transduced hearts,
using Western blot analysis. As a measure of protein load Ponceau staining was used,
due to the different expression of commonly used internal controls in diseased cardiac
tissue, as previously described [54].
The quantification of Western Blot results (Fig. 50) indicates that AAV9 expressing
hpNFAT consensus RNA decoy ODNs significantly decreased the phosphorylation state
of PLN by 72% in comparison to the PBS treatment. As in the previous experiments,
the control AAV9 injection prior to TAC had no effect on the level of phosphorylated
PLN.
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Fig. 50: AAV9-mediated expression of hpNFAT consensus RNA decoy ODNs decreases the phosphorylation
level of PLN (Ser16) in heart tissue. Western blot analysis using a specific antibody that recognises the phosphory-
lated PLN at Ser16. Ponceau staining was used as a loading control. (n=3, ** p<0.01).
Effect of AAV9 injection on fetal gene program
Next, the effect of AAV9 injection on pro-hypertrophic markers ANP, BNP and RCAN-1
was examined. As expected, 6 weeks of pressure overload induced a significant increase
in the expression of fetal genes in the myocardium, as compared to sham-operated
group. Notably, AAV9-mediated delivery of hpNFAT cons RNA decoy ODNs prior to
TAC could significantly decrease the mRNA levels of the three analysed genes. (Fig.
51A).
In addition, BNP protein level was measured in the heart tissue, as well as in plasma
isolated from treated mice by ELISA. Remarkably, prophylactic injection of AAV9 ex-
pressing hpNFAT consensus RNA decoy ODNs significantly reduced BNP plasma level
as shown in Fig. 51B. The control AAV9 had no effect in this context. Similarly, BNP
protein level in plasma isolated from mice subjected to TAC was shown to be 3-fold
diminished in the group which received gene therapy.
Effect of AAV9 injection on cardiac fibrosis
Fibrosis is a hallmark of heart failure and is associated with collagen deposition, con-
tributing to impairment of heart function. It was previously shown that fibrosis is another
factor that leads to TAC-induced cardiac pathology [225].
At first, fibrosis markers were analysed on mRNA level in heart tissue. The results con-
firmed a significant increase in mRNA levels of fibrosis markers collagen-3, TGF-β and
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Fig. 51: AAV9-mediated delivery of hpNFAT consensus RNA decoy ODNs into the myocardium decreases the
expression of TAC-induced pro-hypertrophic markers. (A) Gene expression analysis of ANP, BNP and RCAN-1
in the heart tissue, using RPL32 as a housekeeping gene. Values were normalized to sham-operated mice as control.
(B) BNP protein level was measured by ELISA in plasma and heart protein extracts. (n=3 for sham and PBS injected
groups, n=8 for AAV9 injected groups, * p<0.05, ** p<0.01)
CTGF in the hearts of mice subjected to TAC and injected with PBS (Fig. 52A). How-
ever, when mice were injected with AAV9 expressing hpNFAT consensus RNA decoy
ODNs prior to TAC, a significant decrease in remodelling-associated genes were ob-
served, as demonstrated in Fig. 52A.
Next, collagen deposition was analysed by Masson’s Trichrome staining in heart sec-
tions. Fibrosis was observed to be associated with blood vessels (perivascular fibrosis),
but interstitial fibrosis in between cardiomyocytes was as well noted in myocardium of
TAC-treated animals.
The results prove intense fibrosis in hearts isolated from PBS and AAV9 control injected
mice, while AAV-mediated NFAT1-4 neutralization prior to in vivo hypertrophy induc-
tion significantly reduced the area of collagen deposition, as depicted in Fig. 52B. These
data support the gene expression analysis, proving the beneficial effect of AAV9 medi-
ated hpNFAT consensus RNA decoy ODNs on collagen deposition in the myocardium
of mice subjected to TAC.
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Fig. 52: AAV9-mediated delivery of hpNFAT consensus RNA decoy ODNs into the myocardium decreases
fibrosis markers in heart sections. (A) mRNA levels of fibrosis markers collagen 3, TGF-β and CTGF in cardiac
tissue. Gene expression was normalized to RPL32 as a housekeeping gene (n=3 for sham and PBS injected groups,
n=8 for AAV9 injected groups, * p<0.05, ** p<0.01). (B) Representative left ventricular cross sections revealing
perivascular and interstitial fibrosis. The graphs present the statistical quantification of the percentage of fibrosis
(blue area) in myocardium of mice of different treatment groups. Scale bar represents 20 µm. (n=3 for sham and PBS
injected groups, n=8 for AAV9 injected groups, * p<0.05, ** p<0.01).
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Effect of AAV9 injection on β-MHC protein level
Heart hypertrophy is characterized by re-activation of the β isoform of the myosin heavy
chain, which is expressed under normal conditions in the late stages of embryonic de-
velopment [167]. Therefore, the relative amount of this protein was analysed as an addi-
tional marker of hypertrophic response in the 3 different treatment groups. Immunohis-
tochemical analysis demonstrated that PBS, as well as the control AAV9 injected mice
re-expressed β-MHC in cardiomyocytes, as depicted in Fig. 53, whileAAV9-mediated
hpNFAT RNA decoy ODNs expression significantly reduced the levels of this protein
with 49± 9% as compared to the control.
Fig. 53: AAV9-mediated delivery of hpNFAT consensus RNA decoy ODNs into the myocardium reduces β-
MHC protein level. Representative images depicting β-MHC immunohistochemistry (red) in heart cryosections.
Nuclei were stained with DAPI (blue). The graph shows the statistical summary of the quantification of mean red
fluorescence intensity in different treatment groups. The scale bar represents 10 µm. (n=3 for PBS injected groups,
n=8 for AAV9 injected groups, 20 images analysed/group. *** p<0.001)
5.3.7 Effect of AAV9 injection on protein translation rate
Cardiomyocyte hypertrophy involves an accelerated protein translation rate which can
be determined, as shown in the in vitro experiments, by using the non-radioactive SUn-
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SET assay. This method was further applied for the detection of total protein translation
level in heart tissues of different treatment groups.
Analysis of confocal images revealed a dramatic decrease in mean fluorescence intensity
of the cryosections of mice injected with AAV9 expressing hpNFAT consensus RNA de-
coy ODNs (Fig. 54). As in previous experiments, the control AAV9 had no influence on
the rate of protein translation.
Fig. 54: AAV9-mediated delivery of hpNFAT consensus RNA decoy ODNs decreases the rate of protein trans-
lation. Representative images of anti-puromycin immunohistochemistry (red) which correlates with the total protein
translation rate. The graph depicts the quantification of mean red fluorescence intensity of confocal images in differ-
ent treatment groups. Scale bar represents 20 µm. (n=3 for PBS injected groups, n=8 for AAV9 injected groups, 20
images analysed/group. *** p<0.001).
5.3.8 Effect of AAV9 injection on cardiomyocyte size
Next, cardiomyocyte hypertrophy was addressed directly by measuring cell size. In this
respect, 5 µm thick frozen sections were treated with WGA to label specifically cell
membranes. Prior to staining, cardiomyocyte orientation was analysed. Both long and
short axis were considered for quantification, to have a two dimensional assessment of
cell size. The results clearly confirm that AAV9-mediated hpNFAT consensus RNA de-
coy ODNs expression can normalize cardiomyocyte size in TAC-subjected mice. Cells
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were significantly smaller than cardiomyocytes in the control groups in both width and
length. Injection with AAV9 expressing the mutated control RNA had no effect on car-
diomyocyte size, as shown in Fig. 55.
To further confirm cell size measurements, hematoxilin-eosin staining was performed
Fig. 55: AAV9-mediated delivery of hpNFAT consensus RNA decoy ODNs decreases cardiomyocyte dimen-
sions. Representative images of WGA stainings (red), labeling cell membranes of cells in short and long axis. Car-
diomyocyte width and length were analysed using ImageJ. Scale bar represents 20 µm. (n=3 for PBS injected groups,
n=8 for AAV9 injected groups, 20 images analysed/group, *** p< 0.001).
and relative cardiomyocyte area was analysed. As expected, TAC induced a signifi-
cant increase in cell area as compared to sham operated mice (Fig. 56). Moreover, the
changes in left ventricular wall dimensions, assessed by echocardiography were vali-
dated by this technique, as an increased left ventricular wall thickness was observed
following TAC (Fig. 56). However, injection of AAV9 expressing hpNFAT consensus
RNA decoy ODNs two weeks before TAC had a favourable effect on heart architecture,
as proven in decreased left ventricular wall thickness and reduced cardiomyocyte size
as compared to the controls (Fig. 56).
5.3.9 Effect of AAV9 injection on T-tubule organization
In healthy cardiomyocytes, the T-tubule system is highly organized, with regular spacing
distance of approximately 2 µm, which is essential for excitation-contraction coupling.
It was previously shown that T-tubule remodelling accompanies the transition from heart
5.3 Heart hypertrophy project 97
Fig. 56: AAV9-mediated delivery of hpNFAT consensus RNA decoy ODNs reduces left ventricular and car-
diomyocyte size. Representative images of H&E stainings of heart sections after TAC, as well as sham operated
control mice. The graph shows relative cell area calculated using ImageJ. Values were normalized to the sham group.
Scale bar represents 10 µm. (n=3 for PBS injected groups, n=8 for AAV9 injected groups, 15 images analysed/group,
*** p< 0.001).
hypertrophy to heart failure, and this process was observed in various models of pres-
sure overload [215]. Therefore, the next aim was to determine whether prophylactic
AAV9-mediated NFAT1-4 neutralization can prevent the pathological reorganization of
the T-tubules which precedes heart failure.
As expected, TAC led to a dramatic decrease in T-tubule regularity and density in
cardiomyocytes, as shown in Fig. 57. Similarly, the control AAV9 injected mice pre-
sented with a disrupted T-tubule system. AAV9-mediated hpNFAT consensus RNA de-
coy ODNs expression in cardiomyocytes led to a regular occurrence of T-tubules, as
shown by plotting the fluorescence intensity profile of WGA staining, depicted in Fig.
57A. T-tubule frequency was then analysed by already established regularity markers
T-index, tubularization percentage and T-power. T-index was defined as the percentage
of T-tubule area in cardiomyocytes. Cells presenting T-index above 2 were considered
tubular, and the percentage of tubulated myocytes was further analysed (percentage
tubularization). T-power was considered to be the frequency at which the 2 µm regu-
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lar T-tubule pattern is observed, and was calculated by plotting the power spectrum of
Fourier transformed images (Fig. 57 C). The results of the analysis of these parameters
show a significant increase in T-index, percentage of tubular cells and T-power in car-
diomyocytes of mice receiving gene therapy.
These observations conclude that T-tubule network organization can be rescued by
NFAT1-4 neutralization in the context of TAC-induced left ventricular dysfunction.
Moreover, these results support the conclusions of previous experiments, suggesting
the beneficial effect of the designed AAV9 expressing hpNFAT consensus RNA decoy
ODNs on heart hypertrophy and heart failure in vivo.
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Fig. 57: AAV9-mediated delivery of hpNFAT consensus RNA decoy ODNs improves T-tubule organization in
cardiomyocytes. (A) Representative images of WGA stainings (red) of myocardium cryosections. Note, that the
high red fluorescence background observed in confocal images of the stained tissue next to cell membrane is due
to fibrotic areas around cardiomyocytes. (B) Plot profile of WGA stainings showing the regularity of the T-tubule
system. (C) Statistical quantification of T-index, percentage of tubulated cells and T-power. The graphs on the right
represent the plots obtained after Fourier transformation, showing the frequency of T-tubules at different distances.
Scale bar represents 25 µm. (n=3 for PBS injected groups, n=8 for AAV9 injected groups, 30 images were taken/
group with different magnifications, *** p< 0.001).
6Disussion
6.1 Marfan syndrome
6.1.1 Clinical importance
The main mortality risk of patients suffering from Marfan syndrome is thoracic aortic
aneurysm formation and dissection. Current treatment options such as β-blockers or
aortic root replacement offer only a temporary solution to this cardiovascular compli-
cation and do not provide a long-term treatment. Additionally, conflicting results were
published regarding the benefit of β-blockers on the survival rate of the patients [70].
Furthermore, a trend but not a significant beneficial effect on thoracic diameter was
shown by β-blocker therapy in children and adolescents with Marfan syndrome [67].
Prevastin, a HMG-CoA reductase inhibitor was shown to reduce aortic dilatation in a
mouse model for Marfan syndrome by downregulating MMP expression in the aortic
wall [132]. It has been recently shown that losartan, an angiotensin II type 1 receptor
blocker can be successful in improving, but not fully normalising the architecture of
the elastic fibres in the aorta of mgR/mgR mice [80]. However, when losartan was ad-
ministered to patients suffering of Marfan syndrome, the observed benefits could not be
reproduced for all types of fibrillin-1 mutations [63]. Therefore, the need for a therapeu-
tic strategy for Marfan syndrome is still actual.
The approach investigated in this study provides the possibility to achieve a long term
delivery of the AP-1 decoy ODNs in aortic smooth muscle cells, which can be trans-
lated into a new therapy for prevention of aortic aneurysm formation and dissection
in patients suffering from Marfan syndrome. Moreover, the current study supports the
central role of AP-1 in the development of aortic aneurysms in the context of Marfan
syndrome.
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6.1.2 The role of AP-1 in aortic aneurysm dissection
Defective fibrillin-1 protein leads to the pathological phenotype of Marfan syndrome,
through dysfunctional TGF-β signalling [149], mechanism explained in detail in the
Introduction. By using the mgR/mgR mouse model for this disease [183], the criti-
cal pathways of elastin fragmentation in the aortic wall have been revealed [156]. It
was previously shown that mgR/mgR mice present with severe elastolysis in both tho-
racic and abdominal aorta and are affected by thoracic aneurysm rupture, which limits
their lifespan [183]. The mice show increased MMP activation, inflammatory cells re-
cruitment and elastin degradation, which are typical events that lead to aortic dilatation
[21, 183, 156].
The role of MMPs in the progression of aortic aneurysm development in the context
of Marfan syndrome has already been established [35, 34, 94]. MMPs degrade a high
variety of extracellular matrix components, such as collagens, elastin, fibronectin and
gelatine [190] and consequently lower the stability of the aortic wall. Additionally, aor-
tic samples isolated from Marfan patients were proven to contain highly active MMP9
and MMP2 [146]. Downregulation of MMPs in mgR/mgR mice by treatment with doxy-
cycline, a non-specific MMP inhibitor increased the life span of Marfan mice and de-
creased the incidence of aneurysm dissections. Moreover, a significant improvement in
the elastic fiber architecture was observed [35]. MMP2 and MMP9 were proven to de-
crease SMCs contractility, increase cell apoptosis and promote elastin fragmentation in
the context of thoracic aneurysm in mgR/mgR mice [34].
The AP-1 transcription factor family has been shown to play a pivotal role in MMP
regulation [11]. In a previous study, a significant increase in AP-1 transcription factor
activity was shown in aortic SMCs isolated from mgR/mgR mice, in comparison to wild
type aortic SMCs [4]. Increased AP-1 nuclear translocation resulted in increased MMP2
and MMP9 protein levels in these cells [4]. AP-1 activity is increased in the presence of
TGF-β [211], which could be one of the reasons for the elevated MMP expression levels
detected in mgR/mgR aorta. Interestingly, losartan was shown to decrease AP-1 activ-
ity, which can be one explanation for its therapeutic effect observed in mgR/mgR mice
[172]. A similar mechanism was noted for statins, which inhibit AP-1 nuclear translo-
cation and downregulate target genes in SMCs and endothelial cells [47].
Taking into account the major role of AP-1 in aortic aneurysm progression through up-
regulating MMP expression as well as inflammatory cytokines [182], the use of a decoy
ODN neutralizing this transcription factor family could be translated into a therapeu-
tic approach for preventing aortic aneurysm dissection, as shown in our previous study
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[4]. Treatment of SMCs as well as aortic grafts with decoy ODNs which neutralize
AP-1 downregulated the expression of MMP9 and MMP2, as well as the gelatinease
activity in the tissue, which was as well observed in the present study. Moreover, a ben-
eficial effect on the elastin structure in mgR/mgR aortic cryosections was noted. These
data suggest the central role of the transcription factor in the vessel wall remodelling,
characteristic for Marfan syndrome. In addition, the results attest the potential of AP-1
decoy ODNs to improve the structure of elastic fibers in the aorta and the possibility of
using this nucleic acid drug preventing aortic dissection that is prototypic for Marfan
syndrome [4].
AP-1 decoy ODNs have already been employed in pre-clinical testing in the treatment
of cardiovascular complications. For example, they were proven effective in decreasing
neointima proliferation in a minipig angioplasty model by reducing ET-1 expression
[20]. Moreover, AP-1 neutralization by means of ex vivo treatment with decoy ODNs
was found to be protective against rejection in an allogenic rat heart transplantation
model [189].
6.1.3 Novelty of the study
The present study provides a novel strategy for preventing aortic dilatation and dissec-
tion in the context of Marfan syndrome by aortic transduction with AAV9SLR [208]
expressing shRNA-based decoy ODNs that neutralize AP-1. The designed AAV vector
causes expression within the target cells of a hpAP-1 decoy ODN as shRNA, under the
control of H1 promoter. The innovation of this concept is the continuous production of
the hpAP-1 RNA decoy ODN in the transduced tissue. Consequently, a single applica-
tion of the AAV vector is enough for the long-term expression of the active compound
in transduced cells, making this a suitable therapeutic approach and constituting an im-
provement to the method published in our previous study [4].
Prior research proves that the intracellular production of transcription factors decoy
ODNs by means of plasmid or viral vectors is a feasible method of decoy ODN de-
livery in cells. By using a ssDNA expression vector, the generation of any ssDNA was
proven possible [31]. Initially, this approach was used in the present study to deliver
hpAP-1 decoy ODNs in SMCs. Although this strategy was shown to be effective in
downregulation of AP-1 target genes (data not shown), the designed vector leads to re-
verse transcriptase translation, which may be a disadvantage for further clinical testing
due to its possible side effects. To overcome this drawback, a new strategy was described
in the literature [226]. The NF-κB transcription factor decoy ODNs were generated as
shRNA and successfully inhibited the expression of downstream genes in vitro [226].
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Nevertheless, in vivo experiments did not show so far the possibility of using this strat-
egy for therapeutic purposes. This study uses of a similar approach, in order to achieve
hpAP-1 RNA decoy ODNs production in SMCs.
By using in vitro primary aortic SMCs isolated from fibrillin-1 deficient mgR/mgR
mice, as well as in vivo methods, successful decoy ODNs production and AP-1 target
genes downregulation, as well as positive effects on elastin breaks could be shown.
6.1.4 Hairpin AP-1 decoy ODNs delivery
The ability of cultured cells to take up ”naked” decoy ODNs has already been demon-
strated [33]. The main advantage of this approach is that cells can incorporate the de-
coy ODNs without any auxiliary means and rapidly neutralize the transcription fac-
tor. In contrast to the antisense ODNs, which are transfected into cells by endocy-
totic pathway [68], the mechanisms for decoy ODNs uptake are distinct and consist
of carrier-mediated and receptor-mediated delivery [86]. The results of this study prove
that cationic transfection reagents like Lipofectamine3000 do not improve the nuclear
localization of the hpAP-1 decoy ODNs, confirming the already published data [8].
Furthermore, liposomal mediated transfection led mostly to cytosolic localization of the
fluorescent decoy ODNs, which were mostly localized into liposomal complexes. After-
wards, the decoy ODNs are most likely degraded through the lysosomal pathway [66].
In contrast, treatment with ”naked” decoy ODNs led to mostly nuclear delivery of the
active compound and could immediately exert its role in transcription factor neutraliza-
tion.
The suitable method of delivery of decoy ODNs in vivo depends on the targeted organ.
Systemic administration is, in most cases, the preferred method of administration. In-
deed, the systemic application of decoy ODN containing the promoter binding site for
NF-κB, designed to have a ribbon-circular structure to improve stability, was used in a
mouse abdominal aneurysm model. The DNA molecules were detected in the abdom-
inal aortic wall after tail-vein injection, leading to decreased elastin fragmentation and
reduced the gelatinease activity of MMP9 and MMP2 [135]. Nevertheless, the blood
flow in the thoracic aorta is presumably too high and therefore it allows inadequate
amount of time to pass the endothelial barrier and reach SMCs, the target cells in the
present study.
On the other hand, local aplication of the nucleic acid reduces the risk of degradation
and decreases the side effects caused by nonspecific site of action. At the same time,
it allows an accurate dosage of delivery of the active compound for a fast therapeutic
effect. Decoy ODNs were locally applied at the level of the lungs [118], eyes [98] or
6.1 Marfan syndrome 104
skin [144].
Viral mediated approach of decoy ODN delivery is an effective and targeted option for
transcription factor neutralization for treatment of diverse pathologies. AAVs are the
most frequently used gene delivery vehicles for therapeutic approaches due to of their
non-pathogenic nature and low immunogenity, as well as long-term transduction effi-
ciency [145]. In the present study, hpAP-1 RNA decoy ODNs were delivered in SMCs
by using AAV serotype 9 with modified capsid. The vector was directed to human en-
dothelial cells in vitro and was shown to be significantly more effective in transduc-
ing the target cells as compared to the wild type AAV9 [208]. Importantly, the rate of
AAV9SLR neutralization by AAV antibodies contained in human sera was dramatically
reduced, confirming that the vector is a feasible tool for gene therapy [208]. The ability
of AAV9SLR to transduce endothelial cells was already proven by intradermal injection
of the vector particles [120]. However, this study is the first to show successful SMCs
transduction by AAV9SLR in mgR/mgR mice.
Initially, the evaluation of transduction efficiency of AAV9SLR in the aorta was made
by tail-vein injection of the AAV9SLR vector expressing EGFP. Nevertheless, the green
fluorescent marker was detected neither in SMCs, nor endothelial cells. This could be,
as in the case of ”naked” decoy ODNs, due to the high flow velocity in the thoracic
aorta, not permitting sufficient contact time of the AAV with the tissue in order to allow
successful transduction. Therefore, the application of the viral construct was further per-
formed ex vivo and treated grafts were next implanted into mgR/mgR mice in a model
of renal aortic transplantation, as previously described [184], [4]. This method allowed
the successful transduction of both endothelial cells and SMCs in the aorta, as shown by
CD31 and EGFP immunohistochemistry experiments. Moreover, by using RNA F.I.S.H
method, hpAP-1 RNA decoy ODNs could be detected in transduced cells.
6.1.5 The importance of inflamation in aortic aneurysm development
The role of ROS in the pathogenesis of aortic aneurysms has already been investigated
[131]. ROS increase MCP-1 secretion by SMCs in the aortic wall, thereby stimulating
macrophage infiltration and increasing the migratory capacity of SMCs [177]. Addition-
ally, increased oxidative stress and pro-inflammatory cytokines such as IL-6 and IFN-γ
(Interferon-γ) were found to be present in biopsies isolated from patients undergoing
surgery after thoracic aortic aneurysm [57]. Furthermore, it has been demonstrated that
the aorthopathy observed in Marfan syndrome is partly due to the high amount of ROS
generated in SMCs and macrophages, which was proven to be caused by increased TGF-
β signalling [170], through activation of NOX4 (NADPH oxidase-4) [193]. NOX4 was
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shown to be transcriptionally regulated by AP-1 and SMCs treatment with a decoy ODN
that neutralized the transcription factor led to decreased accumulation of ROS [128]. In
accordance with this study, the treatment with AAV9SLR neutralizing AP-1 could sig-
nificantly reduce the level of ROS produced in aortic grafts of mice which received viral
treatment.
Pro-inflammatory cytokines and oxidative stress enhance SMCs migration rate, as
shown by primary cultures isolated from Marfan syndrome patients [40]. The data pre-
sented here show that AP-1 activation through IL1-β treatment can induce both the level
of ROS production and the migration rate of primary SMCs, which could be decreased
by hpAP-1 decoy ODNs treatment.
On the inflammatory level there is evidence that macrophage infiltration is an early
event that leads to aneurysm development in the context of Marfan syndrome [76].
Macrophages can enhance the rate of elastin degradation through MMP secretion [164].
Elastin fragmentation leads to secretion of elastin-derived peptides, which in turn act as
a chemotactic agent for macrophages [75]. In agreement with these results, mgR/mgR
mice treatment with a monoclonal antibody against the elastin binding domain could de-
crease inflammatory cells infiltration, accompanied by decreased MMP activity in the
aorta of mgR/mgR mice [77].
Moreover, TGF-β signalling and inflammatory pathways were shown to be highly acti-
vated in aorta of Marfan patients [164]. In the same study, immune cells infiltration was
observed in both aortic adventitia and media, and plasma analysis showed increased
concentration of pro-inflammatory cytokines, such as M-CSF (Macrophage colony
stimulating factor), MCP-1, IL-8, IL-17 and INF-γ. The high number of macrophages
present in aortic specimens of Marfan mice lead, in turn, to an increased expression
level of the macrophage elastase MMP12 which further contributes to the elastic lam-
inae degradation and consequently to the aneurysm development [187]. The results of
the present study show that ex vivo treatment with AAV9SLR expressing hp AP-1 RNA
decoy ODNs decreased the amount of macrophages in the adventitia of fibrillin-1 un-
derexpressing mice. Similar to previous studies targeting inflammation in Marfan syn-
drome by indomethacin treatment [78], our data show that MMP12 protein level in
aortic cryosections of treated mice was as well downregulated, which correlated with
less elastin breaks in the media. These results indicate that AP-1 neutralization by
the designed AAV can alter the pro-inflammatory environment which precedes aortic
aneurysm dissection.
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6.1.6 Endothelial permeability in Marfan syndrome
Ex vivo treatment of mgR/mgR aortic grafts with AAV9SLR led to transduction of not
only endothelial cells, but also SMCs of the media, proving the ability of the vector to
pass the endothelial cell layer. This observation is consistent with the previous study
[4], which showed the ability of AP1 decoy ODNs to reach SMCs in mgR/mgR grafts.
In contrast, aortic grafts isolated from wild type mice showed high transduction effi-
ciency of endothelial cells, but considerably reduced EGFP positive SMCs as compared
to mgR/mgR grafts. This can be explained by a dysfunction in the endothelial cell layer
in the aorta of mgR/mgR mice, which was already addressed in the literature [184].
Plasma of Marfan syndrome patients was shown to contain high amounts of endothelial
cells-related products von Willebrand factor antigen and thrombomodulin, proving in-
directly an endothelial dysfunction [19].
Endothelial hyperpermeability was shown to be correlated with inflammatory cell re-
cruitment in various models of vascular diseases [111]. Gelatinases MMP9 and MMP2
were shown to be responsible for the endothelial tight junction protein ZO-1 degrada-
tion in brain vessels [213]. In the current study, we demonstrated that aortic samples
from Marfan mice present decreased ZO-1 protein level in CD31 positive endothelial
cells, which can be a direct explanation for the observed endothelial cell dysfunction.
However, by transduction with AAV9SLR expressing hpAP-1 RNA decoy ODNs, the
tight junction expression could be rescued and brought to similar protein levels as the
ones detected in the wild type controls. These results could further explain the therapeu-
tic effect of the designed AAV9SLR transduction and could be an additional reason for
the decreased macrophage numbers infiltrating the treated aorta.
6.1.7 Targeting other transcription factors for treatment of Marfan syndrome
The present study proves the importance of the transcription family AP-1 in the patho-
genesis of aortic aneurysms in the context of Marfan syndrome. However, the signifi-
cance of other transcription factors should be further considered in order to identify in
more depth the molecular basis of this disease and to advance new therapeutic strategies.
One protein of interest is KLF4. Although the role of this transcription factor was mostly
elucidated during embryonic development [56] as well as in stem cell populations [237],
its function in SMCs was less studied. It is known that the deletion of this transcrip-
tion factor is beneficial in the context of abdominal aortic aneurysms development in
both elastase and angiotensin II infusion models [175]. SMCs specific deletion of KLF4
decreased the pro-inflammatory cytokines MCP1, TNF-α, CCL12 (Chemokine (C-C
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motif) ligand 12), and IL-23 in the aortic wall and the number of elastin breaks was sig-
nificantly reduced in these mice in abdominal aneurysm models. Moreover, KLF4 was
shown to be highly upregulated and activated in samples isolated from human aortic
aneurysms [175]. KLF4 was also shown to have a major role in artherosclerosis patho-
genesis by increasing the pro-inflammatory environment in the plaques. Interestingly,
SMCs conditional knockout of KLF4 led to a dramatic decrease in plaque size and in-
creased plaque stability, accompanied by a reduced number of pro-inflammatory cells
in the vessel wall [186].
A recent study using SMCs differentiated from iPSCs (induced pluripotent stem cells)
derived from Marfan patients also points out the importance of KLF4 in the progression
of the disease [72]. KLF4 was significantly increased on mRNA and protein levels in
Marfan syndrome lines, and silencing this transcription factor with siRNA led to in-
creased deposition of fibrillin-1 in vitro. These data validate KLF4 as another key target
that leads to the phenotype shown by Marfan patients, but also for other vascular dis-
eases with inflammatory component.
It was previously demonstrated that KLF4 expression on the basal level is extremely low,
but it is rapidly induced after injury [122]. The reduced KLF4 expression level detected
by immunohistochemistry in this study further confirms this observation. In contrast,
mgR/mgR aortic cryosections presented significantly increased nuclear translocation of
KLF4 into the nucleus, showing the activation of the transcription factor in mgR/mgR
SMCs.
The activity of other transcription factors such as SMAD family were shown to corre-
late with the severity of thoracic aneurysms in Marfan syndrome [90] and hence decoys
downregulating downstream pathways could be analysed as therapeutic nucleic acid
drugs.
6.1.8 Limitations and perpectives
The main limitation of this study is the mode of application of the viral vector in aortic
grafts. Since AAV9SLR was unable to transduce SMCs after tail vein injection, we used
heterologous transplantation model to reimplant treated grafts. This method is however
impossible to translate into practice in the clinical context. Nevertheless, this procedure
allowed us to show the effects of AAV9SLR-mediated AP-1 neutralization on the elastin
fibers architecture and can be used as a proof of principle study. For further translation
projects, a new viral application method should be developed. One possibility of trans-
fection with hpAP-1 decoy ODNs or of transduction with AAV9SLR expresing hpAP-1
RNA decoy ODNs would be using a celulose-based delivery sheet, as previously de-
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scribed [134]. In addition, a hydrogel-based delivery system was also shown to be an
appropriate vehicle for DNA transfection into the vessel wall [229]. The hydrogel sheet
could be placed around the thoracic aorta, in the areas where aneurysm formation is
evident, and could inhibit its development and dissection.
Furthermore, because of the delivery method we employed, the effect of AAV9SLR
cons on the survival rate of mgR/mgR mice could not be addressed. It was previously
shown [156] that the survival rate of homozygous mgR/mgR mice is poor, due to vascu-
lar complications, specifically aortic aneurysms. Starting with as early as 6 weeks of age,
mgR/mgR mice present fragmented elastin fibers at the level of the aorta, with immune
cells infiltration and medial calcification, which later develop into aortic aneurysms.
In addition, the active AAVs could be applied at different stages of the disease to de-
termine the best time point of transduction to obtain the best results, which could be a
valuable step before translation into further clinical studies.
The mgR/mgR mouse model for Marfan syndrome is a valuable tool for pre-clinical
testing of AAV transfer at the level of the aorta. Nonetheless, large animals model for
Marfan syndrome have already been described [205]. The fibrillin-1 mutant pigs re-
capitulated the features of Marfan syndrome observed in humans and the similarities
between pigs and humans are closer from a physiological point of view. The fibrillin-1
mutant pigs present scoliosis, a feature of Marfan patients, and the histopathology of the
aorta is similar to the one observed in mgR/mgR mice and patients. Using large animal
models would make surgical procedures much easier to execute. For example, the use
of a dispatch catheter was already shown to be a feasible way to deliver a viral vector
in a pig coronary artery [224]. This method allowed as well the transfection of decoy
ODNs into the coronary arteries of minipigs in a model of stent angioplasty [20].
In addition, the possibility of using decoy ODNs neutralizing other transcription factors
important in aneurysm formation could be further assessed. KLF4 activation, described
in detail in the previous section, was shown in mgR/mgR aorta. Decoy ODNs for KLF4
are already described [163], and their efficiency could be tested in Marfan syndrome
model.
6.2 Heart hypertrophy
6.2.1 Clinical importance
Heart hypertrophy represents the response of myocardium to stress conditions, such as
pressure or volume overload or neurohormonal stimuli and represents one of the lead-
ing causes of death in Western countries. This process is an adaptive series of events
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which lead to increased heart size due to cardiomyocyte growth [64]. Although my-
ocardial hypertrophy can help in decreasing wall stress, it can lead to a dilated stage,
with decompensated function and heart failure. The mechanisms of decompensation in-
clude loss of cardiomyocytes through apoptosis, necrosis and autophagy. Consequently,
myocyte replacement with myofibroblasts and intense remodelling of the heart occurs,
accompanied by reduced contractility [48]. Recently, therapeutic strategies focused on
reversing or even blocking the hypertrophic response, which was shown to inhibit heart
failure, even when pressure overload persisted [106]. In the case of translational studies
in human patients, other virus serotypes were confirmed to successfully transduce car-
diomyocytes following intracoronary administration, for instance AAV1.
Traditional pharmacological treatment options include intervention with β-adrenergic
receptor antagonists, inhibitors of angiotensin II and diuretics, all with good short-term
response. However, the 5-year survival is below 50% [155]. Therefore, new therapeutic
strategies are necessary to be established.
6.2.2 Novelty of the study
Therapeutic DNA oligonucleotides have already been tested in the treatment of heart hy-
pertrophy in various models. Antisense oligonucleotides directed against LIF (leukemia
inhibitory factor) and CT-1 (cardiotrophin-1) could downregulate AngII (angiotensin-
II)-induced hypertrophic response in vitro [176]. However, their effects in a heart fail-
ure animal model was not analysed. Inhibition of phospholamban, a SERCA2a inhibitor
through systemic injection of antisense oligonucleotides improved heart function in a
pressure-overload mouse model [138]. Although effective, this approach could lead to
side effects due to the systemic administration route, which is not specific for the target
organ.
AAV mediated oligonucleotide expression in the myocardium could improve the distri-
bution of the nucleic acid into target cells. The advantages of recombinant AAVs is the
ability of transducing both dividing and non-dividing cells, inducing the expression of
the gene of interest without inducing an immune response. Furthermore, several AAV
serotypes were shown to have tropism for the heart [91]. AAV-mediated angiotensino-
gen antisense delivery was shown to reduce heart hypertrophy in a spontaneous hyper-
tension mouse model [103].
The therapeutic effect on myocardium infarction of an NF-κB decoy ODNs has been
previously shown [139]. Treatment with the active compound, but not the scrambled
control before occlusion or immediately after reperfusion could decrease the infarction
size and reduce the inflammatory response [139]. On the other hand, GATA4 decoy
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ODNs failed to reduce ET-1-induced hypertrophic response in neonatal rat cardiomy-
ocytes [159], suggesting that this transcription factor is not essential for the development
of hypertrophy. GATA4 factor activity was shown to be correlated with the expression
of other transcription factors, including NFAT and MEF2 [105]. This could constitute
one of the reasons for unsuccessful reduction of hypertrophic markers and underlines
the complexity of the molecular mechanisms leading to heart failure.
In consistence with the present study, NFAT inhibition was proven to be an effective
method of treatment of pressure overload induced heart hypertrophy [112]. The admin-
istration of VIVIT, an inhibiting peptide after TAC led to decreased fetal gene program,
reduced myocardium weight and improved heart function in comparison to control an-
imals. Nevertheless, the administration of high peptide doses could be problematic for
further clinical translation. Moreover, because of the short half-life of this compound,
repeated injection of VIVIT is required. In contrast, the approach suggested in this study
involves the single systemic injection of the AAV9 for continuous production of the de-
coy ODNs in target tissue, i.e. the myocardium, which is an advantage in comparison to
previous published studies.
The study offers a new preventive one-time treatment for heart hypertrophy and decom-
pensated heart failure. This involves the AAV9-mediated delivery of hp RNA decoy
ODNs that reduce NFAT transcriptional activity. After one-time injection, decoy ODNs
are continuously expressed in transduced cells as shRNAs bearing the consensus bind-
ing site in the promoter region of this transcription factor and can therefore downregulate
the expression of target genes involved in hypertrophic response. This is, to our knowl-
edge, the first AAV-mediated approach for NFAT transcription factor neutralization as a
therapeutic approach for heart hypertrophy. By using cardiomyocyte cell models, suc-
cessful decrease in NFAT-regulated genes was proven. Importantly, a beneficial effect
on heart function was shown in TAC model of pressure overload.
6.2.3 Regulation of fetal gene program in heart hypertrophy
Synthesis of natriuretic peptides ANP and BNP is increased in the late fetal and early
neonatal development stages, remarkably decreasing in the adult myocardium [25]. The
reexpression of fetal gene program is a common characteristic of failing myocardium,
representing a reliable marker of heart dysfunction. Several studies showed the corre-
lation between BNP plasma levels and prognosis of heart failure patients [203]. Raised
BNP protein concentration detected in plasma correlate with the severity of heart dis-
ease and mortality rate. BNP was shown to decrease following therapy [104].
The role of NFAT in the BNP reexpression in the hypertrophied myocardium has been
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previously addressed [207]. Following nuclear translocation, NFAT synergizes with
GATA4 to activate fetal gene program [137, 209]. In the present study, the importance
of NFAT in the reactivation of ANP and BNP was further confirmed. Neutralization of
this transcription factor in vitro by means of ”naked” hpNFAT decoy ODNs, as well
as AAV expressing hpNFAT RNA decoy ODNs led to a significant downregulation of
the fetal gene program on mRNA and protein level in HL-1 cells stimulated with ET-1.
Remarkably, the results could be reproduced in vivo in TAC-induced heart hypertrophy
model.
Additionally, hypertrophic response includes the myosin heavy chain switch, which in-
volves the β-MHC isoform reexpression and downregulation of α-MHC [123]. Trans-
genic mice expressing only β-MHC under basal levels presented a more pronounced
hypertrophy under isoproterenol stimulation than wild type controls, showing the impor-
tance of this isoform in the disease progression [108]. The myosin switch was shown in
various models of pathologic hypertrophy but not by physiological stimuli, such as exer-
cise [179], [123] and is induced by pressure-overload [123]. The increase in the protein
levels of β isoform of MHC was proven to influence heart function through reduced AT-
Pase activity of this isoform and decreased contractility of expressing myocytes [109].
This can be an adaptive response to stress stimuli and has the role of increasing the
metabolic efficiency.
The results of immunofluorescence experiments presented in this study show a signif-
icant increase in β-MHC protein level in ET-1 stimulated HL-1 cells. Similarly, it was
noted a clear re-expression of the β isoform following TAC in the mouse myocardium.
Taking into account that the myosin switch is a reversible process and β-MHC expres-
sion is downregulated after removal of the pathological stimuli [79], the effect of hpN-
FAT RNA decoy ODNs was further analysed. In a similar manner as the ANP and BNP
expression levels, hpNFAT decoy ODNs reduced β-MHC protein level both in vitro and
in vivo, in myocardium cryosections. This finding confirms the protective effect of the
designed vector on heart hypertrophy.
Myocardium growth is accompanied by myocyte hypertrophy, while cardiomyocyte di-
vision is almost non-existent [154]. This process involves the elevation of protein trans-
lation rate [83], by a significant increase in the level of protein synthesis as compared to
proteolysis. Pro-hypertrophic stimuli, such as ET-1, isoproterenol or AngII regulate the
ribosome number in myocytes, as well as translational capacity [18].
The investigation of the exact mechanism through which NFAT inhibition leads to de-
creased protein translation level, as proven in this study, was not one of our purposes.
However, UBF (Upstream binding factor), which is critical for increasing translation
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efficiency in the context of heart hypertrophy [17], was shown to have an NFAT binding
site in the promoter region [46]. Additionally, NFAT regulates RCAN1-4 which in turn
upregulates eIF4E (Eukaryotic initiation factor 4E) [114], another key player of global
protein synthesis [204].
Protein translation level was measured as well in the context of TAC-induced heart hy-
pertrophy. The results are in consistence with previous studies [143], [142], proving a
significant TAC-induced increase in protein synthesis in PBS-treated mice, as well as
in the animals injected with AAV9 expressing hpNFAT mut RNA decoy ODNs. Im-
portantly, treatment with AAV9 expressing hpNFAT cons RNA decoy ODNs led to a
decrease in the level of global protein translation, proving reduced hypertrophic growth
in cardiomyocytes.
6.2.4 Cardiomyocyte architecture in heart failure
Heart failure is accompanied by structural changes observed in cardiomyocytes. More
speciffically, cell hypertrophy is complemented by an increase in sarcomerogenesis [50]
and decrease in the regularity of T-tubules [126].
In the present study, cardiomyocyte size in tissue sections was quantified using two
different validated approaches, specifically WGA and H&E staining. The evaluation of
the measurements reveals that NFAT neutralization by RNA decoy ODNs leads to de-
creased TAC-induced myocyte dimensions, suggesting decreased hypertrophy. In line
with these data, a decreased HW/TL ratio was observed in AAV9 treated mice.
In addition to increased myocardium weight, left ventricular dysfunction leads to no-
table lung remodelling [30]. TAC induces lung edema, fibrosis and inflammatory cell
infiltration. Therefore, LW/TL ratio is a reliable parameter to assess the severity of heart
failure [206]. In mice treated with hpNFAT RNA cons decoy ODNs - generating AAV9
prior to TAC, it was noted a decrease in LW/TL measurements. These results further
confirm the preventive effect of decreased NFAT activity not only on heart hypertrophy,
but also on heart failure.
Transverse tubules are membranes invaginations found in muscle cells which play a crit-
ical role in excitation-coupling. Structural changes in T-tubules arrangement has been
described in models of heart failure [74]. The T-tubule disorganization was observed in
a pressure-overload model starting from the incipient phase of left ventricular dysfunc-
tion and more rapidly during the transition of hypertrophy to heart failure. The degree
of remodelling was correlated to the severity of the disease [215]. In addition, loss of
T-tubule regularity was observed in failing human and rat cardiomyocytes [126]. The
analysis of T-tubules arrangement in myocardium of mice subjected to TAC shows a
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more regular pattern in the hpNFAT cons RNA decoy ODNs, while in the control ani-
mals presented detubulation of parts of cardiomyocytes. This observation can account
for the severe heart function in the control group and for the progression of the disease
into heart failure. More experiments have to be performed to address if NFAT is a direct
factor of T-tubule disarrangement in the myocardium of mice subjected to TAC.
6.2.5 Remodeling of extracelular matrix in heart failure
Pressure overload or hypertension induces severe remodelling in the myocardium, asso-
ciated with pro-inflammatory cells infiltration and extracellular matrix deposition. The
amount of excess fibrotic tissue was shown to be correlated with the heart failure stage
[178], proving the major role of this process in the development of the disease. Intersti-
tial fibrosis is a beneficial event in the early stages of myocardium hypertrophy, being an
adaptation to increased cardiomyocyte size. However, excessive collagen deposition due
to chronic stress increases myocardium stiffness and decreases the contractility [39].
Previous studies on this topic show the emerging role of TGF-β in the progression of
cardiac fibrosis. Transgenic mice overexpressing TGF-β show heart hypertrophy char-
acterized by increased cardiomyocyte dimensions, as well as elevated fibrosis and ab-
normalities in heart function [171]. TGF-β inhibition ameliorates heart disease in a
model of pressure overload and hypertension [113, 87]. Interestingly, TGF-β-mediated
production of collagen 1 and fibronectin was proven to be NFAT-regulated in fibroblasts
[238].
In the current study, the effect of hpNFAT RNA decoy ODNs on TAC-induced fibrosis
was examined. As previously described [230], stenosis of the transverse aorta caused
increased collagen deposition both in the interstitial and perivascular areas, as shown
by Masson’s Trichrome staining. However, the injection of the active AAV9 expressing
hpNFAT cons RNA decoy ODNs decreased the fibrotic area. These results were con-
firmed on the mRNA level by a significant decrease in collagen 3, TGF-β and CTGF
gene expression. The reduced fibrosis noted in AAV9 treated mice could account for the
improvement in the cardiac performance.
In consistence to these results, NFAT inhibition through injection of FTY-720, a com-
pound used in treatment for multiple sclerosis, was shown to reverse cardiac fibrosis in
TAC-subjected mice [121]. Reduction in periostin protein level was proven to be respon-
sible for this beneficial effect. This protein is an extracellular matrix component which
is present in low amount in the myocardium on basal conditions, but its expression is
remarkably increased in failing hearts [151]. Moreover, NFAT activity was shown to
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be significantly higher in idiopathic pulmonary fibrosis, leading to intense lung remod-
elling and fibroblast proliferation [198].
6.2.6 NFAT transcription factors involved in heart hypertrophy
The designed decoy ODNs used in the present study are highly specific for NFAT1,
NFAT2, NFAT3 and NFAT4. The four members are dephosphorylated by calcineurin
and lead to the activation of the fetal gene program and initiation of hypertrophy [137].
The expression of all four proteins was detected in the myocardium [16]. NFAT1 de-
ficiency ameliorated heart hypertrophy in a pressure-overload model, showing the im-
portance of this transcription factor in the development of the disease [16]. NFAT3 as-
sociates with GATA4, GATA5 and GATA6 transcription factors to drive BNP expres-
sion [137]. NFAT4 deficient mice develop a low grade of calcineurin transgene-induced
hypertrophy. However, the effect was incomplete, proving that other transcription are
necessary for disease development [221].
The specificity of the decoy ODNs was shown by analysing NFAT5 activity in vitro
after ODNs treatment. In contrast to NFAT1-4 transcription factors, which contain sim-
ilar sequence identity, NFAT5 relates to the other members of the NFAT family only
through the Rel-like DNA-binding domain and lacks the calcineurin-binding domain
[124]. NFAT5 is involved in the response to osmotic stress by controlling transporter
molecules and enzymes that replace electrolytes with uncharged organic compounds
[32]. Homozygoous mice lacking NFAT5 showed embryonic lethality, impaired car-
diomyocyte function, with reduced spontanous beating activity and decreased myocyte
density [127]. Therefore, the assessment of NFAT5 activation in hpNFAT decoy ODNs
treated cardiomyocytes was critical. The experiments demonstrated that neither the
”naked” hpNFAT decoy ODNs, nor AAV6 expressing the shRNA decoy ODNs affects
NFAT5 nuclear translocation in osmotically challenged HL-1 cardiomyocytes. More-
over, there was no difference in the expression of genes involved in adaptation to os-
motic stress. Taken together, these findings suggest that hpNFAT decoy ODNs treatment
does not influence NFAT5 function.
6.2.7 Limitations and perspectives
The present study demonstrates an approach of preventing heart hypertrophy and its
transition into heart failure, by RNA decoy ODNs which neutralize the activity of NFAT.
The in vivo experimental model consisted of AAV9 injection two weeks prior to TAC,
in order to allow the generation of the active RNA decoy ODNs in the myocardium.
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Nevertheless, in the case of heart failure patients, a prophylactic AAV administration is
not possible. Therefore, another set of experiments is required, which show the effect
of the designed AAV9 after hypertrophy is established and ventricular dysfunction is
noted.
Although AAV9 has tropism for muscle cells and the transduction efficiency of car-
diomyocytes is high, this virus serotype was shown to transduce other organs and cell
types [95]. The transduction efficiency of cardiomyocytes with AAV9, presented in this
study, is consistent with previous published results [95, 152] which show an almost 100
% transduction efficiency of cardiomyocytes after tail-vein systemic delivery of AAV9.
However, liver, skeletal muscle and lung transduction was also observed in mice, al-
though the infection efficiency in these organs was proven to be much reduced as com-
pared to the myocardium [61]. In addition, AAV9 was shown to be able to pass the
brain blood barrier and transduce with high efficiency neuronal cells [61]. Nevertheless,
for further successful and safe translation into a clinical approach, an AAV serotype
with more specificity for the heart should be used. An AAV9 with targeted capsid to
cardiomyocytes, selected from a random library, has been developed and was shown to
target the heart [231]. Moreover, the AAV2 harbouring the cardiac myosin light chain
promoter fused with CMV immediate-early enhancer [136] increased cardiomyocytes
transduction efficiency following systemic injection, as compared to AAV2 containing
CMV promoter. Moreover, the addition of a targeting capsid peptide to this new tran-
scriptionally targeted AAV2 further improved vector specificity [136].
The mouse model of transverse aortic constriction is already a well-characterized heart
hypertrophy system and allows the analysis of the molecular mechanisms of transition
of hypertrophy into heart failure. The procedure mimics human aortic stenosis, mak-
ing it a clinically relevant model to study the disease [44]. The main advantage of this
model is the possibility to quantify the degree of stenosis by measuring the pressure
gradient through the constriction site by means of echocardiography. TAC induces rapid
cardiac dysfunction, as well as fibrosis [12] and depending on the needle size used to
produce the banding, heart failure. One limitation of this model is the rapid onset of the
stenosis, which cannot be correlated to the patient situation. TAC surgery is normally
performed in young mice, which is also a difference to the clinical situation. Other ap-
proach for investigation of in vivo mechanisms of heart failure consist of genetically
engineered mouse models, which do not entirely mimick the patient situation. In ad-
dition, isoproterenol treatment was shown to induce heart hypertrophy in mice, but a
clear heart failure phenotype can be developed only with using high dosage of the cate-
cholamine, which was shown to have high mortality rate in this model [71]. Therefore,
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the effect of the described AAV9 vector on heart function could be studied in different
animal models in which heart failure has different aetiology, such as hypertensive heart
failure [173], neurohormonal stress models [102] or genetic models. This could expand
the therapeutic application of the hpNFAT RNA decoy ODNs. Moreover, through this
method, the role of NFAT in the progression of other types of heart disease could be
investigated.
In addition, the use of a large animal model is a prerequisite for clinical translation.
There are significant differences between the cardiovascular system of humans and mice
in respect to oxygen consumption, heart rate and contractile protein expression [81],
[49], making large animals experiments a critical step towards clinical application.
Moreover, the present study only proved the stable transduction of cardiomyocytes and
hpNFAT decoy ODNs expression following AAV9 injection on a limited time span.
However, before clinical translation, a long-term study should be performed to show the
stability of the transgene in the cardiac tissue.
6.3 Conclusions
The recent advances in the discovery of molecular mechanisms of diseases made it pos-
sible to advance new therapeutic strategies targeting dysfunctional protein expression.
The selective neutralization of transcription factor activity through decoy ODNs is one
of the possibilities of altering gene expression. In this study, we proved successful RNA
decoy ODNs generation through AAV transduction. This method allows the continuous
downregulation of specific genes in target cells and can be applied to a variety of dis-
orders with abnormal transcription factor activity. Moreover, the amount of hp decoy
ODNs produced in transduced cells was proven to be sufficient to downregulate genes
regulated by the transcription factor and to show a therapeutic effect.
The efficiency of this approach was demonstrated in two disease models, namely Mar-
fan syndrome and heart hypertrophy in which blocking the activity of AP-1 and NFAT
was aimed, respectively.
In the context of Marfan syndrome, the data presented show the possibility of deliv-
ering RNA decoy ODNs that neutralize AP-1 in aortic SMCs by means of an AAV
construct. This allowed the transduction of the target cells, as well as endothelial cells,
which afterwards expressed the active decoy ODNs in high amounts. Through this treat-
ment, a significant reduction in the activity of the transcription factor was demonstrated,
as shown by decreased downstream genes expression, as well as decreased number of
elastin breaks in mgR/mgR grafts. The method proposed here could be further translated
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into a new therapeutic approach to improve the characteristic elastin fibers remodelling
observed in this Marfan syndrome model.
In the present study, the focus is limited on the development of a method to inhibit aor-
tic aneurysm formation and dissection in the context of Marfan disease. However, the
beneficial effects of AP-1 inhibition by hpAP-1 RNA decoy ODNs expressed through
AAV9SLR transduction could be translated and explored in other vascular diseases
with activated AP-1 activity or with inflammatory component. For example, abnormal-
ities in SMCs function were observed in non-hereditary thoracic aneurysms, abdominal
aneurysms [2] and aging-induced vascular calcification and hyperplasia [197]. There-
fore, a similar method of transcription factor targeting could be evaluated in other dis-
ease models.
Reducing NFAT activity through the same concept by means of AAV9-mediated ex-
pression of hpNFAT decoy ODNs in cardiomyocytes was evaluated in an experimen-
tal model of pressure overload hypertrophy. AAV9-mediated hpNFAT RNA decoy
ODNs generation into the myocardium decreased hypertrophic and fibrotic markers,
and treated mice presented a significant improvement in heart function in comparison to
controls. Additionally, heart failure marker LW/TL ration was dramatically reduced and
the T tubule system structure was shown to be more regular than in control myocytes.
In conclusion, AAV9 expressing hpNFAT decoy ODNs can prevent heart hypertrophy
and inhibit its transition into heart failure. This approach shows, once again, the impor-
tance of inhibiting myocardium hypertrophy in order to prevent the transition into the
decompensated phase of chronic heart failure.
7Acknowledgements
”It won’t be easy, but it will be worth it”
they say... And so it was. Everyone knows that PhD years are a demanding journey. You
have to grow, you have to learn and become the person worthy of it. In a world aiming
for instant gratification, you have to never lose focus, never give up and appreciate those
who support you.
First of all, I would like to thank Prof. Hecker for the chance of working in the lab
on two projects I loved and in which I invested inexhaustible passion, for his expert
guidance and support. I am grateful to have worked with Andreas and Nina, the best
supervisors anyone could ever hope for. I am happy to have met wonderful colleagues
and friends in the Institute of Physiology and Pathophysiology, who were there for me
when I needed advice, and especially Franzi, Nadine and Manu for technical support.
Moreover, I must thank Gerd for all his help and patience with grant applications.
I have to express my gratitude to Prof. Kirsch and the whole Institute for Anatomy and
Cell Biology, for the friendly working environment and for knowledgeable suggestions
during progress reports. I am tremendously thankful to Prof. Oliver Mu¨ller and his lab
for all their help and wonderful discussions, as well as to Prof. Klaus Kallenbach, Rawa
and Max for their support with the surgeries, and to the liebe Antje, for all her assistence
during these years.
Special thanks go to Markus, for always being there for me and supporting my much-
needed coffee addiction, and to my lovely twin sister, my soul mate. I am indebted to
my mom, for encouraging me and shaping who I am today. I will be forever thankful to
have met my friends Herr Sachindra and Herr Elias, for being my two other musketeers,
and to my SFB-friends, especially Laura, my ”partner in crime” for everything.
I couldn’t have done it alone... thank you, for helping me grow, learn and hopefully
become the person worth it.
8References
[1] A´gg B, Benke K, Szilveszter B, Po´los M, Daro´czi L, Odler B, Nagy ZB, Tarr F,
Merkely B, Szabolcs Z (2014) Possible extracardiac predictors of aortic dissec-
tion in Marfan syndrome. BMC Cardiovascular Disorders 14: 47
[2] Airhart N, Brownstein BH, Cobb JP, Schierding W, Arif B, Ennis TL, Thomp-
son RW, Curci JA (2017) Smooth muscle cells from abdominal aortic aneurysms
are unique and can independently and synergistically degrade insoluble elastin.
Journal of Vascular Surgery 60: 1033–1042
[3] Akazawa H, Komuro I (2003) Roles of cardiac transcription factors in cardiac
hypertrophy. Circulation Research 92: 1079–1088
[4] Arif R, Zaradzki M, Remes A, Seppelt P, Kunze R, Schro¨der H, Schwill S, Ens-
minger SM, Robinson PN, Karck M, Mu¨ller OJ, Hecker M, Wagner AH, Kallen-
bach K (2017) AP-1 oligodeoxynucleotides reduce aortic elastolysis in a murine
model of Marfan syndrome. Molecular Therapy: Nucleic Acids 9: 69–79
[5] Atchison RW, Casto BC, Hammon WM (1965) Adenovirus-associated defective
virus particles. Science 149: 754–755
[6] Bartlett JS, Wilcher R, Samulski RJ (2000) Infectious entry pathway of adeno-
associated virus and adeno-associated virus vectors. J Virol 74: 2777–2785
[7] Bass GT, Ryall KA, Katikapalli A, Taylor BE, Dang ST, Acton ST, Saucerman
JJ (2012) Automated image analysis identifies signaling pathways regulating dis-
tinct signatures of cardiac myocyte hypertrophy. Journal of Molecular and Cellu-
lar Cardiology 52: 923–930
[8] Bene A, Kurten RC, Chambers TC (2004) Subcellular localization as a limiting
factor for utilization of decoy oligonucleotides. Nucleic Acids Res 32: e142–e142
[9] Benke K, A´gg B, Szilveszter B, Tarr F, Nagy ZB, Plos M, Darczi L, Merkely B,
Szabolcs Z (2013) The role of transforming growth factor-β in Marfan syndrome.
Cardiology Journal 3: 227–234
References 120
[10] Bera A, Sen D (2017) Promise of adeno-associated virus as a gene therapy vector
for cardiovascular diseases. Heart Failure Reviews
[11] Bergman N MR, Cheng S, Honbo N, Piacentini L, Karliner JS, Lovett DH (2003)
A functional AP-1 site regulates matrix metalloproteinase 2 transcription by car-
diac cells through interactions with JunB-Fra1 and JunB-FosB heterodimers. Bio-
chemical Journal 369: 485–496
[12] Bernardo BC, Nguyen SS, Gao XM, Tham YK, Ooi JYY, Patterson NL, Kiriazis
H, Su Y, Thomas CJ, Lin RCY, Du XJ, McMullen JR (2016) Inhibition of miR-
154 protects against cardiac dysfunction and fibrosis in a mouse model of pressure
overload. Scientific Reports 6: 22442–22450
[13] Bernardo BC, Weeks KL, Pretorius L, McMullen JR (2010) Molecular distinc-
tion between physiological and pathological cardiac hypertrophy: Experimental
findings and therapeutic strategies. Pharmacology & Therapeutics 128: 191 – 227
[14] Bickelhaupt S, Erbel C, Timke C, Wirkner U, Dadrich M, Flechsig P, Tietz A,
Pfhler J, Gross W, Peschke P, Hoeltgen L, Katus HA, Grne HJ, Nicolay NH, Saf-
frich R, Debus J, Sternlicht MD, Seeley TW, Lipson KE, Huber PE (2017) Effects
of CTGF blockade on attenuation and reversal of radiation-induced pulmonary fi-
brosis. JNCI: Journal of the National Cancer Institute 109: djw339
[15] Bostick B, Shin JH, Yue Y, Wasala NB, Lai Y, Duan D (2012) AAV micro-
dystrophin gene therapy alleviates stress-induced cardiac death but not myocar-
dial fibrosis in 21-m-old mdx mice, an end-stage model of Duchenne muscular
dystrophy cardiomyopathy. Journal of Molecular and Cellular Cardiology 53:
217–222
[16] Bourajjaj M, Armand AS, da Costa Martins PA, Weijts B, van der Nagel R, Heen-
eman S, Wehrens XH, De Windt LJ (2008) NFATc2 is a necessary mediator of
calcineurin-dependent cardiac hypertrophy and heart failure. Journal of Biologi-
cal Chemistry 283: 22295–22303
[17] Brandenburger Y, Arthur JF, Woodcock EA, Du XJ, Gao Xm, Autelitano DJ,
Rothblum LI, Hannan RD (2003) Cardiac hypertrophy in vivo is associated with
increased expression of the ribosomal gene transcription factor UBF. FEBS Let-
ters 548: 79–84
[18] Brandenburger Y, Jenkins A, Autelitano DJ, Hannan RD (2001) Increased expres-
sion of UBF is a critical determinant for rrna synthesis and hypertrophic growth
of cardiac myocytes. The FASEB Journal 2051–2053
[19] Bridges AB, Gray JR, McLaren M, Tamei H, Belch JJF (1993) Endothelial cell
and platelet function in Marfan’s syndrome. Endothelium 1: 203–206
References 121
[20] Buchwald AB, Wagner AH, Webel C, Hecker M (2002) Decoy oligodeoxynu-
cleotide against activator protein-1 reduces neointimal proliferation after coro-
nary angioplasty in hypercholesterolemic minipigs. Journal of the American Col-
lege of Cardiology 39: 732 – 738
[21] Bunton TE, Biery NJ, Myers L, Gayraud B, Ramirez F, Dietz HC (2001) Pheno-
typic alteration of vascular smooth muscle cells precedes elastolysis in a mouse
model of Marfan syndrome. Circulation Research 88: 37–43
[22] Burchfield JS, Xie M, Hill JA (2013) Pathological ventricular remodeling. Cir-
culation 128: 388–400
[23] Byrne M, Power J, Preovolos A, Mariani J, Hajjar R, Kaye D (2008) Recircu-
lating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an
experimental model of heart failure in large animals. Gene Therapy 15: 1550–
1557
[24] Cahill TJ, Ashrafian H, Watkins H (2013) Genetic cardiomyopathies causing
heart failure. Circulation Research 113: 660–675
[25] Cameron VA, Aitken GD, Ellmers LJ, Kennedy MA, Espiner EA (1996) The sites
of gene expression of atrial, brain, and C-type natriuretic peptides in mouse fetal
development: temporal changes in embryos and placenta. Endocrinology 137:
817–824
[26] Campistol JM, Iigo P, Larios S, Bescos M, Oppenheimer F (2001) Role of TGF-
β1 in the progression of chronic allograft nephropathy. Nephrology Dialysis
Transplantation 16: 114–116
[27] Cao M, Khan JA, Kang BY, Mehta JL, Hermonat PL (2012) Dual AAV/IL-10
plus STAT3 anti-inflammatory gene delivery lowers atherosclerosis in LDLR KO
mice, but without increased benefit. Int J Vasc Med 2012: 524235–52442
[28] Cao M, Theus SA, Straub KD, Figueroa JA, Mirandola L, Chiriva-Internati M,
Hermonat PL (2015) AAV2/8-human FOXP3 gene therapy shows robust anti-
atherosclerosis efficacy in ldlr-ko mice on high cholesterol diet. J Transl Med 13:
235–243
[29] Carta L, Smaldone S, Zilberberg L, Loch D, Dietz HC, Rifkin DB, Ramirez F
(2009) p38 MAPK is an early determinant of promiscuous Smad2/3 signaling in
the aortas of fibrillin-1-null mice. Journal of Biological Chemistry 284: 5630–
5636
[30] Chen Y, Guo H, Xu D, Xu X, Wang H, Hu X, Lu Z, Kwak D, Xu Y, Gunther R,
Huo Y, Weir EK (2012) Left ventricular failure produces profound lung remodel-
References 122
ing and pulmonary hypertension in mice: heart failure causes severe lung disease.
Hypertension 59: 1170–1178
[31] Chen Y, McMicken HW (2003) Intracellular production of DNA enzyme by a
novel single-stranded dna expression vector. Gene Ther 10: 1776–1780
[32] Cheung CY, Ko BC (2013) NFAT5 in cellular adaptation to hypertonic stress –
regulations and functional significance. Journal of Molecular Signaling 8: 5–12
[33] Christelle L, Ali TH, Fanny B, Valeri M, An C, Florence C, Alexei B, Remi
F (2007) Cell death in NFκB-dependent tumour cell lines as a result of NFκB
trapping by linker-modified hairpin decoy oligonucleotide. FEBS Letters 581:
1143–1150
[34] Chung AW, Au Yeung K, Sandor GG, Judge DP, Dietz HC, van Breemen C (2007)
Loss of elastic fiber integrity and reduction of vascular smooth muscle contraction
resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in
the thoracic aortic aneurysm in Marfan syndrome. Circulation Research 101:
512–522
[35] Chung AW, Yang HHC, Radomski MW, van Breemen C (2008) Long-term doxy-
cycline is more effective than atenolol to prevent thoracic aortic aneurysm in
Marfan syndrome through the inhibition of matrix metalloproteinase-2 and -9.
Circulation Research 102: 73–85
[36] Claycomb WC, Lanson NA, Stallworth BS, Egeland DB, Delcarpio JB, Bahinski
A, Izzo NJ (1998) HL-1 cells: A cardiac muscle cell line that contracts and re-
tains phenotypic characteristics of the adult cardiomyocyte. Proceedings of the
National Academy of Sciences 95: 2979–2984
[37] Cohn RD, van Erp C, Habashi JP, Soleimani AA, Klein EC, Lisi MT, Gamradt M,
ap Rhys CM, Holm TM, Loeys BL, Ramirez F, Judge DP, Ward CW, Dietz HC
(2007) Angiotensin II type 1 receptor blockade attenuates TGF-β-induced failure
of muscle regeneration in multiple myopathic states. Nat Med 13: 204–210
[38] Coselli JS, Volguina IV, LeMaire SA, Sundt TM, Connolly HM, Stephens EH,
Schaff HV, Milewicz DM, Vricella LA, Dietz HC, Minard CG, Miller DC (2014)
Early and 1-year outcomes of aortic root surgery in patients with Marfan syn-
drome: A prospective, multicenter, comparative study. The Journal of Thoracic
and Cardiovascular Surgery 147: 1758–1767
[39] Creemers EE, Pinto YM (2011) Molecular mechanisms that control interstitial
fibrosis in the pressure-overloaded heart. Cardiovascular Research 89: 265–272
[40] Crosas-Molist E, Meirelles T, Lo´pez-Luque J, Serra-Peinado C, Selva J, Caja
L, Gorbenko del Blanco D, Uriarte JJ, Bertran E, Mendiza´bal Y, Herna´ndez V,
References 123
Garcı´a-Calero C, Busnadiego O, Condom E, Toral D, Castella` M, Forteza A,
Navajas D, Sarri E, Rodrı´guez-Pascual F, Dietz HC, Fabregat I, Egea G (2015)
Vascular smooth muscle cell phenotypic changes in patients with Marfan syn-
drome. Arteriosclerosis, Thrombosis, and Vascular Biology 35: 960–972
[41] Dagenais GR, Yusuf S, Bourassa MG, Yi Q, Bosch J, Lonn EM, Kouz S, Grover
J (2001) Effects of ramipril on coronary events in high-risk persons. Circulation
104: 522–526
[42] Davis E (1994) Immunolocalization of microfibril and microfibril-associated pro-
teins in the subendothelial matrix of the developing mouse aorta. Journal of Cell
Science 107: 727–736
[43] Daya S, Berns KI (2008) Gene therapy using adeno-associated virus vectors. Clin
Microbiol Rev 21: 583–593
[44] deAlmeida AC, van Oort RJ, Wehrens XH (2010) Transverse aortic constriction
in mice. J Vis Exp 1729–1736
[45] Dearth CL, Goh Q, Marino JS, Cicinelli PA, Torres-Palsa MJ, Pierre P, Worth RG,
Pizza FX (2013) Skeletal muscle cells express ICAM-1 after muscle overload and
ICAM-1 contributes to the ensuing hypertrophic response. PLOS ONE 8: 1–13
[46] Dhr S, Torres-Montaner A, Astola A, Garca-Cozar FJ, Pendn C, Bolvar J, Val-
divia MM (2001) Short communication: Molecular analysis of the 5 region of
human ribosomal transcription factor UBF. DNA Sequence 12: 267–272
[47] Dichtl W, Dulak J, Frick M, Alber HF, Schwarzacher SP, Ares MP, Nilsson J,
Pachinger O, Weidinger F (2003) HMG-CoA reductase inhibitors regulate in-
flammatory transcription factors in human endothelial and vascular smooth mus-
cle cells. Arteriosclerosis, Thrombosis, and Vascular Biology 23: 58–63
[48] Diwan A, Dorn GW (2007) Decompensation of cardiac hypertrophy: Cellular
mechanisms and novel therapeutic targets. Physiology 22: 56–64
[49] Dixon JA, Spinale FG (2009) Large animal models of heart failure. Circulation:
Heart Failure 2: 262–271
[50] Dorn GW, Robbins J, Sugden PH (2003) Phenotyping hypertrophy. Circulation
Research 92: 1171–1175
[51] Drawnel FM, Archer CR, Roderick HL (2013) The role of the paracrine/autocrine
mediator endothelin-1 in regulation of cardiac contractility and growth. British
Journal of Pharmacology 168: 296–317
[52] Duan DD (2010) A leakage leads to failure. Hypertension 55: 849–851
[53] Dufour A, Sampson NS, Li J, Kuscu C, Rizzo RC, DeLeon JL, Zhi J, Jaber N,
Liu E, Zucker S, Cao J (2011) Small-molecule anticancer compounds selectively
References 124
target the hemopexin domain of matrix metalloproteinase-9. Cancer Research 71:
4977–4988
[54] Eaton SL, Roche SL, Llavero Hurtado M, Oldknow KJ, Farquharson C, Gilling-
water TH, Wishart TM (2013) Total protein analysis as a reliable loading control
for quantitative fluorescent western blotting. PLOS ONE 8: 1–9
[55] Eduardo Carren˜o J, Apablaza F, Ocaranza MP, Jalil JE (2006) Cardiac hypertro-
phy: Molecular and cellular events. Revista Espan˜ola de Cardiologı´a (English
Edition) 59: 473–486
[56] Ehlermann J, Pfisterer P, Schorle H (2003) Dynamic expression of Krppel-
like factor 4 (Klf4), a target of transcription factor AP-2α during murine mid-
embryogenesis. The Anatomical Record Part A: Discoveries in Molecular, Cel-
lular, and Evolutionary Biology 273A: 677–680
[57] Ejiri J, Inoue N, Tsukube T, Munezane T, Hino Y, Kobayashi S, Hirata Ki,
Kawashima S, Imajoh-Ohmi S, Hayashi Y, Yokozaki H, Okita Y, Yokoyama M
(2003) Oxidative stress in the pathogenesis of thoracic aortic aneurysm. Protec-
tive role of statin and angiotensin II type 1 receptor blocker. Cardiovascular Re-
search 59: 988–996
[58] Esposito G, Rapacciuolo A, Naga Prasad SV, Takaoka H, Thomas SA, Koch WJ,
Rockman HA (2002) Genetic alterations that inhibit in vivo pressure-overload hy-
pertrophy prevent cardiac dysfunction despite increased wall stress. Circulation
105: 85–92
[59] Finkbohner R, Johnston D, Crawford ES, Coselli J, Milewicz DM (1995) Marfan
syndrome. Circulation 91: 728–733
[60] Flanagan WM, Corthesy B, Bram RJ, Crabtree GR (1991) Nuclear association of
a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature 352:
803–807
[61] Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK (2009)
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes.
Nat Biotech 27: 59–65
[62] Frank K, Kranias EG (2000) Phospholamban and cardiac contractility. Annals of
Medicine 32: 572–578
[63] Franken R, den Hartog A, Radonic T, Micha D, Maugeri A, van Dijk FS, Meijers-
Heijboer HE, Timmermans J, Scholte AJ, van den Berg MP, Groenink M, Mulder
BJ, Zwinderman AH, de Waard V, Pals G (2015) Beneficial outcome of losartan
therapy depends on type of FBN1 mutation in Marfan syndrome. Circulation:
Cardiovascular Genetics 8: 383–388
References 125
[64] Frey N, Katus HA, Olson EN, Hill JA (2004) Hypertrophy of the heart. Circula-
tion 109: 1580–1589
[65] Frisk M, Koivuma¨ki JT, Norseng PA, Maleckar MM, Sejersted OM, Louch WE
(2014) Variable T-tubule organization and calcium homeostasis across the atria.
American Journal of Physiology - Heart and Circulatory Physiology 307: H609–
H620
[66] Fujiwara Y, Wada K, Kabuta T (2017) Lysosomal degradation of intracellular
nucleic acidsmultiple autophagic pathways. The Journal of Biochemistry 161:
145–154
[67] Gao L, Mao Q, Wen D, Zhang L, Zhou X, Hui R (2011) The effect of beta-blocker
therapy on progressive aortic dilatation in children and adolescents with Marfans
syndrome: a meta-analysis. Acta Paediatrica 100: 101–105
[68] Garcia-Chaumont C, Seksek O, Grzybowska J, Borowski E, Bolard J (2000) De-
livery systems for antisense oligonucleotides. Pharmacology & Therapeutics 87:
255–277
[69] Garcia-Menendez L, Karamanlidis G, Kolwicz S, Tian R (2013) Substrain spe-
cific response to cardiac pressure overload in C57BL/6 mice. Am J Physiol Heart
Circ Physiol 305: H397–H402
[70] Gersony DR, McClaughlin MA, Jin Z, Gersony WM (2006) The effect of beta-
blocker therapy on clinical outcome in patients with Marfan’s syndrome: A meta-
analysis. International Journal of Cardiology 114: 303–308
[71] Gomes AC, Falca˜o-Pires I, Pires AL, Bra´s-Silva C, Leite-Moreira AF (2013) Ro-
dent models of heart failure: an updated review. Heart Failure Reviews 2: 219–
249
[72] Granata A, Serrano F, Bernard WG, McNamara M, Low L, Sastry P, Sinha S
(2017) An iPSC-derived vascular model of Marfan syndrome identifies key me-
diators of smooth muscle cell death. Nat Genet 49: 97–109
[73] Grimm D, Kay MA, Kleinschmidt JA (2003) Helper virus-free, optically con-
trollable, and two-plasmid-based production of adeno-associated virus vectors of
serotypes 1 to 6. Molecular Therapy 7: 839–850
[74] Guo A, Zhang C, Wei S, Chen B, Song LS (2013) Emerging mechanisms of T-
tubule remodelling in heart failure. Cardiovascular Research 98: 204–215
[75] Guo G, Booms P, Halushka M, Dietz HC, Ney A, Stricker S, Hecht J, Mundlos
S, Robinson PN (2006) Induction of macrophage chemotaxis by aortic extracts
of the mgr Marfan mouse model and a GxxPG-containing fibrillin-1 fragment.
Circulation 114: 1855–1862
References 126
[76] Guo G, Gehle P, Doelken S, Martin-Ventura JL, von Kodolitsch Y, Hetzer R,
Robinson PN (2011) Induction of macrophage chemotaxis by aortic extracts from
patients with Marfan syndrome is related to elastin binding protein. PLoS One 6:
1855–62
[77] Guo G, Muoz-Garca B, Ott CE, Grnhagen J, Mousa SA, Pletschacher A, von
Kodolitsch Y, Knaus P, Robinson PN (2013) Antagonism of GxxPG fragments
ameliorates manifestations of aortic disease in Marfan syndrome mice. Human
Molecular Genetics 22: 433–443
[78] Guo G, Ott CE, Grnhagen J, Muoz-Garca B, Pletschacher A, Kallenbach K, von
Kodolitsch Y, Robinson P (2013) Indomethacin prevents the progression of tho-
racic aortic aneurysm in Marfan syndrome mice. Aorta 1: 5–12
[79] Gupta M, Zak R (1992) Reversibility of load-induced changes in myosin heavy
chain gene expression. American Journal of Physiology - Regulatory, Integrative
and Comparative Physiology 262: 346–349
[80] Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L,
Klein EC, Liu G, Calvi C, Podowski M, Neptune ER, Halushka MK, Bedja D,
Gabrielson K, Rifkin DB, Carta L, Ramirez F, Huso DL, Dietz HC (2006) Losar-
tan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan
syndrome. Science 312: 117–121
[81] Haghighi K, Kolokathis F, Pater L, Lynch RA, Asahi M, Gramolini AO, Fan
GC, Tsiapras D, Hahn HS, Adamopoulos S, Liggett SB, II GWD, MacLennan
DH, Kremastinos DT, Kranias EG (2003) Human phospholamban null results in
lethal dilated cardiomyopathy revealing a critical difference between mouse and
human. The Journal of Clinical Investigation 111: 869–876
[82] Han P, Li W, Lin CH, Yang J, Shang C, Nurnberg ST, Jin KK, Xu W, Lin CY, Lin
CJ, Xiong Y, Chien HC, Zhou B, Ashley E, Bernstein D, Chen PS, Chen HSV,
Quertermous T, Chang CP (2014) A long noncoding RNA protects the heart from
pathological hypertrophy. Nature 514: 102–106
[83] Hannan R, Jenkins A, Jenkins A, Brandenburger Y (2003) Cardiac hypertrophy:
A matter of translation. Clinical and Experimental Pharmacology and Physiology
30: 517–527
[84] Harding SE (2005) The failing cardiomyocyte. Heart Failure Clinics 1: 171–181
[85] Hecker M, Wagner AH (2017) Transcription factor decoy technology: A thera-
peutic update. Biochemical Pharmacology 144: 29 – 34
[86] Hecker M, Wagner S, Henning SH, Wagner AH (2008) Therapeutic Oligonu-
cleotides, chap. Decoy oligodeoxynucleotides to treat inflammatory diseases,
References 127
Chapter 8, 163188. The name of the publisher, Royal Society of Chemistry
[87] Hocher B, Godes M, Olivier J, Weil J, Eschenhagen T, Slowinski T, Neumayer
HH, Bauer C, Paul M, Pinto Y (2002) Inhibition of left ventricular fibrosis by
tranilast in rats with renovascular hypertension. Journal of hypertension 20: 745–
51
[88] Holm TM, Habashi JP, Doyle JJ, Bedja D, Chen Y, van Erp C, Lindsay ME,
Kim D, Schoenhoff F, Cohn RD, Loeys BL, Thomas CJ, Patnaik S, Marugan JJ,
Judge DP, Dietz HC (2011) Noncanonical TGF-β signaling contributes to aortic
aneurysm progression in Marfan syndrome mice. Science 332: 358–361
[89] Hong HM, Song EJ, Oh E, Kabir MH, Lee C, Yoo YS (2011) Endothelin-1- and
isoproterenol-induced differential protein expression and signaling pathway in
HL-1 cardiomyocytes. Proteomics 11: 283–297
[90] Horbelt D, Guo G, Robinson PN, Knaus P (2010) Quantitative analysis of
TGFβR2 mutations in Marfan-syndrome-related disorders suggests a correlation
between phenotypic severity and Smad signaling activity. Journal of Cell Science
123: 4340–4350
[91] Hulot JS, Ishikawa K, Hajjar RJ (2016) Gene therapy for the treatment of heart
failure: promise postponed. European Heart Journal 37: 1651–1658
[92] Ijaz T, Tilton RG, Brasier AR (2016) Cytokine amplification and macrophage ef-
fector functions in aortic inflammation and abdominal aortic aneurysm formation.
Journal of Thoracic Disease 8: 746–754
[93] Ikonomidis JS, Barbour JR, Amani Z, Stroud RE, Herron AR, McClister DM,
Camens SE, Lindsey ML, Mukherjee R, Spinale FG (2005) Effects of deletion
of the Matrix Metalloproteinase 9 gene on development of murine thoracic aortic
aneurysms. Circulation 112: 242–248
[94] Ikonomidis JS, Jones JA, Barbour JR, Stroud RE, Clark LL, Kaplan BS, Zeeshan
A, Bavaria JE, Gorman JH, Spinale FG, Gorman RC (2006) Expression of matrix
metalloproteinases and endogenous inhibitors within ascending aortic aneurysms
of patients with Marfan syndrome. Circulation 114: 365–370
[95] Inagaki K, Fuess S, Storm TA, Gibson GA, Mctiernan CF, Kay MA, Nakai H
(2006) Robust systemic transduction with AAV9 vectors in mice: Efficient global
cardiac gene transfer superior to that of AAV8. Mol Ther 14: 45–53
[96] Jensen EC (2013) Quantitative analysis of histological staining and fluorescence
using ImageJ. The Anatomical Record 296: 378–381
[97] Jiang J, Wakimoto H, Seidman JG, Seidman CE (2013) Allele-specific silencing
of mutant MYH6 transcripts in mice suppresses hypertrophic cardiomyopathy.
References 128
Science 342: 111–114
[98] Jo N, Ogata N, Aoki M, Otsuji T, Morishita R, Kaneda Y, Matsumura M (2002)
Effective transfection of a cis element decoy of the nuclear factor-κB binding site
into the experimental choroidal neovascularization. Current Eye Research 24:
465–473
[99] Kaartinen V, Warburton D (2003) Fibrillin controls TGF-β activation. Nat Genet
33: 331–332
[100] Kawamura T, Ono K, Morimoto T, Akao M, Iwai-Kanai E, Wada H, Sowa N,
Kita T, Hasegawa K (2004) Endothelin-1 dependent Nuclear Factor of Activated
T Lymphocyte signaling associates with transcriptional coactivator p300 in the
activation of the B cell leukemia-2 promoter in cardiac myocytes. Circulation
Research 94: 1492–1499
[101] Keane MG, Pyeritz RE (2008) Medical management of Marfan syndrome. Cir-
culation 117: 2802–2813
[102] Kim JB, Porreca GJ, Song L, Greenway SC, Gorham JM, Church GM, Seidman
CE, Seidman JG (2007) Polony multiplex analysis of gene expression (PMAGE)
in mouse hypertrophic cardiomyopathy. Science 316: 1481–1484
[103] Kimura B, Mohuczy D, Tang X, Phillips MI (2001) Attenuation of hypertension
and heart hypertrophy by adeno-associated virus delivering angiotensinogen an-
tisense. Hypertension 37: 376–380
[104] Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, von Scheidt W
(2001) Role of brain natriuretic peptide in risk stratification of patients with con-
gestive heart failure. Journal of the American College of Cardiology 38: 1934 –
1941
[105] Kohli S, Ahuja S, Rani V (2011) Transcription factors in heart: Promising thera-
peutic targets in cardiac hypertrophy. Curr Cardiol Rev 7: 262–271
[106] Koitabashi N, Kass DA (2012) Reverse remodeling in heart failure - mechanisms
and therapeutic opportunities. Nat Rev Cardiol 9: 147–157
[107] Kotterman MA, Schaffer DV (2014) Engineering adeno-associated viruses for
clinical gene therapy. Nat Rev Genet 15: 445–451
[108] Krenz M, Robbins J (2004) Impact of β-myosin heavy chain expression on car-
diac function during stress. Journal of the American College of Cardiology 44:
2390 – 2397
[109] Krenz M, Sanbe A, Bouyer-Dalloz F, Gulick J, Klevitsky R, Hewett TE, Osinska
HE, Lorenz JN, Brosseau C, Federico A, Alpert NR, Warshaw DM, Perryman
References 129
MB, Helmke SM, Robbins J (2003) Analysis of myosin heavy chain functionality
in the heart. Journal of Biological Chemistry 278: 17466–17474
[110] Krum H, Abraham WT (2005) Heart failure. The Lancet 373: 941–955
[111] Kumar P, Shen Q, Pivetti CD, Lee ES, Wu MH, Yuan SY (2009) Molecular mech-
anisms of endothelial hyperpermeability: implications in inflammation. Expert
Reviews in Molecular Medicine 11
[112] Kuriyama M, Matsushita M, Tateishi A, Moriwaki A, Tomizawa K, Ishino K,
Sano S, Matsui H (2006) A cell-permeable NFAT inhibitor peptide prevents
pressure-overload cardiac hypertrophy. Chemical Biology and Drug Design 67:
238–243
[113] Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K, Imaizumi T
(2002) Transforming growth factor-β function blocking prevents myocardial fi-
brosis and diastolic dysfunction in pressure-overloaded rats. Circulation 106:
130–135
[114] Lee HJ, Kim YS, Sato Y, Cho YJ (2009) RCAN1-4 knockdown attenuates cell
growth through the inhibition of Ras signaling. FEBS Letters 583: 2557–2564
[115] Lehmann LH, Rostosky JS, Buss SJ, Kreusser MM, Krebs J, Mier W, Enseleit F,
Spiger K, Hardt SE, Wieland T, Haass M, Lscher TF, Schneider MD, Parlato R,
Grne HJ, Haberkorn U, Yanagisawa M, Katus HA, Backs J (2014) Essential role
of sympathetic endothelin A receptors for adverse cardiac remodeling. Proceed-
ings of the National Academy of Sciences 111: 13499–13504
[116] Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP (1990) Prognos-
tic implications of echocardiographically determined left ventricular mass in the
Framingham heart study. New England Journal of Medicine 322: 1561–1566
[117] Li M, Abdollahi A, Gro¨ne HJ, Lipson KE, Belka C, Huber PE (2009) Late
treatment with imatinib mesylate ameliorates radiation-induced lung fibrosis in
a mouse model. Radiation Oncology 4: 66–75
[118] Li YT, He B, Wang YZ, Wang J (2009) Effects of intratracheal administration of
NFκB decoy oligodeoxynucleotides on long-term cigarette smoke-induced lung
inflammation and pathology in mice. Respiratory Research 10: 79–93
[119] Lim DS, Lutucuta S, Bachireddy P, Youker K, Evans A, Entman M, Roberts R,
Marian AJ (2001) Angiotensin II blockade reverses myocardial fibrosis in a trans-
genic mouse model of human hypertrophic cardiomyopathy. Circulation 103:
789–791
[120] Lin JC, Lin SC, Chen WY, Yen YT, Lai CW, Tao MH, Lin YL, Miaw SC, Wu-
Hsieh BA (2014) Dengue viral protease interaction with NFκB inhibitor results
References 130
in endothelial cell apoptosis and hemorrhage development. The Journal of Im-
munology 193: 1258–1267
[121] Liu W, Zi M, Tsui H, Chowdhury SK, Zeef L, Meng QJ, Travis M, Prehar S, Berry
A, Hanley NA, Neyses L, Xiao RP, Oceandy D, Ke Y, Solaro RJ, Cartwright EJ,
Lei M, Wang X (2013) A novel immunomodulator, FTY-720 reverses existing
cardiac hypertrophy and fibrosis from pressure overload by targeting NFAT sig-
naling and periostin: Clinical perspective. Circulation: Heart Failure 6: 833–844
[122] Liu Y, Sinha S, McDonald OG, Shang Y, Hoofnagle MH, Owens GK (2005)
Kruppel-like factor 4 abrogates myocardin-induced activation of smooth muscle
gene expression. Journal of Biological Chemistry 280: 9719–9727
[123] Lo´pez JE, Myagmar BE, Swigart PM, Montgomery MD, Haynam S, Bigos M,
Rodrigo MC, Simpson PC (2011) β-myosin heavy chain is induced by pressure
overload in a minor subpopulation of smaller mouse cardiac myocytes. Novelty
and significance. Circulation Research 109: 629–638
[124] Lopez-Rodrguez C, Aramburu J, Rakeman A, Rao A (1999) NFAT5, a constitu-
tively nuclear NFAT protein that does not cooperate with Fos and Jun. Proceed-
ings of the National Academy of Sciences of the United States of America 96:
7214–7219
[125] LR G (2010) Heart failure. Annals of Internal Medicine 152: ITC6–1
[126] Lyon AR, MacLeod KT, Zhang Y, Garcia E, Kanda GK, Lab MJ, Korchev YE,
Harding SE, Gorelik J (2009) Loss of T-tubules and other changes to surface to-
pography in ventricular myocytes from failing human and rat heart. Proceedings
of the National Academy of Sciences 106: 6854–6859
[127] Mak MC, Lam KM, Chan PK, Lau YB, Tang WH, Yeung PKK, Ko BCB, Chung
SMS, Chung SK (2011) Embryonic lethality in mice lacking the nuclear factor
of activated T cells 5 protein due to impaired cardiac development and function.
PLOS ONE 6: 1–8
[128] Manea A, Manea SA, Gafencu AV, Raicu M, Simionescu M (2008) AP-1 de-
pendent transcriptional regulation of NADPH oxidase in human aortic smooth
muscle cells. Arteriosclerosis, Thrombosis, and Vascular Biology 28: 878–885
[129] Mao N, Gu T, Shi E, Zhang G, Yu L, Wang C (2015) Phenotypic switching of
vascular smooth muscle cells in animal model of rat thoracic aortic aneurysm.
Interactive CardioVascular and Thoracic Surgery 21: 62–70
[130] Matt P, Schoenhoff F, Habashi J, Holm T, Van Erp C, Loch D, Carlson OD, Gris-
wold BF, Fu Q, De Backer J, Loeys B, Huso DL, McDonnell NB, Van Eyk JE, Di-
References 131
etz HC (2009) Circulating Transforming Growth Factor-β in Marfan syndrome.
Circulation 120: 526–532
[131] McCormick ML, Gavrila D, Weintraub NL (2007) Role of oxidative stress in the
pathogenesis of abdominal aortic aneurysms. Arteriosclerosis, Thrombosis, and
Vascular Biology 27: 461–469
[132] McLoughlin D, McGuinness J, Byrne J, Terzo E, Huuskonen V, McAllister H,
Black A, Kearney S, Kay E, Hill AD, Dietz HC, Redmond JM (2011) Pravastatin
reduces Marfan aortic dilation. Circulation 124: S168–S173
[133] Mietzsch M, Broecker F, Reinhardt A, Seeberger PH, Heilbronn R (2014) Differ-
ential adeno-associated virus serotype-specific interaction patterns with synthetic
heparins and other glycans. Journal of Virology 88: 2991–3003
[134] Miyake T, Aoki M, Nakashima H, Kawasaki T, Oishi M, Kataoka K, Tanemoto
K, Ogihara T, Kaneda Y, Morishita R (2006) Prevention of abdominal aortic
aneurysms by simultaneous inhibition of NFκB and ets using chimeric decoy
oligonucleotides in a rabbit model. Gene Ther 13: 695–704
[135] Miyake T, Aoki M, Osako MK, Shimamura M, Nakagami H, Morishita R (2010)
Systemic administration of ribbon-type decoy oligodeoxynucleotide against
NFκB prevents abdominal aortic aneurysm in rat model. Molecular Therapy 19:
181–187
[136] Mller OJ, Leuchs B, Pleger ST, Grimm D, Franz WM, Katus HA, Kleinschmidt
JA (2006) Improved cardiac gene transfer by transcriptional and transductional
targeting of adeno-associated viral vectors. Cardiovascular Research 70: 70–78
[137] Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR,
Olson EN (1998) A calcineurin-dependent transcriptional pathway for cardiac
hypertrophy. Cell 93: 215–228
[138] Morihara H, Yamamoto T, Oiwa H, Tonegawa K, Tsuchiyama D, Kawakatsu
I, Obana M, Maeda M, Mohri T, Obika S, Fujio Y, Nakayama H (2016) Phos-
pholamban inhibition by a single dose of locked nucleic acid antisense oligonu-
cleotide improves cardiac contractility in pressure overload-induced systolic dys-
function in mice. Journal of Cardiovascular Pharmacology and Therapeutics 22:
273–282
[139] Morishita R, Sugimoto T, Aoki M, Kida I, Tomita N, Moriguchi A, Maeda K,
Sawa Y, Kaneda Y, Higaki J, Ogihara T (1997) In vivo transfection of cis element
decoy against nuclear factor-κb binding site prevents myocardial infarction. Nat
Med 3: 894–899
References 132
[140] Muller OJ, Kaul F, Weitzman MD, Pasqualini R, Arap W, Kleinschmidt JA, Tre-
pel M (2003) Random peptide libraries displayed on adeno-associated virus to
select for targeted gene therapy vectors. Nat Biotech 21: 1040–1046
[141] Murdoch JL, Walker BA, Halpern BL, Kuzma JW, McKusick VA (1972) Life
expectancy and causes of death in the Marfan syndrome. New England Journal
of Medicine 286: 804–808
[142] Nagai R, Low RB, Stirewalt WS, Alpert NR, Litten RZ (1988) Efficiency and
capacity of protein synthesis are increased in pressure overload cardiac hypertro-
phy. American Journal of Physiology - Heart and Circulatory Physiology 255:
325–328
[143] Nagatomo Y, Carabello BA, Hamawaki M, Nemoto S, Matsuo T, McDermott PJ
(1999) Translational mechanisms accelerate the rate of protein synthesis during
canine pressure-overload hypertrophy. American Journal of Physiology - Heart
and Circulatory Physiology 277: 2176–2184
[144] Nakamura H, Aoki M, Tamai K, Oishi M, Ogihara T, Kaneda Y, Morishita R
(2002) Prevention and regression of atopic dermatitis by ointment containing
NFκB decoy oligodeoxynucleotides in NC/Nga atopic mice model. Journal of
Allergy and Clinical Immunology 109: S86–S87
[145] Naso MF, Tomkowicz B, Perry WL, Strohl WR (2017) Adeno-associated virus
(AAV) as a vector for gene therapy. BioDrugs 31: 317–334
[146] Nataatmadja M, West M, West J, Summers K, Walker P, Nagata M, Watanabe T
(2003) Abnormal extracellular matrix protein transport associated with increased
apoptosis of vascular smooth muscle cells in Marfan syndrome and bicuspid aor-
tic valve thoracic aortic aneurysm. Circulation 108: 329—334
[147] Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC,
Chowdary P, Riddell A, Pie AJ, Harrington C, O’Beirne J, Smith K, Pasi J, Glader
B, Rustagi P, Ng CY, Kay MA, Zhou J, Spence Y, Morton CL, Allay J, Coleman
J, Sleep S, Cunningham JM, Srivastava D, Basner-Tschakarjan E, Mingozzi F,
High KA, Gray JT, Reiss UM, Nienhuis AW, Davidoff AM (2011) Adenovirus-
associated virus vector mediated gene transfer in Hemophilia B. New England
Journal of Medicine 365: 2357–2365
[148] Naud P, Guasch E, Nattel S (2010) Physiological versus pathological cardiac
electrical remodelling: potential basis and relevance to clinical management. J
Physiol 588: 4855–4856
[149] Neptune ER, Frischmeyer PA, Arking DE, Myers L, Bunton TE, Gayraud B,
Ramirez F, Sakai LY, Dietz HC (2003) Dysregulation of TGF-β activation con-
References 133
tributes to pathogenesis in Marfan syndrome. Nat Genet 33: 407–411
[150] Ng CM, Cheng A, Myers LA, Martinez-Murillo F, Jie C, Bedja D, Gabrielson
KL, Hausladen JM, Mecham RP, Judge DP, Dietz HC (2004) TGF-βdependent
pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. The
Journal of Clinical Investigation 114: 1586–1592
[151] Oka T, Xu J, Kaiser RA, Melendez J, Hambleton M, Sargent MA, Lorts A, Brun-
skill EW, Dorn GW, Conway SJ, Aronow BJ, Robbins J, Molkentin JD (2007)
Genetic manipulation of periostin expression reveals a role in cardiac hypertro-
phy and ventricular remodeling. Circulation Research 101: 313–321
[152] Pacak CA, Mah CS, Thattaliyath BD, Conlon TJ, Lewis MA, Cloutier DE, Zolo-
tukhin I, Tarantal AF, Byrne BJ (2006) Recombinant AAV9 leads to preferential
cardiac transduction in vivo. Circulation Research 99: 3–9
[153] Pachori AS, Melo LG, Zhang L, Loda M, Pratt RE, Dzau VJ (2004) Potential for
germ line transmission after intramyocardial gene delivery by adeno-associated
virus. Biochemical and Biophysical Research Communications 3: 528–533
[154] Pasumarthi KB, Field LJ (2002) Cardiomyocyte cell cycle regulation. Circulation
Research 90: 1044–1054
[155] Pazos-Lo´pez P, Peteiro-Va´zquez J, Carcı´a-Campos A, Garcı´a-Bueno L, de Torres
JPA, Castro-Beiras A (2011) The causes, consequences, and treatment of left or
right heart failure. Vasc Health Risk Manag 7: 237–254
[156] Pereira L, Lee SY, Gayraud B, Andrikopoulos K, Shapiro SD, Bunton T,
Biery NJ, Dietz HC, Sakai LY, Ramirez F (1999) Pathogenetic sequence for
aneurysm revealed in mice underexpressing fibrillin-1. Proceedings of the Na-
tional Academy of Sciences 96: 3819–3823
[157] Peter AK, Bjerke MA, Leinwand LA (2016) Biology of the cardiac myocyte in
heart disease. Molecular Biology of the Cell 27: 2149–2160
[158] Pfaff MW (2001) A new mathematical model for relative quantification in real-
time RT PCR. Nucleic Acids Res 29: 2003–2007
[159] Pikkarainen S, Kerkela¨ R, Po¨ntinen J, Majalahti-Palviainen T, Tokola H, Eskeli-
nen S, Vuolteenaho O, Ruskoaho H (2002) Decoy oligonucleotide characteriza-
tion of GATA-4 transcription factor in hypertrophic agonist induced responses of
cardiac myocytes. Journal of Molecular Medicine 80: 51–60
[160] Pillay S, Meyer NL, Puschnik AS, Davulcu O, Diep J, Ishikawa Y, Jae LT, Wosen
JE, Nagamine CM, Chapman MS, Carette JE (2016) An essential receptor for
adeno-associated virus infection. Nature 530: 108–112
References 134
[161] Piva R, Gambari R (2002) Transcription factor decoy (TFD) in breast cancer re-
search and treatment. Technology in Cancer Research & Treatment 1: 405–416
[162] Raake PW, Schlegel P, Ksienzyk J, Reinkober J, Barthelmes J, Schinkel S, Pleger
S, Mier W, Haberkorn U, Koch WJ, Katus HA, Most P, Mller OJ (2013) AAV6
βARKct cardiac gene therapy ameliorates cardiac function and normalizes the
catecholaminergic axis in a clinically relevant large animal heart failure model.
European Heart Journal 34: 1437–1447
[163] Rad SMAH, Bamdad T, Sadeghizadeh M, Arefian E, Lotfinia M, Ghanipour M
(2015) Transcription factor decoy against stem cells master regulators, Nanog
and Oct-4: a possible approach for differentiation therapy. Tumor Biology 36:
2621–2629
[164] Radonic T, de Witte P, Groenink M, de Waard V, Lutter R, van Eijk M, Jansen
M, Timmermans J, Kempers M, Scholte AJ, Hilhorst-Hofstee Y, van den Berg
MP, van Tintelen JP, Pals G, Baars MJH, Mulder BJM, Zwinderman AH (2012)
Inflammation aggravates disease severity in Marfan syndrome patients. PLOS
ONE 7: 1–9
[165] Rao RK, Basuroy S, Rao VU, Karnaky Jr KJ, Gupta A (2002) Tyrosine phospho-
rylation and dissociation of occludin-ZO-1 and E-cadherin-β-catenin complexes
from the cytoskeleton by oxidative stress. Biochem J 368: 471–481
[166] Reinkober J, Tscheschner H, Pleger ST, Most P, Katus HA, Koch WJ, Raake
PWJ (2012) Targeting GRK2 by gene therapy for heart failure: benefits above
β-blockade. Gene Ther 19: 686–693
[167] Reiser PJ, Portman MA, Ning XH, Moravec CS (2001) Human cardiac myosin
heavy chain isoforms in fetal and failing adult atria and ventricles. American
Journal of Physiology - Heart and Circulatory Physiology 280: H1814–H1820
[168] Rincon MY, VandenDriessche T, Chuah MK (2015) Gene therapy for cardiovas-
cular disease: advances in vector development, targeting, and delivery for clinical
translation. Cardiovascular Research 108: 4–20
[169] Robinson PN, Godfrey M (2000) The molecular genetics of Marfan syndrome
and related microfibrillopathies. Journal of Medical Genetics 37: 9–25
[170] Romaniello F, Mazzaglia D, Pellegrino A, Grego S, Fiorito R, Ferlosio A,
Chiariello L, Orlandi A (2014) Aortopathy in Marfan syndrome: an update. Car-
diovascular Pathology 23: 261–266
[171] Rosenkranz S, Flesch M, Amann K, Haeuseler C, Kilter H, Seeland U, Schlu¨ter
KD, Bo¨hm M (2002) Alterations of β-adrenergic signaling and cardiac hypertro-
References 135
phy in transgenic mice overexpressing TGF-β. American Journal of Physiology
- Heart and Circulatory Physiology 283: H1253–H1262
[172] Ruiz-Ortega M, Lorenzo O´, Rupe´rez M, Blanco J, Egido J (2001) Systemic in-
fusion of angiotensin II into normal rats activates nuclear factor- and AP-1 in the
kidney. The American Journal of Pathology 158: 1743–1756
[173] Rysa¨ J, Leskinen H, Ilves M, Ruskoaho H (2005) Distinct upregulation of extra-
cellular matrix genes in transition from hypertrophy to hypertensive heart failure.
Hypertension 45: 927–933
[174] Sakai S, Kimura T, Wang Z, Shimojo N, Maruyama H, Homma S, Kuga K, Ya-
maguchi I, Aonuma K, Miyauchi T (2012) Endothelin-1induced cardiomyocyte
hypertrophy is partly regulated by transcription factor II-F interacting C-terminal
domain phosphatase of rna polymerase II. Life Sciences 91: 572 – 577
[175] Salmon M, Johnston WF, Woo A, Pope NH, Su G, Upchurch GR, Owens GK,
Ailawadi G (2013) KLF4 regulates abdominal aortic aneurysm morphology and
deletion attenuates aneurysm formation. Circulation 128: 163–174
[176] Sano M, Fukuda K, Kodama H, Pan J, Saito M, Matsuzaki J, Takahashi T, Makino
S, Kato T, Ogawa S (2000) Interleukin-6 family of cytokines mediate angiotensin
II-induced cardiac hypertrophy in rodent cardiomyocytes. Journal of Biological
Chemistry 275: 29717–29723
[177] Satriano JA, Shuldiner M, Hora K, Xing Y, Shan Z, Schlondorff D (1993) Oxygen
radicals as second messengers for expression of the monocyte chemoattractant
protein, MCP-1, and the monocyte colony-stimulating factor, CSF-1, in response
to tumor necrosis factor-alpha and immunoglobulin G. evidence for involvement
of reduced nicotinamide adenine dinucleotide phosphate NADPH-dependent ox-
idase. The Journal of Clinical Investigation 92: 1564–1571
[178] Schelbert EB, Piehler KM, Zareba KM, Moon JC, Ugander M, Messroghli DR,
Valeti US, Chang CCH, Shroff SG, Diez J, Miller CA, Schmitt M, Kellman P,
Butler J, Gheorghiade M, Wong TC (2015) Myocardial fibrosis quantified by ex-
tracellular volume is associated with subsequent hospitalization for heart failure,
death, or both across the spectrum of ejection fraction and heart failure stage.
Journal of the American Heart Association 4
[179] Scheuer J, Malhotra A, Hirsch C, Capasso J, Schaible TF (1982) Physiologic car-
diac hypertrophy corrects contractile protein abnormalities associated with patho-
logic hypertrophy in rats. J Clin Invest 70: 1300–1305
[180] Schiattarella GG, Hill JA (2015) Inhibition of hypertrophy is a good therapeu-
tic strategy in ventricular pressure overload response to Schiattarella and Hill.
References 136
Circulation 131: 1435–1447
[181] Schmidt EK, Clavarino G, Ceppi M, Pierre P (2009) SUnSET, a nonradioactive
method to monitor protein synthesis. Nature Methods 6: 275–277
[182] Schonthaler HB, Guinea-Viniegra J, Wagner EF (2011) Targeting inflammation
by modulating the Jun/AP-1 pathway. Annals of the Rheumatic Diseases 70:
109–112
[183] Schwill S, Seppelt P, Gru¨nhagen J, Ott CE, Jugold M, Ruhparwar A, Robinson
PN, Karck M, Kallenbach K (2013) The fibrillin-1 hypomorphic mgr/mgr murine
model of Marfan syndrome shows severe elastolysis in all segments of the aorta.
Journal of Vascular Surgery 57: 1628–1636
[184] Seppelt PC, Schwill S, Weymann A, Arif R, Weber A, Zaradzki M, Richter K,
Ensminger S, Robinson PN, Wagner AH, Karck M, Klaus K (2016) Loss of en-
dothelial barrier in Marfan mice (mgr/mgr) results in severe inflammation after
adenoviral gene therapy. PLoS ONE 11: 891–921
[185] Shah AS, White DC, Emani S, Kypson AP, Lilly RE, Wilson K, Glower DD,
Lefkowitz RJ, Koch WJ (2001) In vivo ventricular gene delivery of a β-adrenergic
receptor kinase inhibitor to the failing heart reverses cardiac dysfunction. Circu-
lation 103: 1311–1316
[186] Shankman LS, Gomez D, Cherepanova OA, Salmon M, Alencar GF, Haskins
RM, Swiatlowska P, Newman AAC, Greene ES, Straub AC, Isakson B, Ran-
dolph GJ, Owens GK (2015) KLF4-dependent phenotypic modulation of smooth
muscle cells has a key role in atherosclerotic plaque pathogenesis. Nat Med 21:
628–637
[187] Song Y, Xie Y, Liu F, Zhao C, Yu R, Ban S, Ye Q, Wen J, Wan H, Li X, Ma R,
Meng Z (2013) Expression of matrix metalloproteinase-12 in aortic dissection.
BMC Cardiovascular Disorders 13: 34–45
[188] Stachler MD, Bartlett JS (2006) Mosaic vectors comprised of modified AAV1
capsid proteins for efficient vector purification and targeting to vascular endothe-
lial cells. Gene Ther 13: 926–931
[189] Stadlbauer TH, Wagner AH, Hlschermann H, Fiedel S, Fingerhuth H, Tillmanns
H, Bohle RM, Hecker M (2008) AP-1 and STAT-1 decoy oligodeoxynucleotides
attenuate transplant vasculopathy in rat cardiac allografts. Cardiovascular Re-
search 79: 698–705
[190] Sternlicht MD, Werb Z (2001) How matrix metalloproteinases regulate cell be-
haviour. Annu Rev Cell Dev Biol 17: 463–516
References 137
[191] Stojanovic T, Wagner AH, Schndube FA, Hecker M (2012) Cardiac Transplan-
tation, vol. 20, chap. Pre-Transplant Therapy in Experimental Heart Transplanta-
tion, 143–156. InTech
[192] Stuart A, Williams A (2007) Marfan’s syndrome and the heart. Arch Dis Child
92: 351–356
[193] Sturrock A, Cahill B, Norman K, Huecksteadt TP, Hill K, Sanders K, Karwande
SV, Stringham JC, Bull DA, Gleich M, Kennedy TP, Hoidal JR (2006) Trans-
forming growth factor-1 induces Nox4 NAD(P)H oxidase and reactive oxygen
species-dependent proliferation in human pulmonary artery smooth muscle cells.
American Journal of Physiology - Lung Cellular and Molecular Physiology 290:
L661–L673
[194] Su H, Arakawa-Hoyt J, Kan YW (2002) Adeno-associated viral vector-mediated
hypoxia response element-regulated gene expression in mouse ischemic heart
model. Proceedings of the National Academy of Sciences 99: 9480–9485
[195] Suckau L, Fechner H, Chemaly E, Krohn S, Hadri L, Kockska¨mper J, Wester-
mann D, Bisping E, Ly H, Wang X, Kawase Y, Chen J, Liang L, Sipo I, Vetter R,
Weger S, Kurreck J, Erdmann V, Tschope C, Pieske B, Lebeche D, Schultheiss
HP, Hajjar RJ, Poller WC (2009) Long-term cardiac-targeted RNA interference
for the treatment of heart failure restores cardiac function and reduces pathologi-
cal hypertrophy. Circulation 119: 1241–1252
[196] Summers KM, Raza S, van Nimwegen E, Freeman TC, Hume DA (2010) Co-
expression of FBN1 with mesenchyme-specific genes in mouse cell lines: impli-
cations for phenotypic variability in Marfan syndrome. Eur J Hum Genet 18:
1209–1215
[197] Sun Z (2015) Aging, arterial stiffness and hypertension. Hypertension 65: 252–
256
[198] Szema AM, Forsyth E, Ying B, Hamidi SA, Chen JJ, Hwang S, Li JC, Saba-
tini Dwyer D, Ramiro-Diaz JM, Giermakowska W, Gonzalez Bosc LV (2017)
NFATc3 and VIP in idiopathic pulmonary fibrosis and chronic obstructive pul-
monary disease. PLOS ONE 12: 1–18
[199] Tada Y, Yagi K, Kitazato KT, Tamura T, Kinouchi T, Shimada K, Matsushita N,
Nakajima N, Satomi J, Kageji T, Nagahiro S (2010) Reduction of endothelial
tight junction proteins is related to cerebral aneurysm formation in rats. Journal
of Hypertension 28: 18831891
[200] Ten Dijke P, Arthur HM (2007) Extracellular control of TGF-β signalling in vas-
cular development and disease. Nat Rev Mol Cell Biol 8: 857–869
References 138
[201] Thomas SP, Bircher-Lehmann L, Thomas SA, Zhuang J, Saffitz JE, Kle´ber AG
(2000) Synthetic strands of neonatal mouse cardiac myocytes. Circulation Re-
search 87: 467–473
[202] Tomita T, Takeuchi E, Tomita N, Morishita R, Kaneko M, Yamfamoto K, Nakase
T, Seki H, Kato K, Kaneda Y, Ochi T (1999) Suppressed severity of collagen-
induced arthritis by in vivo transfection of NFκB decoy oligodeoxynucleotides as
a gene therapy. Arthritis and Rheumatism 42: 2532–2542
[203] Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, Ohnishi M,
Sugimoto Y, Kinoshita M (1997) Attenuation of compensation of endogenous
cardiac natriuretic peptide system in chronic heart failure. Circulation 96: 509–
516
[204] Tuxworth WJ, Saghir AN, Spruill LS, Menick DR, McDermott PJ (2004) Regula-
tion of protein synthesis by eIF4E phosphorylation in adult cardiocytes: the con-
sequence of secondary structure in the 5’-untranslated region of mRNA. Biochem
J 378: 73–82
[205] Umeyama K, Watanabe K, Watanabe M, Horiuchi K, Nakano K, Kitashiro M,
Matsunari H, Kimura T, Arima Y, Sampetrean O, Nagaya M, Saito M, Saya
H, Kosaki K, Nagashima H, Matsumoto M (2016) Generation of heterozygous
fibrillin-1 mutant cloned pigs from genome-edited foetal fibroblasts. Scientific
Reports 6: 24413–24423
[206] van Nierop BJ, van Assen HC, van Deel ED, Niesen LBP, Duncker DJ, Strijkers
GJ, Nicolay K (2013) Phenotyping of left and right ventricular function in mouse
models of compensated hypertrophy and heart failure with cardiac MRI. PLOS
ONE 8: 1–9
[207] van Rooij E, Doevendans PA, de Theije CC, Babiker FA, Molkentin JD, De Windt
LJ (2002) Requirement of NFAT in calcineurin-mediated cardiomyocyte hyper-
trophy. Journal of Biological Chemistry 277: 48617–48626
[208] Varadi K, Michelfelder S, Korff T, Hecker M, Trepel M, Katus H, Kleinschmidt
J, Mller OJ (2012) Novel random peptide libraries displayed on AAV serotype 9
for selection of endothelial cell-directed gene transfer vectors. Gene Therapy 19:
800–809
[209] Vega RB, Bassel-Duby R, Olson EN (2003) Control of cardiac growth and func-
tion by calcineurin signaling. Journal of Biological Chemistry 278: 36981–36984
[210] Velagaleti RS, Pencina MJ, Murabito JM, Wang TJ, Parikh NI, D’Agostino RB,
Levy D, Kannel WB, Vasan RS (2008) Long-term trends in the incidence of heart
failure after myocardial infarction. Circulation 118: 2057–2062
References 139
[211] Verrecchia F, Vindevoghel L, Lechleider RJ, Uitto J, Roberts AB, Mauviel A
(2001) Smad3/AP-1 interactions control transcriptional responses to TGF-β in a
promoter-specific manner. Oncogene 20: 3332–3340
[212] Wagenseil JE, Mecham RP (2007) New insights into elastic fiber assembly. Birth
Defects Research Part C: Embryo Today: Reviews 81: 229–240
[213] Wang Q, Zhou Y, Qi Y, Liu Hy, Ding GS, Yang L, Qiu B, Xu S, Guo Z (2011)
Synthetic gelatinases inhibitor attenuates electromagnetic pulse-induced blood-
brain barrier disruption by inhibiting gelatinases-mediated ZO-1 degradation in
rats. Toxycology 285: 31–38
[214] Wang Z, Zhu T, Qiao C, Zhou L, Wang B, Zhang J, Chen C, Li J, Xiao X (2005)
Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart.
Nat Biotech 23: 321–328
[215] Wei S, Guo A, Chen B, Kutschke W, Xie YP, Zimmerman K, Weiss RM, Ander-
son ME, Cheng H, Song LS (2010) T-tubule remodeling during transition from
hypertrophy to heart failure. Novelty and significance. Circulation Research 107:
520–531
[216] Whelan RS, Kaplinskiy V, Kitsis RN (2010) Cell death in the pathogenesis of
heart disease: Mechanisms and significance. Annual Review of Physiology 72:
19–44
[217] White SJ, Nicklin SA, Bu¨ning H, Brosnan MJ, Leike K, Papadakis ED, Hallek
M, Baker AH (2004) Targeted gene delivery to vascular tissue in vivo by tropism-
modified adeno-associated virus vectors. Circulation 109: 513–519
[218] Wierzbicki AS, Viljoen A (2013) Alipogene tiparvovec: gene therapy for lipopro-
tein lipase deficiency. Expert Opinion on Biological Therapy 13: 7–10
[219] Wile BM, Ban K, Yoon YS, Bao G (2014) Molecular beacon-enabled purification
of living cells by targeting cell type-specific mRNAs. Nature Protocols 9: 2411–
2424
[220] Wilkins BJ, Dai YS, Bueno OF, Parsons SA, Xu J, Plank DM, Jones F, Kimball
TR, Molkentin JD (2004) Calcineurin/NFAT coupling participates in pathologi-
cal, but not physiological cardiac hypertrophy. Circulation Research 94: 110–118
[221] Wilkins BJ, De Windt LJ, Bueno OF, Braz JC, Glascock BJ, Kimball TF,
Molkentin JD (2002) Targeted disruption of NFATc3, but not NFATc4, reveals
an intrinsic defect in calcineurin-mediated cardiac hypertrophic growth. Molec-
ular and Cellular Biology 22: 7603–7613
[222] Williamson MR, Shuttleworth A, Canfield AE, Black RA, Kielty CM (2007) The
role of endothelial cell attachment to elastic fibre molecules in the enhancement
References 140
of monolayer formation and retention, and the inhibition of smooth muscle cell
recruitment. Biomaterials 28: 5307 – 5318
[223] Wise SG, Waterhouse A, Michael P, Ng MK (2012) Extracellular matrix
molecules facilitating vascular biointegration. J Funct Biomater 3: 569–587
[224] Wu CH, Lin CS, Hung JS, Wu CJ, Lo PH, Jin G, Shyy YJ, Mao SJT, Chien S
(2001) Inhibition of neointimal formation in porcine coronary artery by a Ras
mutant. Journal of Surgical Research 99: 100–106
[225] Xia Y, Lee K, Li N, Corbett D, Mendoza L, Frangogiannis NG (2009) Charac-
terization of the inflammatory and fibrotic response in a mouse model of cardiac
pressure overload. Histochemistry and Cell Biology 131: 471–481
[226] Xiao X, Gang Y, Wang H, Wang J, Zhao L, Xu L, Liu Z (2015) Double-stranded
RNA transcribed from vector-based oligodeoxynucleotide acts as transcription
factor decoy. Biochemical and Biophysical Research Communications 457: 221
– 226
[227] Xie M, Burchfield JS, Hill JA (2013) Pathological ventricular remodeling. Cir-
culation 128: 1021–1030
[228] Xiong W, Knispel RA, Dietz HC, Ramirez F, Baxter BT (2017) Doxycycline de-
lays aneurysm rupture in a mouse model of Marfan syndrome. Journal of Vascular
Surgery 47: 166–172
[229] Yamasaki K, Asai T, Shimizu M, Aoki M, Hashiya N, Sakonjo H, Makino H,
Kaneda Y, Ogihara T, Morishita R (2003) Inhibition of NFκB activation using
cis-element decoy of nfκb binding site reduces neointimal formation in porcine
balloon-injured coronary artery model. Gene Ther 10: 356–364
[230] Yang J, Savvatis K, Kang JS, Fan P, Zhong H, Schwartz K, Barry V, Mikels-
Vigdal A, Karpinski S, Kornyeyev D, Adamkewicz J, Feng X, Zhou Q, Shang C,
Kumar P, Phan D, Kasner M, Lo´pez B, Diez J, Wright KC, Kovacs RL, Chen PS,
Quertermous T, Smith V, Yao L, Tscho¨pe C, Chang CP (2016) Targeting LOXL2
for cardiac interstitial fibrosis and heart failure treatment. Nature Communica-
tions 7: 13710–13728
[231] Ying Y, Muller OJ, Goehringer C, Leuchs B, Trepel M, Katus HA, Klein-
schmidt JA (2010) Heart-targeted adeno-associated viral vectors selected by in
vivo biopanning of a random viral display peptide library. Gene Ther 17: 980–
990
[232] Yuan HF, Huang H, Li XY, Guo W, Xing W, Sun ZY, Liang HP, Yu J, Chen DF,
Wang ZG, Hao J, Xu X (2013) A dual AP-1 and SMAD decoy ODN suppresses
References 141
tissue fibrosis and scarring in mice. Journal of Investigative Dermatology 133:
1080 – 1087
[233] Yusuf S, Pepine CJ, Garces C, Pouleur H, Rousseau M, Salem D, Kostis J, Bene-
dict C, Bourassa M, Pitt B (1992) Effect of Enalapril on myocardial infarction
and unstable angina in patients with low ejection fractions. The Lancet 340:
1173–1178
[234] Zacchigna S, Zentilin L, Giacca M (2014) Adeno-associated virus vectors as
therapeutic and investigational tools in the cardiovascular system. Circulation
Research 114: 1827–1846
[235] Zarain-Herzberg A, Fragoso-Medina J, Estrada-Avils R (2011) Calcium-
regulated transcriptional pathways in the normal and pathologic heart. IUBMB
Life 63: 847–855
[236] Zeyer KA, Reinhardt DP (2015) Fibrillin-containing microfibrils are key signal
relay stations for cell function. J Cell Commun Signal 9: 351356
[237] Zhang P, Andrianakos R, Yang Y, Liu C, Lu W (2010) Kruppel-like factor 4
(Klf4) prevents embryonic stem cell differentiation by regulating Nanog gene
expression. Journal of Biological Chemistry 285: 9180–9189
[238] Zimmerman KA, Graham LV, Pallero MA, Murphy-Ullrich JE (2013) Calretic-
ulin regulates transforming growth factor-β-stimulated extracellular matrix pro-
duction. Journal of Biological Chemistry 288: 14584–14598
[239] Zincarelli C, Soltys S, Rengo G, Rabinowitz JE (2008) Analysis of AAV
serotypes 1-9 mediated gene expression and tropism in mice after systemic in-
jection. Molecular Therapy 16: 1073–1080
[240] Zsebo K, Yaroshinsky A, Rudy JJ, Wagner K, Greenberg B, Jessup M, Hajjar
RJ (2014) Long-term effects of AAV1/SERCA2a gene transfer in patients with
severe heart failure. Novelty and significance. Circulation Research 114: 101–108
